



(12) **EUROPEAN PATENT APPLICATION**


(43) Date of publication: **01.02.2012 Bulletin 2012/05** (51) Int Cl.: **A61K 38/16<sup>(2006.01)</sup> A61P 1/00<sup>(2006.01)</sup>**  
 (21) Application number: **10171494.7**  
 (22) Date of filing: **28.04.2005**

<p>(84) Designated Contracting States:  <b>AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR</b></p> <p>(30) Priority: <b>28.04.2004 AU 2004201774</b>  <b>11.02.2005 AU 2005900650</b></p> <p>(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:  <b>05738143.6 / 1 755 639</b></p> <p>(27) Previously filed application:  <b>28.04.2005 PCT/GB2005/001621</b></p> <p>(71) Applicant: <b>BTG International Limited</b>  <b>London EC4M 7RD (GB)</b></p>	<p>(72) Inventors:  <ul style="list-style-type: none"> <li>• <b>Anderson, Robert</b>  <b>Melbourne, Victoria 3050 (AU)</b></li> <li>• <b>Beissbath, Tim</b>  <b>69120, Heidelberg (DE)</b></li> <li>• <b>Tye-Din, Jason</b>  <b>Melbourne, Victoria 3050 (AU)</b></li> </ul> </p> <p>(74) Representative: <b>Dolan, Anthony Patrick</b>  <b>BTG International Limited</b>  <b>5 Fleet Place</b>  <b>London EC4M 7RD (GB)</b></p> <p>Remarks:                      This application was filed on 30-07-2010 as a divisional application to the application mentioned under INID code 62.</p>
---	---

(54) **Epitopes related to coeliac disease**

(57) The invention herein disclosed is related to preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

**Figure 1**



**EP 2 412 380 A1**

**Description**

**[0001]** The invention relates to epitopes useful in the diagnosis and therapy of coeliac disease, including diagnostics, therapeutics, kits, and methods of using the foregoing.

**[0002]** Coeliac disease is caused by an immune mediated hypersensitivity to dietary gluten. Gluten proteins in wheat, rye, barley and in some cases oats are toxic in coeliac disease. Gluten is composed of alpha/beta, gamma and omega gliadins, and low and high molecular weight (LMW and HMW) glutenins in wheat, hordeins in barley, secalins in rye and avenins in oats. Hordeins and secalins are homologous to gamma and omega gliadins and low and high molecular weight glutenins in wheat. Avenins are phylogenetically more distant than hordeins and secalins from wheat gluten.

**[0003]** The goal of research in coeliac disease has been to define the toxic components of gluten by defining the peptides that stimulate gluten-specific T-cells. Precise definition of gluten epitopes permits development of new diagnostics, therapeutics, tests for gluten contamination in food and non-toxic grains that retain the cooking/baking qualities of traditional gluten. Many of these applications require a comprehensive understanding of all rather than the most common toxic peptides in gluten.

**[0004]** Genes encoding HLA-DQ2 and/or HLA-DQ8 are present in over 99% of individuals with coeliac disease compared to approximately 35% of the general Caucasian population. Gluten-derived peptides (epitopes) bound to HLA-DQ2 or HLA-DQ8 stimulate specific T-cells. HLA-DQ2 and DQ8-restricted epitopes include a "core" 9 amino acid sequence that directly interacts with the peptide binding groove of HLA-DQ2 or DQ8 and with cognate T-cell receptors. In general, libraries of overlapping peptides (usually 15 to 20mers) containing all unique 10 or 12mer peptides in an antigen have been used to map HLA class 11-restricted T-cells epitopes.

**[0005]** A series of gluten peptides are known to activate gluten specific T-cells in coeliac disease. Previous studies have identified gluten peptides from selected gluten proteins or gluten digests. T-cell clones and lines isolated from intestinal biopsies have been used to screen these gluten components.

**[0006]** Modification of gluten by the enzyme, tissue transglutaminase (tTG) present in intestinal tissue, substantially increases gluten's stimulatory capacity on gluten specific T-cells. Most of the known epitopes for gluten-specific T-cells correspond to tTG-deamidated gluten peptides. Transglutaminase mediates deamidation of specific glutamine residues (to glutamate) in gluten. Glutamine-containing sequences susceptible to deamidation by tTG generally conform to a motif: QXPX or QXX(FYMILVW) (see Vader W. et al 2002 J. Exp. Med. 195:643-649, PCT WO 03/066079, and Fleckenstein B. 2002. J Biol Chem 277:34109-16). The motif for peptides that bind to HLA-DQ2 and that are susceptible to deamidation by tTG has been used to predict certain gluten epitopes (Vader et al J Exp Med 2002 J. Exp. Med. 195: 643-649, PCT WO 03/066079).

**[0007]** However, other groups have identified epitopes for gluten-specific intestinal T-cell clones and lines using panels of eleven recombinant alpha/beta (11) and five gamma gliadins (Arentz-Hansen H. 2000. J. Exp. Med. 191:603-612, Arentz-Hansen H. 2002. Gastroenterology 123:803-809, PCT WO 02/083722), and lysates of purified gluten proteins (Sjostrom H. et al 1998. Scand. J. Immunol. 48,111-115; van de Wal, Y. et al 1998. J. Immunol. 161(4):1585-1588; van de Wal, Y. et al 1999. Eur. J. Immunol. 29:3133-3139; Vader W. et al 2002. Gastroenterology 122:1729-1737.).

**[0008]** Our work has exploited the observation that gluten challenge *in vivo* induces HLA-DQ2 restricted CD4+ gluten-specific T-cells in peripheral blood expressing a gut-homing integrin (alpha4beta7). This technique allowed the mapping of the dominant epitope in A-gliadin (57-73 QE65) (Anderson, RP et al 2000. Nat. Med. 6:337-342., WO 01/25793). A-gliadin 57-73 QE65 corresponds to two overlapping epitopes identified using intestinal T-cell clones (Arentz-Hansen H. et al 2000. J. Exp. Med. 191:603-612, Arentz-Hansen H. et al 2002. Gastroenterology 123:803-809). The advantage of *in vivo* gluten challenge to induce gluten specific T-cells is that any food can be consumed and the resulting T-cells induced in blood (quantified in peripheral blood using a simple overnight interferon gamma ELISPOT assay) will have been stimulated *in vivo* by endogenously presented epitopes, rather than primed *in vitro* by a synthetic or purified antigen. Overnight assays of fresh polyclonal peripheral blood T-cells also avoid the potential for artefacts associated with the lengthy purification of T-cell clones.

**[0009]** Interestingly, T-cell clones and lines specific for several gamma-gliadin epitopes (Arentz-Hansen H. 2002. Gastroenterology 123:803-809, PCT WO 02/083722) cross-react with the originally defined A-gliadin epitope 57-73 QE65.

**[0010]** Although there is substantial homology within the alpha/beta gliadins, earlier work (see WO 03/104273) has shown that the dominant epitope recognized in HLA-DQ2-associated coeliac disease, "A-gliadin 57-73 QE65", is encoded by a minority of the alpha/beta gliadins present in Genbank.

**SUMMARY OF THE INVENTION**

**[0011]** The current study set out to develop a method that would allow mapping of all T-cell epitopes in gluten. Consumption of wheat bread (200g daily for 3 days) or oats (100g daily for 3 days) was used to induce gluten or avenin-specific T-cells in peripheral blood (collected 6 days after beginning the challenge). Peripheral blood mononuclear cells

(PBMC) were assessed in overnight interferon gamma ELISPOT assays using a library of gluten and avenin peptides including all unique 12mer sequences included in every Genbank entry for wheat gluten and/or oat avenins. This goal was achieved by establishing an algorithm to design peptides spanning all potential epitopes in gluten proteins in Genbank (2922 20mers included all 14 964 unique 9mers - potential T-cell epitopes), adapting the interferon-gamma ELISPOT assay to a high throughput assay capable of screening over 1000 peptides with a single individual's blood and developing bioinformatics tools to analyse and interpret the data generated.

**[0012]** A series of 41 "superfamilies" of wheat gluten peptides were identified as putative T-cell epitopes. Superfamilies shared motifs in which a limited level of redundancy was allowed. Many of the most potent families include known T-cell epitopes including the previously described dominant epitope, A-gliadin 57-73.

**[0013]** Through comprehensive mapping of gluten epitopes using PBMC after gluten challenge, the inventors have found a series of novel gliadin, LMW and HMW glutenin, and avenin epitopes for coeliac disease associated with HLA-DQ2 and HLA-DQ8. Novel epitopes were identified for HLA-DQ2 and HLA-DQ8-associated coeliac disease. HLA-DQ2 and HLA-DQ8 associated coeliac disease are genetically and functionally distinct in terms of the range of T-cell epitopes that are recognized. In addition, three peptides present in avenin proteins of oats also activated peripheral blood mononuclear cells (PBMC) following oats challenge in HLA-DQ2+ coeliac subjects, the first time oats epitopes have been defined. Identification of avenin peptides recognized by T-cells following oats challenge *in vivo* provides a molecular basis for the observed occasional relapse of coeliacs following oat exposure (Lundin KEA et al. 2003 Gut 52:1649-52) and may provide a basis for a predictive diagnostic or genetic de-toxication of oats.

**[0014]** The data presented here will provide a comprehensive basis for definition of both common "dominant" and occasional "weak" T-cell epitopes in coeliac disease. This information is the platform for functional applications such as diagnostics, food tests, immunotherapeutics and prophylactics, and for design of non-toxic gluten proteins useful in modified grains.

**[0015]** In particular, through comprehensive mapping of gluten T cell epitopes, the inventors have found epitopes bioactive in coeliac disease in HLA-DQ2+ patients in wheat gliadins and glutenins, having similar core sequences (e.g., SEQ ID NOS: 1-199) and similar extended sequences (e.g., SEQ ID NOS:200-1554, 1555-1655, 1656-1671, and 1830-1903). The inventors have also found epitopes bioactive in coeliac disease in HLA-DQ2+ patients in: oat avenins having similar core sequences (e.g., SEQ ID NOS: 1684-1695) and similar extended sequences (e.g., SEQ ID NOS: 1672-1683, 1696-1698, and 1764-1768); rye secalins (SEQ ID NOS: 1769-1786); and barley hordeins (SEQ ID NOS: 1787-1829). Additionally, epitopes bioactive in coeliac disease in HLA-DQ8+ patients have been identified in wheat gliadins having similar core sequences (e.g., SEQ ID NOS: 1699-1721) and similar extended sequences (e.g., SEQ ID NOS: 1722-1763 and 1908-1927). This comprehensive mapping thus provides dominant epitopes recognized by T cells in coeliac patients. Thus, the methods of the invention described herein may be performed using any of these identified epitopes, and analogues and equivalents thereof. That is, the agents of the invention include these epitopes. Additionally, combinations of epitopes, i.e., "combitopes" or single peptides comprising two or more epitopes, have been shown to induce equivalent responses as the individual epitopes, indicating that several epitopes may be utilized for therapeutic, diagnostic, and other uses of the invention. Such combitopes may be in the form of, e.g., SEQ ID NO: 1906. Preferably, the agents of the invention include one or more of the epitopes having the sequences listed recited in SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 and analogues and equivalents thereof as defined herein.

**[0016]** Preferred agents that are bioactive in coeliac disease in HLA-DQ8+ patients possess a glutamine in a sequence that suggests susceptibility to deamidation separated by seven residues from a second glutamine also susceptible to deamidation (e.g., as found in QGSFQPSQQ) wherein the deamidated sequences are high affinity binders for HLA-DQ8 following deamidation by tTG (The binding motif for HLA-DQ8 favours glutamate at positions 1 and 9.) In a less preferred embodiment, the agent possesses glutamine residues susceptible to deamidation but not separated by seven residues from a second glutamine susceptible to tTG-mediated deamidation.

**[0017]** The invention thus provides a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, comprising the steps of: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising an amino acid sequence selected from SEQ ID NOS: 1-1927, preferably selected from SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, or an equivalent sequence from a naturally occurring gluten protein, (ii) an analogue of (i) which is capable of being recognised by a T cell receptor that recognises (i), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iii) a product comprising two or more agents as defined in (i) or (ii); and (b) determining *in vitro* whether T cells in the sample recognise the agent, with recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

**[0018]** The term "gluten protein" encompasses alpha/beta, gamma and omega gliadins, and low and high molecular weight (LMW and HMW) glutenins in wheat, hordeins in barley, secalins in rye, and avenins in oats. The invention is particularly concerned with gliadins and avenins.

**[0019]** The invention also provides use of the agent for the preparation of a diagnostic means for use in a method of

diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, said method comprising determining whether T cells of the individual recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

5 [0020] The finding of epitopes which are modified by transglutaminase also allows diagnosis of coeliac disease based on determining whether other types of immune response to these epitopes are present. Thus the invention also provides a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising determining the presence of an antibody that binds to the epitope in a sample from the individual, the presence of the antibody indicating that the individual has, or is susceptible to, coeliac disease.

10 [0021] The invention provides a method of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence as defined above is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

15 [0022] The invention also provides a mutant gluten protein whose wild-type sequence can be modified by a transglutaminase to a sequence that comprises an epitope comprising sequence as defined above, but which mutant gluten protein has been modified in such a way that it does not contain sequence which can be modified by a transglutaminase to a sequence that comprises such an epitope comprising sequence; or a fragment of such a mutant gluten protein which is at least 7 amino acids long (e.g., at least 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids long) and which comprises sequence which has been modified in said way.

20 [0023] The invention also provides a protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises the agent, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

[0024] Additionally the invention provides a food that comprises the proteins defined above.

25 [0025] The invention additionally provides the agent, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent. Also provided is an antagonist of a T cell which has a T cell receptor that recognises (i), optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells. Additionally provided is the agent or an analogue that binds an antibody (that binds the agent) for use in a method of treating or preventing coeliac disease in an individual by tolerising the individual to prevent the production of such an antibody.

30 [0026] The invention also provides methods of preventing or treating coeliac disease comprising administering to an individual at least one agent selected from: a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of SEQ ID NOS: 1-1927, preferably from the group consisting of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, and equivalents thereof; and b) an analogue of a) which is capable of being recognised by a T cell receptor that recognises the peptide of a) and which is not more than 50 amino acids in length. In some embodiments, the agent is HLA-DQ2-restricted, HLA-DQ8-restricted or one agent is HLA-DQ2-restricted and a second agent is HLA-DQ8-restricted. In some embodiments, the agent comprises a wheat epitope, an oat epitope, a rye epitope, a barley epitope or any combination thereof either as a single agent or as multiple agents.

35 [0027] The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an agent as described above and pharmaceutically acceptable carrier or diluent.

40 [0028] The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined above, and a pharmaceutically acceptable carrier or diluent.

45 [0029] The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a composition for tolerising an individual to a gluten protein to suppress the production of a T cell or antibody response to an agent as defined above, which composition comprises an agent as defined above.

50 [0030] The present invention also provides methods of preventing or treating coeliac disease by 1) diagnosing coeliac disease in an individual by either: a) contacting a sample from the host with at least one agent selected from: i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-1927, preferably selected from the group consisting of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, and equivalents thereof; and ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease; or b) administering an agent as defined above and determining *in vivo* whether T cells in the individual recognise the agent, recognition of the agent indicating that the individual has or is susceptible to coeliac disease; and 2) administering to an individual diagnosed as having, or being susceptible to, coeliac disease a therapeutic agent for preventing or treating coeliac disease.

**[0031]** The present invention also provides agents as defined above, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent.

**[0032]** The present invention also provides antagonists of a T cell which has a T cell receptor as defined above, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells.

**[0033]** The present invention also provides proteins that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent as defined above, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

**[0034]** The present invention also provides pharmaceutical compositions comprising an agent or antagonist as defined and a pharmaceutically acceptable carrier or diluent.

**[0035]** The present invention also provides compositions for tolerising an individual to a gluten protein to suppress the production of a T cell or antibody response to an agent as defined above, which composition comprises an agent as defined above.

**[0036]** The present invention also provides compositions for antagonising a T cell response to an agent as defined above, which composition comprises an antagonist as defined above.

**[0037]** The present invention also provides mutant gluten proteins whose wild-type sequence can be modified by a transglutaminase to a sequence which is an agent as defined above, which mutant gluten protein comprises a mutation which prevents its modification by a transglutaminase to a sequence which is an agent as defined above; or a fragment of such a mutant gluten protein which is at least 7 amino acids long (e.g., at least 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids long) and which comprises the mutation.

**[0038]** The present invention also provides polynucleotides that comprise a coding sequence that encodes a protein or fragment as defined above.

**[0039]** The present invention also provides cells comprising a polynucleotide as defined above or which have been transformed with such a polynucleotide.

**[0040]** The present invention also provides mammals that expresses a T cell receptor as defined above.

**[0041]** The present invention also provides methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: a) contacting a sample from the host with at least one agent selected from i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-1927, preferably selected from the group consisting of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, and equivalents thereof; and ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and b) determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

**[0042]** The present invention also provides methods of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

**[0043]** The present invention also provides methods of identifying an antagonist of a T cell, which T cell recognises an agent as defined above, comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response, the detecting of any such decrease in said ability indicating that the substance is an antagonist.

**[0044]** The present invention also provides kits for carrying out any of the methods described above comprising an agent as defined above and a means to detect the recognition of the peptide by the T cell.

**[0045]** The present invention also provides methods of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal as defined above which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product.

**[0046]** The present invention also provides processes for the production of a protein encoded by a coding sequence as defined above which process comprises: a) cultivating a cell described above under conditions that allow the expression of the protein; and optionally b) recovering the expressed protein.

**[0047]** The present invention also provides methods of obtaining a transgenic plant cell comprising transforming a plant cell with a vector as described above to give a transgenic plant cell.

**[0048]** The present invention also provides methods of obtaining a first-generation transgenic plant comprising regenerating a transgenic plant cell transformed with a vector as described above to give a transgenic plant.

**[0049]** The present invention also provides methods of obtaining a transgenic plant seed comprising obtaining a transgenic seed from a transgenic plant obtainable as described above.

**[0050]** The present invention also provides methods of obtaining a transgenic progeny plant comprising obtaining a

second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by a method as described above, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

**[0051]** The present invention also provides transgenic plant cells, plants, plant seeds or progeny plants obtainable by any of the methods described above.

**[0052]** The present invention also provides transgenic plants or plant seeds comprising plant cells as described above.

**[0053]** The present invention also provides transgenic plant cell calluses comprising plant cells as described above obtainable from a transgenic plant cell, first-generation plant, plant seed or progeny as defined above.

**[0054]** The present invention also provides methods of obtaining a crop product comprising harvesting a crop product from a plant according to any method described above and optionally further processing the harvested product.

**[0055]** The present invention also provides food that comprises a protein as defined above.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0056]**

Figure 1 shows a method to generate all possible peptide epitopes from a group of proteins.

Figure 2 shows Genbank accession numbers for gluten gene products present in the Genbank database on 16th June 2003.

Figure 3A shows an expectation maximization (EM) algorithm to analyze data from ELISpot.

Figure 3B shows a test on a dataset of patients with coeliac disease.

Figure 4 shows an iterative procedure to find minimal set of responsive epitopes.

Figure 5 shows gliadin and glutenin sequences (SEQ ID NOS: 1-1554). In the "consensus" column, letters in lower case use the standard one letter amino acid code, but letters in upper case have a different meaning: E=[e or q], F=[f or y or w], I=[i or 1 or v], S=[s or t], R=[r or k or h]. The "sequence" column uses the standard one letter amino acid code.

Figure 6 shows gluten peptides that stimulate gamma interferon in PBMC collected 6 days after gluten challenge in HLA-DQ2+ coeliac disease volunteers (SEQ ID NOS: 1555-1655). The indicated 9mers are common to 200 groups of bioactive "structurally" related 20mer peptides. The gluten sequences are ranked according to the bioactivity X proportion of subjects responding.

Figure 7 shows the results of a wheat challenge experiment (SEQ ID NOS: 1656-1671). These peptides gave high quality responses (indicated 'Y') in ten subjects (A-J) after wheat challenge.

Figure 8 shows Avenin peptides (+/-deamidation by tTG) that stimulate interferon- $\gamma$  in PBMC collected 6 days after gluten challenge in HLA-DQ2+ coeliac disease volunteers (SEQ ID NOS: 1672-1698). Those marked with a \* are optimal unique 20mers inducing IFN- $\gamma$  after oats challenge.

Figure 9 shows the most potent 40 20mers (SEQ ID NOS: 1699-1763) in two HLA-DQ8 (not HLA-DQ2) subjects grouped according to shared core sequences. The core sequence of group 6 (QGSFQPSQQ) corresponds to the alpha-gliadin epitope described by van de Wal et al (J. Immunol. 1998, 161(4):1585-1588). The maximum response in Subject A was 271 SFC (medium alone, no peptide response: 4 SFC), and in B it was 26 SFC (medium alone, no peptide response: 1 SFC).

Figure 10 shows the amino acid sequence of A-gliadin (SEQ ID NO: 1928) based on amino acid sequencing.

## DETAILED DESCRIPTION OF THE INVENTION

**[0057]** The term "coeliac disease" encompasses a spectrum of conditions caused by varying degrees of gluten sensitivity, including a severe form characterised by a flat small intestinal mucosa (hyperplastic villous atrophy) and other forms characterised by milder symptoms.

**[0058]** The individual mentioned above (in the context of diagnosis or therapy) is human. They may have coeliac

disease (symptomatic or asymptomatic) or be suspected of having it. They may be on a gluten free diet. They may be in an acute phase response (for example they may have coeliac disease, but have only ingested gluten in the last 24 hours before which they had been on a gluten free diet for 14 to 28 days).

**[0059]** The individual may be susceptible to coeliac disease, such as a genetic susceptibility (determined for example by the individual having relatives with coeliac disease or possessing genes which cause predisposition to coeliac disease).

### ***The agent***

**[0060]** The agent is typically a peptide, for example of length 7 to 50 amino acids, such as 10 to 40, 12 to 35 or 15 to 30 amino acids in length.

**[0061]** The agent may be the peptide represented by any of SEQ ID NOS: 1-1927 or an epitope comprising sequence that comprises any of SEQ ID NOS: 1-1927 which is an isolated oligopeptide derived from a gluten protein; or an equivalent of these sequences from a naturally occurring gluten protein. In a further set of embodiments of the invention, the agent is any peptide epitope of an oat gluten (e.g. any T cell epitope of an avenin).

**[0062]** Preferably, the agent is the peptide represented by any of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 or an epitope comprising sequence that comprises any of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 which is an isolated oligopeptide derived from a gluten protein; or an equivalent of these sequences from a naturally occurring gluten protein.

**[0063]** Thus the epitope may be a derivative of a naturally occurring gluten protein, particularly from a wheat or oat gluten. Such a derivative is typically a fragment of the gluten protein, or a mutated derivative of the whole protein or fragment. Therefore the epitope of the invention does not include the naturally occurring whole gluten protein, and does not include other whole naturally occurring gluten proteins.

**[0064]** Typically such fragments will be at least 7 amino acids in length (e.g., at least 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in length).

**[0065]** Typically such fragments will be recognised by T cells to at least the same extent that the agents from which they are derived are recognised in any of the assays described herein using samples from coeliac disease patients.

**[0066]** The agent may be the peptide represented by any of SEQ ID NOS: 1-1927, preferably the peptide represented by any of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 or a protein comprising a sequence corresponding to any of SEQ ID NOS: 1-1927, preferably comprising a sequence corresponding to any of from SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 (such as fragments of a gluten protein comprising any of SEQ ID NOS: 1-1927 and preferably any of from SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927, for example after the gluten protein has been treated with transglutaminase). Bioactive fragments of such sequences are also agents of the invention. Typically such fragments will be at least 7 amino acids in length (e.g., at least 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in length). Sequences equivalent to any of SEQ ID NOS: 1-1927 or analogues of these sequences are also agents of the invention.

**[0067]** In the case where the epitope comprises a sequence equivalent to the above epitopes (including fragments) from another gluten protein (e.g. any of the gluten proteins mentioned herein or any gluten proteins which cause coeliac disease), such equivalent sequences will correspond to a fragment of a gluten protein typically treated (partially or fully) with transglutaminase. Such equivalent peptides can be determined by aligning the sequences of other gluten proteins with the gluten protein from which the original epitope derives (for example using any of the programs mentioned herein). Transglutaminase is commercially available (e.g. Sigma T-5398).

**[0068]** The agent which is an analogue is capable of being recognised by a TCR which recognises (i). Therefore generally when the analogue is added to T cells in the presence of (i), typically also in the presence of an antigen presenting cell (APC) (such as any of the APCs mentioned herein), the analogue inhibits the recognition of (i), i.e. the analogue is able to compete with (i) in such a system.

**[0069]** The analogue may be one which is capable of binding the TCR which recognises (i). Such binding can be tested by standard techniques. Such TCRs can be isolated from T cells which have been shown to recognise (i) (e.g. using the method of the invention). Demonstration of the binding of the analogue to the TCRs can then shown by determining whether the TCRs inhibit the binding of the analogue to a substance that binds the analogue, e.g. an antibody to the analogue. Typically the analogue is bound to a class II MHC molecule (e.g. HLA-DQ2) in such an inhibition of binding assay.

**[0070]** Typically the analogue inhibits the binding of (i) to a TCR. In this case the amount of (i) which can bind the TCR in the presence of the analogue is decreased. This is because the analogue is able to bind the TCR and therefore

competes with (i) for binding to the TCR.

[0071] T cells for use in the above binding experiments can be isolated from patients with coeliac disease, for example with the aid of the method of the invention. Other binding characteristics of the analogue may also be the same as (i), and thus typically the analogue binds to the same MHC class II molecule to which the peptide binds (HLA-DQ2 or -DQ8).

The analogue typically binds to antibodies specific for (i), and thus inhibits binding of (i) to such antibodies.

[0072] The analogue is typically a peptide. It may have homology with (i), typically at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99% homology with (i), for example over a region of at least 7, 8, 9, 10, 11, 12, 13, 14, 15 or more (such as the entire length of the analogue and/or (i), or across the region which contacts the TCR or binds the MHC molecule) contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those of skill in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").

[0073] For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux et al (1984) Nucleic Acids Research 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or align sequences (typically on their default settings), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10.

[0074] Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information on the world wide web through the Internet at, for example, "www.ncbi.nlm.nih.gov". This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al*, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

[0075] The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5877. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0076] The homologous peptide analogues typically differ from (i) by 1, 2, 3, 4, 5, 6, 7, 8 or more mutations (which may be substitutions, deletions or insertions). These mutations may be measured across any of the regions mentioned above in relation to calculating homology. The substitutions are preferably 'conservative'. These are defined according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

[0077] Typically the amino acids in the analogue at the equivalent positions to amino acids in (i) that contribute to binding the MHC molecule or are responsible for the recognition by the TCR, are the same or are conserved.

[0078] Typically the analogue peptide comprises one or more modifications, which may be natural post-translation modifications or artificial modifications. The modification may provide a chemical moiety (typically by substitution of a hydrogen, e.g. of a C-H bond), such as an amino, acetyl, hydroxy or halogen (e.g. fluorine) group or carbohydrate group.

Typically the modification is present on the N or C terminus.

**[0079]** The analogue may comprise one or more non-natural amino acids, for example amino acids with a side chain different from natural amino acids. Generally, the non-natural amino acid will have an N terminus and/or a C terminus. The non-natural amino acid may be an L- or a D- amino acid.

**[0080]** The analogue typically has a shape, size, flexibility or electronic configuration that is substantially similar to (i). It is typically a derivative of (i). In one embodiment the analogue is a fusion protein comprising the sequence of any of SEQ ID NOS: 1-1927 and non-gluten sequence. Preferably, the analogue according to this embodiment is a fusion protein comprising the sequence of any of SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, 1764-1768, 1769-1786, 1787-1829, 1895-1903, 1906, and 1908-1927 and non-gluten sequence

**[0081]** In one embodiment the analogue is or mimics (i) bound to a MHC class II molecule. 2, 3, 4 or more of such complexes may be associated or bound to each other, for example using a biotin/streptavidin based system, in which typically 2, 3 or 4 biotin labelled MHC molecules bind to a streptavidin moiety. This analogue typically inhibits the binding of the (i)/MHC Class II complex to a TCR or antibody which is specific for the complex.

**[0082]** The analogue is typically an antibody or a fragment of an antibody, such as a Fab or F(ab')<sub>2</sub> fragment. The analogue may be immobilised on a solid support, particularly an analogue that mimics peptide bound to a MHC molecule.

**[0083]** The analogue is typically designed by computational means and then synthesised using methods known in the art. Alternatively the analogue can be selected from a library of compounds. The library may be a combinatorial library or a display library, such as a phage display library. The library of compounds may be expressed in the display library in the form of being bound to a MHC class II molecule, such as HLA-DQ2 or -DQ8. Analogues are generally selected from the library based on their ability to mimic the binding characteristics (i). Thus they may be selected based on ability to bind a TCR or antibody which recognises (i).

**[0084]** Typically analogues will be recognised by T cells to at least the same extent as any of the agents (i), for example at least to the same extent as the equivalent epitope is recognised in any of the assays described herein, typically using T cells from coeliac disease patients. Analogues may be recognised to these extents *in vivo* and thus may be able to induce coeliac disease symptoms to at least the same extent as any of the agents mentioned herein (e.g. in a human patient or animal model).

**[0085]** Analogues may be identified in a method comprising determining whether a candidate substance is recognised by a T cell receptor that recognises an epitope of the invention, recognition of the substance indicating that the substance is an analogue. Such TCRs may be any of the TCRs mentioned herein, and may be present on T cells. Any suitable assay mentioned herein can be used to identify the analogue. In one embodiment this method is carried out *in vivo*. As mentioned above preferred analogues are recognised to at least the same extent as the equivalent epitope, and so the method may be used to identify analogues which are recognised to this extent.

**[0086]** In one embodiment the method comprises determining whether a candidate substance is able to inhibit the recognition of an epitope of the invention, inhibition of recognition indicating that the substance is an analogue.

**[0087]** The agent may be a product comprising at least 2, 5, 10 or 20 agents as defined by (i) or (ii). Typically the composition comprises epitopes of the invention (or equivalent analogues) from different gluten proteins, such as any of the species or variety of or types of gluten protein mentioned herein. Preferred compositions comprise at least one epitope of the invention, or equivalent analogue, from all of the glutes present in any of the species or variety mentioned herein, or from 2, 3, 4 or more of the species mentioned herein (such as from the panel of species consisting of wheat, rye, barley, oats and triticale). Thus, the agent may be monovalent or multivalent.

**[0088]** According to certain embodiments of the invention, the agent does not have or is not based on a sequence disclosed in WO 02/083722 and/or WO 01/25793 and/or WO03/104273 and/or recited in any of SEQ ID NOS: 1555-1577, 1580-1581, 1584-1586, 1594-1599, 1621-1622 and/or is not an agent derived from A-gliadin, the sequence of which is given in Figure 10.

**[0089]** Within SEQ ID NOS: 1-1927, a preferred subset is SEQ ID NOS: 1-1763. Within SEQ ID NOS: 1764-1927, preferred subsets are: (a) oat sequences 1764-1768, (b) rye sequences 1769-1786, (c) barley sequences 1787-1829, (d) wheat sequences 1895-1903, (e) wheat DQ8 sequences 1908-1927, and (f) combitope sequence 1906. Other preferred subsets are: (a) 1764-1768, (b) 1769-1773, (c) 1774-1786, (d) 1787-1792, (e) 1793-1829, (f) 1830-1894, (g) 1895-1903, (h) 1830-1903, (i) 1904-1906, (j) 1908-1916, (k) 1917-1927, and (l) 1908-1913, 1915-1923 and 1925-1927.

**[0090]** Within SEQ ID NOS: 1578-1579, 1582-1583, 1587-1593, 1600-1620, 1623-1655, 1656-1671, 1672-1698, 1699-1763, & 1764-1927, particularly preferred wheat epitopes are SEQ ID NOS: 1656-1671, 1830-1903, and 1907-1927.

**[0091]** Within SEQ ID NOS: 1830-1894 (Table 1), some sequences have N-terminal and C-terminal glycines. The invention extends to these sequences omitting the C-terminal glycine and/or the N-terminal glycine. Preferably, both the C-terminal glycine and the N-terminal glycine are omitted.

**Diagnosis**

**[0092]** As mentioned above the method of diagnosis of the invention may be based on the detection of T cells that bind the agent or on the detection of antibodies that recognise the agent.

**[0093]** The T cells that recognise the agent in the method (which includes the use mentioned above) are generally T cells that have been pre-sensitised *in vivo* to one or more gluten proteins. As mentioned above such antigen-experienced T cells have been found to be present in the peripheral blood.

**[0094]** In the method the T cells can be contacted with the agent *in vitro* or *in vivo*, and determining whether the T cells recognise the agent can be performed *in vitro* or *in vivo*. Thus the invention provides the agent for use in a method of diagnosis practiced on the human body. Different agents are provided for simultaneous, separate or sequential use in such a method.

**[0095]** The *in vitro* method is typically carried out in aqueous solution into which the agent is added. The solution will also comprise the T cells (and in certain embodiments the APCs discussed below). The term 'contacting' as used herein includes adding the particular substance to the solution.

**[0096]** Determination of whether the T cells recognise the agent is generally accomplished by detecting a change in the state of the T cells in the presence of the agent or determining whether the T cells bind the agent. The change in state is generally caused by antigen specific functional activity of the T cell after the TCR binds the agent. The change of state may be measured inside (e.g. change in intracellular expression of proteins) or outside (e.g. detection of secreted substances) the T cells.

**[0097]** The change in state of the T cell may be the start of or increase in secretion of a substance from the T cell, such as a cytokine, especially IFN- $\gamma$ , IL-2 or TNF- $\alpha$ . Determination of IFN- $\gamma$  secretion is particularly preferred. The substance can typically be detected by allowing it to bind to a specific binding agent and then measuring the presence of the specific binding agent/substance complex. The specific binding agent is typically an antibody, such as polyclonal or monoclonal antibodies. Antibodies to cytokines are commercially available, or can be made using standard techniques.

**[0098]** Typically the specific binding agent is immobilised on a solid support. After the substance is allowed to bind the solid support can optionally be washed to remove material which is not specifically bound to the agent. The agent/substance complex may be detected by using a second binding agent that will bind the complex. Typically the second agent binds the substance at a site which is different from the site which binds the first agent. The second agent is preferably an antibody and is labelled directly or indirectly by a detectable label.

**[0099]** Thus the second agent may be detected by a third agent that is typically labelled directly or indirectly by a detectable label. For example the second agent may comprise a biotin moiety, allowing detection by a third agent which comprises a streptavidin moiety and typically alkaline phosphatase as a detectable label.

**[0100]** In one embodiment the detection system which is used is the *ex-vivo* ELISPOT assay described in WO 98/23960. In that assay IFN- $\gamma$  secreted from the T cell is bound by a first IFN- $\gamma$  specific antibody that is immobilised on a solid support. The bound IFN- $\gamma$  is then detected using a second IFN- $\gamma$  specific antibody which is labelled with a detectable label. Such a labelled antibody can be obtained from MABTECH (Stockholm, Sweden). Other detectable labels which can be used are discussed below.

**[0101]** The change in state of the T cell that can be measured may be the increase in the uptake of substances by the T cell, such as the uptake of thymidine. The change in state may be an increase in the size of the T cells, or proliferation of the T cells, or a change in cell surface markers on the T cell.

**[0102]** In one embodiment the change of state is detected by measuring the change in the intracellular expression of proteins, for example the increase in intracellular expression of any of the cytokines mentioned above. Such intracellular changes may be detected by contacting the inside of the T cell with a moiety that binds the expressed proteins in a specific manner and which allows sorting of the T cells by flow cytometry.

**[0103]** In one embodiment when binding the TCR the agent is bound to an MHC class II molecule (typically HLA-DQ2 or -DQ8), which is typically present on the surface of an antigen presenting cell (APC). However as mentioned herein other agents can bind a TCR without the need to also bind an MHC molecule.

**[0104]** Generally the T cells which are contacted in the method are taken from the individual in a blood sample, although other types of samples which contain T cells can be used. The sample may be added directly to the assay or may be processed first. Typically the processing may comprise diluting of the sample, for example with water or buffer. Typically the sample is diluted from 1.5 to 100 fold, for example 2 to 50 or 5 to 10 fold.

**[0105]** The processing may comprise separation of components of the sample. Typically mononuclear cells (MCs) are separated from the samples. The MCs will comprise the T cells and APCs. Thus in the method the APCs present in the separated MCs can present the peptide to the T cells. In another embodiment only T cells, such as only CD4 T cells, can be purified from the sample. PBMCs, MCs and T cells can be separated from the sample using techniques known in the art, such as those described in Lavani et al (1997) J. Exp. Med. 186, p859-865.

**[0106]** In one embodiment, the T cells used in the assay are in the form of unprocessed or diluted samples, or are freshly isolated T cells (such as in the form of freshly isolated MCs or PBMCs) which are used directly *ex vivo*, i.e. they

are not cultured before being used in the method. Thus the T cells have not been restimulated in an antigen specific manner *in vitro*. However the T cells can be cultured before use, for example in the presence of one or more of the agents, and generally also exogenous growth promoting cytokines. During culturing the agent(s) are typically present on the surface of APCs, such as the APC used in the method. Pre-culturing of the T cells may lead to an increase in the sensitivity of the method. Thus the T cells can be converted into cell lines, such as short term cell lines (for example as described in Ota et al (1990) Nature 346, p183-187).

**[0107]** The APC that is typically present in the method may be from the same individual as the T cell or from a different host. The APC may be a naturally occurring APC or an artificial APC. The APC is a cell that is capable of presenting the peptide to a T cell. It is typically a B cell, dendritic cell or macrophage. It is typically separated from the same sample as the T cell and is typically co-purified with the T cell. Thus the APC may be present in MCs or PBMCs. The APC is typically a freshly isolated *ex vivo* cell or a cultured cell. It may be in the form of a cell line, such as a short term or immortalised cell line. The APC may express empty MHC class II molecules on its surface.

**[0108]** In the method one or more (different) agents may be used. Typically the T cells derived from the sample can be placed into an assay with all the agents which it is intended to test or the T cells can be divided and placed into separate assays each of which contain one or more of the agents.

**[0109]** The invention also provides the agents such as two or more of any of the agents mentioned herein (e.g. the combinations of agents which are present in the composition agent discussed above) for simultaneous separate or sequential use (eg. for *in vivo* use).

**[0110]** In one embodiment agent *per se* is added directly to an assay comprising T cells and APCs. As discussed above the T cells and APCs in such an assay could be in the form of MCs. When agents that can be recognised by the T cell without the need for presentation by APCs are used then APCs are not required. Analogues which mimic the original (i) bound to a MHC molecule are an example of such an agent.

**[0111]** In one embodiment the agent is provided to the APC in the absence of the T cell. The APC is then provided to the T cell, typically after being allowed to present the agent on its surface. The peptide may have been taken up inside the APC and presented, or simply be taken up onto the surface without entering inside the APC.

**[0112]** The duration for which the agent is contacted with the T cells will vary depending on the method used for determining recognition of the peptide. Typically  $10^5$  to  $10^7$ , preferably  $5 \times 10^5$  to  $10^6$  PBMCs are added to each assay. In the case where agent is added directly to the assay its concentration is from  $10^{-1}$  to  $10^3$   $\mu\text{g/ml}$ , preferably 0.5 to  $50 \mu\text{g/ml}$  or 1 to  $10 \mu\text{g/ml}$ .

**[0113]** Typically the length of time for which the T cells are incubated with the agent is from 4 to 24 hours, preferably 6 to 16 hours. When using *ex vivo* PBMCs it has been found that  $0.3 \times 10^6$  PBMCs can be incubated in  $10 \mu\text{g/ml}$  of peptide for 12 hours at  $37^\circ\text{C}$ .

**[0114]** The determination of the recognition of the agent by the T cells may be done by measuring the binding of the agent to the T cells (this can be carried out using any suitable binding assay format discussed herein). Typically T cells which bind the agent can be sorted based on this binding, for example using a FACS machine. The presence of T cells that recognise the agent will be deemed to occur if the frequency of cells sorted using the agent is above a "control" value. The frequency of antigen-experienced T cells is generally 1 in  $10^6$  to 1 in  $10^3$ , and therefore whether or not the sorted cells are antigen-experienced T cells can be determined.

**[0115]** The determination of the recognition of the agent by the T cells may be measured *in vivo*. Typically the agent is administered to the host and then a response which indicates recognition of the agent may be measured. The agent is typically administered intradermally or epidermally. The agent is typically administered by contacting with the outside of the skin, and may be retained at the site with the aid of a plaster or dressing. Alternatively the agent may be administered by needle, such as by injection, but can also be administered by other methods such as ballistics (e.g. the ballistics techniques which have been used to deliver nucleic acids). EP-A-0693119 describes techniques that can typically be used to administer the agent. Typically from 0.001 to 1000  $\mu\text{g}$ , for example from 0.01 to 100  $\mu\text{g}$  or 0.1 to 10  $\mu\text{g}$  of agent is administered.

**[0116]** In one embodiment a product can be administered which is capable of providing the agent *in vivo*. Thus a polynucleotide capable of expressing the agent can be administered, typically in any of the ways described above for the administration of the agent. The polynucleotide typically has any of the characteristics of the polynucleotide provided by the invention which is discussed below. The agent is expressed from the polynucleotide *in vivo*. Typically from 0.001 to 1000  $\mu\text{g}$ , for example from 0.01 to 100  $\mu\text{g}$  or 0.1 to 10  $\mu\text{g}$  of polynucleotide is administered.

**[0117]** Recognition of the agent administered to the skin is typically indicated by the occurrence of inflammation (e.g. induration, erythema or oedema) at the site of administration. This is generally measured by visual examination of the site.

**[0118]** The method of diagnosis based on the detection of an antibody that binds the agent is typically carried out by contacting a sample from the individual (such as any of the samples mentioned here, optionally processed in any manner mentioned herein) with the agent and determining whether an antibody in the sample binds the agent, such a binding indicating that the individual has, or is susceptible to coeliac disease. Any suitable format of binding assay may be used, such as any such format mentioned herein.

## Therapy

**[0119]** The identification of the immunodominant epitope and other epitopes described herein allows therapeutic products to be made which target the T cells which recognise this epitope (such T cells being ones which participate in the immune response against gluten proteins). These findings also allow the prevention or treatment of coeliac disease by suppressing (by tolerisation) an antibody or T cell response to the epitope(s).

**[0120]** Certain agents of the invention bind the TCR that recognises the epitope of the invention (as measured using any of the binding assays discussed above) and cause tolerisation of the T cell that carries the TCR. Such agents, optionally in association with a carrier, can therefore be used to prevent or treat coeliac disease.

**[0121]** Generally tolerisation can be caused by the same peptides which can (after being recognised by the TCR) cause antigen specific functional activity of the T cell (such as any such activity mentioned herein, e.g. secretion of cytokines). Such agents cause tolerisation when they are presented to the immune system in a 'tolerising' context.

**[0122]** Tolerisation leads to a decrease in the recognition of a T cell or antibody epitope by the immune system. In the case of a T cell epitope this can be caused by the deletion or anergising of T cells that recognise the epitope. Thus T cell activity (for example as measured in suitable assays mentioned herein) in response to the epitope is decreased. Tolerisation of an antibody response means that a decreased amount of specific antibody to the epitope is produced when the epitope is administered.

**[0123]** Methods of presenting antigens to the immune system in such a context are known and are described for example in Yoshida et al. Clin. Immunol. Immunopathol. 82, 207-215 (1997), Thureau et al. Clin. Exp. Immunol. 109, 370-6 (1997), and Weiner et al. Res. Immunol. 148, 528-33 (1997). In particular certain routes of administration can cause tolerisation, such as oral, nasal or intraperitoneal. Tolerisation may also be accomplished via dendritic cells and tetramers presenting peptide. Particular products which cause tolerisation may be administered (e.g. in a composition that also comprises the agent) to the individual. Such products include cytokines, such as cytokines that favour a Th2 response (e.g. IL-4, TGF- $\beta$  or IL-10). Products or agent may be administered at a dose that causes tolerisation.

**[0124]** The invention provides a protein that comprises a sequence able to act as an antagonist of the T cell (which T cell recognises the agent). Such proteins and such antagonists can also be used to prevent or treat coeliac disease. The antagonist will cause a decrease in the T cell response. In one embodiment, the antagonist binds the TCR of the T cell (generally in the form of a complex with HLA-DQ2 or -DQ8) but instead of causing normal functional activation causing an abnormal signal to be passed through the TCR intracellular signalling cascade, which causes the T cell to have decreased function activity (e.g. in response to recognition of an epitope, typically as measured by any suitable assay mentioned herein).

**[0125]** In one embodiment the antagonist competes with epitope to bind a component of MHC processing and presentation pathway, such as an MHC molecule (typically HLA-DQ2 or -DQ8). Thus the antagonist may bind HLA-DQ2 or -DQ8 (and thus be a peptide presented by this MHC molecule) or a homologue thereof.

**[0126]** Methods of causing antagonism are known in the art. In one embodiment the antagonist is a homologue of the epitopes mentioned above and may have any of the sequence, binding or other properties of the agent (particularly analogues). The antagonists typically differ from any of the above epitopes (which are capable of causing a normal antigen specific function in the T cell) by 1, 2, 3, 4 or more mutations (each of which may be a substitution, insertion or deletion). Such antagonists are termed "altered peptide ligands" or "APL" in the art. The mutations are typically at the amino acid positions that contact the TCR.

**[0127]** For example, the antagonist may differ from the epitope by a substitution within the sequence that is equivalent to the sequence represented by amino acids 64 to 67 of A-gliadin (the sequence of A-gliadin is given in Figure 10). Thus preferably the antagonist has a substitution at the equivalent of position 64, 65 or 67. Preferably the substitution is 64W, 67W, 67M or 65T.

**[0128]** Since the T cell immune response to the epitope of the invention in an individual is polyclonal, more than one antagonist may need to be administered to cause antagonism of T cells of the response which have different TCRs. Therefore the antagonists may be administered in a composition which comprises at least 2, 4, 6 or more different antagonists, which each antagonise different T cells.

**[0129]** The invention also provides a method of identifying an antagonist of a T cell (which recognises the agent), comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response (e.g. using any suitable assay mentioned herein), the detecting of any such decrease in said ability indicating that the substance is an antagonist.

**[0130]** In one embodiment, the antagonists (including combinations of antagonists to a particular epitope) or tolerising (T cell and antibody tolerising) agents are present in a composition comprising at least 2, 4, 6 or more antagonists or agents which antagonise or tolerate to different epitopes of the invention, for example to the combinations of epitopes discussed above in relation to the agents which are a product comprising more than one substance.

**Testing whether a composition is capable of causing coeliac disease**

**[0131]** As mentioned above the invention provides a method of determining whether a composition is capable of causing coeliac disease comprising detecting the presence of a protein sequence which is capable of being modified by a transglutaminase to a sequence comprising the agent or epitope of the invention (such as transglutaminase activity may be a human intestinal transglutaminase activity). Typically this is performed by using a binding assay in which a moiety which binds to the sequence in a specific manner is contacted with the composition and the formation of sequence/moiety complex is detected and used to ascertain the presence of the agent. Such a moiety may be any suitable substance (or type of substance) mentioned herein, and is typically a specific antibody. Any suitable format of binding assay can be used (such as those mentioned herein).

**[0132]** In one embodiment, the composition is contacted with at least 2, 5, 10 or more antibodies which are specific for epitopes of the invention from different gluten proteins, for example a panel of antibodies capable of recognising the combinations of epitopes discussed above in relation to agents of the invention which are a product comprising more than one substance.

**[0133]** The composition typically comprises material from a plant that expresses a gluten protein which is capable of causing coeliac disease (for example any of the gluten proteins or plants mentioned herein). Such material may be a plant part, such as a harvested product (e.g. seed). The material may be processed products of the plant material (e.g. any such product mentioned herein), such as a flour or food that comprises the gluten protein. The processing of food material and testing in suitable binding assays is routine, for example as mentioned in Kricka LJ, J. Biolumin. Chemilumin. 13, 189-93 (1998).

**Binding assays**

**[0134]** The determination of binding between any two substances mentioned herein may be done by measuring a characteristic of either or both substances that changes upon binding, such as a spectroscopic change.

**[0135]** The binding assay format may be a 'band shift' system. This involves determining whether the presence of one substance (such as a candidate substance) advances or retards the progress of the other substance during gel electrophoresis.

**[0136]** The format may be a competitive binding method which determines whether the one substance is able to inhibit the binding of the other substance to an agent which is known to bind the other substance, such as a specific antibody.

**Mutant gluten proteins**

**[0137]** The invention provides a gluten protein in which an epitope sequence of the invention, or sequence which can be modified by a transglutaminase to provide such a sequence has been mutated so that it no longer causes, or is recognised by, a T cell response that recognises the epitope. In this context the term recognition refers to the TCR binding the epitope in such a way that normal (not antagonistic) antigen-specific functional activity of the T cell occurs.

**[0138]** Methods of identifying equivalent epitopes in other gluten proteins are discussed above. The wild type of the mutated gluten protein is one which causes coeliac disease. Such a mutated gluten protein may have homology with the wild type of the mutated gluten protein, for example to the degree mentioned above (in relation to the analogue) across all of its sequence or across 15, 30, 60, 100 or 200 contiguous amino acids of its sequence. The sequences of other natural gluten proteins are known in the art.

**[0139]** The mutated gluten protein will not cause coeliac disease or will cause decreased symptoms of coeliac disease. Typically the mutation decreases the ability of the epitope to induce a T cell response. The mutated epitope may have a decreased binding to HLA-DQ2 or -DQ8, a decreased ability to be presented by an APC or a decreased ability to bind to or to be recognised (i.e. cause antigen-specific functional activity) by T cells that recognise the agent. The mutated gluten protein or epitope will therefore show no or reduced recognition in any of the assays mentioned herein in relation to the diagnostic aspects of the invention.

**[0140]** The mutation may be one or more deletions, additions or substitutions of length 1 to 3, 4 to 6, 6 to 10, 11 to 15 or more in the epitope, for example across any of SEQ ID NOS: 1-1927; or across equivalents thereof. Preferably the mutant gluten protein has at least one mutation in the sequence of any of SEQ ID NO: 1-1927. A preferred mutation is at the position equivalent to position 65 in A-gliadin (see Figure 10). Preferably, a naturally occurring glutamine is substituted to histidine, tyrosine, tryptophan, lysine, proline, or arginine.

**[0141]** The invention thus also provides use of a mutation (such as any of the mutations in any of the sequences discussed herein) in an epitope of a gluten protein, which epitope is an epitope of the invention, to decrease the ability of the gluten protein to cause coeliac disease.

**[0142]** In one embodiment the mutated sequence is able to act as an antagonist. Thus the invention provides a protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent of the

invention, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

[0143] The invention also provides proteins which are fragments of the above mutant gluten proteins, which are at least 7 amino acids long (e.g. at least 8, 9, 10, 11, 12, 13, 14, 15, 30, 60, 100, 150, 200, or 250 amino acids long) and which comprise the mutations discussed above which decrease the ability of the gluten protein to be recognised. Any of the mutant proteins (including fragments) mentioned herein may also be present in the form of fusion proteins, for example with other gluten proteins or with non-gluten proteins.

[0144] The equivalent wild type protein to the mutated gluten protein is typically from a graminaceous monocotyledon, such as a plant of a genus selected from *Triticum*, *Secale*, *Hordeum*, *Triticale* or *Avena*, (e.g. wheat, rye, barley, oats or triticale). For example, the protein may be an  $\alpha$ ,  $\alpha\beta$ ,  $\beta$ ,  $\gamma$  or  $\omega$  gliadin or an avenin.

#### Kits

[0145] The invention also provides a kit for carrying out the method comprising one or more agents and optionally a means to detect the recognition of the agent by the T cell. Typically the different agents are provided for simultaneous, separate or sequential use. Typically the means to detect recognition allows or aids detection based on the techniques discussed above.

[0146] Thus the means may allow detection of a substance secreted by the T cells after recognition. The kit may thus additionally include a specific binding moiety for the substance, such as an antibody. The moiety is typically specific for IFN- $\gamma$ . The moiety is typically immobilised on a solid support. This means that after binding the moiety the substance will remain in the vicinity of the T cell which secreted it. Thus "spots" of substance/moiety complex are formed on the support, each spot representing a T cell which is secreting the substance. Quantifying the spots, and typically comparing against a control, allows determination of recognition of the agent.

[0147] The kit may also comprise a means to detect the substance/moiety complex. A detectable change may occur in the moiety itself after binding the substance, such as a colour change. Alternatively a second moiety directly or indirectly labelled for detection may be allowed to bind the substance/moiety complex to allow the determination of the spots. As discussed above the second moiety may be specific for the substance, but binds a different site on the substance than the first moiety.

[0148] The immobilised support may be a plate with wells, such as a microtitre plate. Each assay can therefore be carried out in a separate well in the plate.

[0149] The kit may additionally comprise medium for the T cells, detection moieties or washing buffers to be used in the detection steps. The kit may additionally comprise reagents suitable for the separation from the sample, such as the separation of PBMCs or T cells from the sample. The kit may be designed to allow detection of the T cells directly in the sample without requiring any separation of the components of the sample.

[0150] The kit may comprise an instrument which allows administration of the agent, such as intradermal or epidermal administration. Typically such an instrument comprises plaster, dressing or one or more needles. The instrument may allow ballistic delivery of the agent. The agent in the kit may be in the form of a pharmaceutical composition.

[0151] The kit may also comprise controls, such as positive or negative controls. The positive control may allow the detection system to be tested. Thus the positive control typically mimics recognition of the agent in any of the above methods. Typically in the kits designed to determine recognition *in vitro* the positive control is a cytokine. In the kit designed to detect *in vivo* recognition of the agent the positive control may be antigen to which most individuals should response.

[0152] The kit may also comprise a means to take a sample containing T cells from the host, such as a blood sample. The kit may comprise a means to separate mononuclear cells or T cells from a sample from the host.

#### ***Polynucleotides, cells, transgenic mammals and antibodies***

[0153] The invention also provides a polynucleotide which is capable of expression to provide the agent or mutant gluten proteins. Typically the polynucleotide is DNA or RNA, and is single or double stranded. The polynucleotide will preferably comprise at least 50 bases or base pairs, for example 50 to 100, 100 to 500, 500 to 1000 or 1000 to 2000 or more bases or base pairs. The polynucleotide therefore comprises a sequence which encodes the sequence of any of SEQ ID NO: 1-1927 or any of the other agents mentioned herein. To the 5' and 3' of this coding sequence the polynucleotide of the invention has sequence or codons which are different from the sequence or codons 5' and 3' to these sequences in the corresponding gluten protein gene.

[0154] 5' and/or 3' to the sequence encoding the peptide the polynucleotide has coding or non-coding sequence. Sequence 5' and/or 3' to the coding sequence may comprise sequences which aid expression, such as transcription and/or translation, of the sequence encoding the agent. The polynucleotide may be capable of expressing the agent prokaryotic or eukaryotic cell. In one embodiment the polynucleotide is capable of expressing the agent in a mammalian cell, such as a human, primate or rodent (e.g. mouse or rat) cell.

**[0155]** A polynucleotide of the invention may hybridise selectively to a polynucleotide that encodes a gluten protein from which the agent is derived at a level significantly above background. Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C). However, such hybridisation may be carried out under any suitable conditions known in the art (see Sambrook et al (1989), Molecular Cloning: A Laboratory Manual). For example, if high stringency is required, suitable conditions include 0.2 x SSC at 60°C. If lower stringency is required, suitable conditions include 2 x SSC at 60°C.

**[0156]** Agents or proteins of the invention may be encoded by the polynucleotides described herein.

**[0157]** The polynucleotide may form or be incorporated into a replicable vector. Such a vector is able to replicate in a suitable cell. The vector may be an expression vector. In such a vector the polynucleotide of the invention is operably linked to a control sequence which is capable of providing for the expression of the polynucleotide. The vector may contain a selectable marker, such as the ampicillin resistance gene.

**[0158]** The polynucleotide or vector may be present in a cell. Such a cell may have been transformed by the polynucleotide or vector. The cell may express the agent. The cell will be chosen to be compatible with the said vector and may for example be a prokaryotic (bacterial), yeast, insect or mammalian cell. The polynucleotide or vector may be introduced into host cells using conventional techniques including calcium phosphate precipitation, DEAE-dextran transfection, or electroporation.

**[0159]** The invention provides processes for the production of the proteins of the invention by recombinant means. This may comprise (a) cultivating a transformed cell as defined above under conditions that allow the expression of the protein; and preferably (b) recovering the expressed polypeptide. Optionally, the polypeptide may be isolated and/or purified, by techniques known in the art.

**[0160]** The invention also provides TCRs which recognise (or bind) the agent, or fragments thereof which are capable of such recognition (or binding). These can be present in the any form mentioned herein (e.g. purity) discussed herein in relation to the protein of the invention. The invention also provides T cells which express such TCRs which can be present in any form (e.g. purity) discussed herein for the cells of the invention.

**[0161]** The invention also provides monoclonal or polyclonal antibodies which specifically recognise the agents (such as any of the epitopes of the invention) and which recognise the mutant gluten proteins (and typically which do not recognise the equivalent wild-type gluten proteins) of the invention, and methods of making such antibodies. Antibodies of the invention bind specifically to these substances of the invention.

**[0162]** For the purposes of this invention, the term "antibody" includes antibody fragments such as Fv, F(ab) and F(ab')<sub>2</sub> fragments, as well as single-chain antibodies.

**[0163]** A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein (1975) Nature 256, 495-497).

**[0164]** An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. -Human antibody may be prepared by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

**[0165]** For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

**[0166]** The polynucleotide, agent, protein or antibody of the invention, may carry a detectable label. Detectable labels which allow detection of the secreted substance by visual inspection, optionally with the aid of an optical magnifying means, are preferred. Such a system is typically based on an enzyme label which causes colour change in a substrate, for example alkaline phosphatase causing a colour change in a substrate. Such substrates are commercially available, e.g. from BioRad. Other suitable labels include other enzymes such as peroxidase, or protein labels, such as biotin; or radioisotopes, such as <sup>32</sup>P or <sup>35</sup>S. The above labels may be detected using known techniques.

**[0167]** Polynucleotides, agents, proteins, antibodies or cells of the invention may be in substantially purified form. They may be in substantially isolated form, in which case they will generally comprise at least 80% e.g. at least 90, 95, 97 or 99% of the polynucleotide, peptide, antibody, cells or dry mass in the preparation. The polynucleotide, agent, protein or antibody is typically substantially free of other cellular components. The polynucleotide, agent, protein or antibody may be used in such a substantially isolated, purified or free form in the method or be present in such forms in the kit.

**[0168]** The invention also provides a transgenic non-human mammal which expresses a TCR of the invention. This may be any of the mammals discussed herein (e.g. in relation to the production of the antibody). Preferably the mammal

has, or is susceptible, to coeliac disease. The mammal may also express HLA-DQ2 or -DQ8 or HLA-DR3-DQ2 and/or may be given a diet comprising a gluten protein which causes coeliac disease (e.g. any of the gluten proteins mentioned herein). Thus the mammal may act as an animal model for coeliac disease.

5 [0169] The invention also provides a method of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal of the invention which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product. Such a product may be used to treat or prevent coeliac disease.

10 [0170] The invention provides therapeutic (including prophylactic) agents or diagnostic substances (the agents, proteins and polynucleotides of the invention). These substances are formulated for clinical administration by mixing them with a pharmaceutically acceptable carrier or diluent. For example they can be formulated for topical, parenteral, intravenous, intramuscular, subcutaneous, intraocular, intradermal, epidermal or transdermal administration. The substances may be mixed with any vehicle which is pharmaceutically acceptable and appropriate for the desired route of administration. The pharmaceutically carrier or diluent for injection may be, for example, a sterile or isotonic solution such as  
15 Water for Injection or physiological saline, or a carrier particle for ballistic delivery.

[0171] The dose of the substances may be adjusted according to various parameters, especially according to the agent used; the age, weight and condition of the patient to be treated; the mode of administration used; the severity of the condition to be treated; and the required clinical regimen. As a guide, the amount of substance administered by injection is suitably from 0.01 mg/kg to 30 mg/kg, Preferably from 0.1 mg/kg to 10 mg/kg.

20 [0172] The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

[0173] The substances of the invention may thus be used in a method of treatment of the human or animal body, or in a diagnostic method practised on the human body. In particular they may be used in a method of treating or preventing coeliac disease. The invention also provide the agents for use in a method of manufacture of a medicament for treating  
25 or preventing coeliac disease. Thus the invention provides a method of preventing or treating coeliac disease comprising administering to a human in need thereof a substance of the invention (typically a non-toxic effective amount thereof).

[0174] The agent of the invention can be made using standard synthetic chemistry techniques, such as by use of an automated synthesizer. The agent may be made from a longer polypeptide e.g. a fusion protein, which polypeptide typically comprises the sequence of the peptide. The peptide may be derived from the polypeptide by for example  
30 hydrolysing the polypeptide, such as using a protease; or by physically breaking the polypeptide. The polynucleotide of the invention can be made using standard techniques, such as by using a synthesiser.

***Plant cells and plants that express mutant gluten proteins or express proteins comprising sequences which can act as antagonists***

35 [0175] The cell of the invention may be a plant cell, such as a cell of a graminaceous monocotyledonous species. The species may be one whose wild-type form expresses gluten proteins, such as any of the gluten proteins mentioned herein. Such a gluten protein may cause coeliac disease in humans. The cell may be of wheat, maize, oats, rye, rice, barley, triticale, sorghum, or sugar cane. Typically the cell is of the *Triticum* genus, such as *aestivum*, *spelta*, *polonicum* or *monococcum*.

40 [0176] The plant cell of the invention is typically one which does not express one or more wild-type gluten proteins (such as any of the gluten proteins mentioned herein which may cause coeliac disease), or one which does not express one or more gluten proteins comprising a sequence that can be recognised by a T cell that recognises the agent. Thus if the wild-type plant cell did express such a gluten protein then it may be engineered to prevent or reduce the expression  
45 of such a gluten protein or to change the amino acid sequence of the gluten protein so that it no longer causes coeliac disease (typically by no longer expressing the epitope of the invention).

[0177] This can be done for example by introducing mutations into 1, 2, 3 or more or all of such gluten protein genes in the cell, for example into coding or non-coding (e.g. promoter regions). Such mutations can be any of the type or length of mutations discussed herein (e.g., in relation to homologous proteins). The mutations can be introduced in a  
50 directed manner (e.g., using site directed mutagenesis or homologous recombination techniques) or in a random manner (e.g. using a mutagen, and then typically selecting for mutagenised cells which no longer express the gluten protein (or a gluten protein sequence which causes coeliac disease)).

[0178] In the case of plants or plant cells that express a protein that comprises a sequence able to act as an antagonist such a plant or plant cell may express a wild-type gluten protein (e.g. one which causes coeliac disease). Preferably  
55 though the presence of the antagonist sequence will cause reduced coeliac disease symptoms (such as no symptoms) in an individual who ingests a food comprising protein from the plant or plant cell.

[0179] The polynucleotide which is present in (or which was transformed into) the plant cell will generally comprise promoter capable of expressing the mutant gluten protein the plant cell. Depending on the pattern of expression desired,

the promoter may be constitutive, tissue- or stage-specific; and/or inducible. For example, strong constitutive expression in plants can be obtained with the CAMV 35S, Rubisco ssu, or histone promoters. Also, tissue-specific or stage-specific promoters may be used to target expression of protein of the invention to particular tissues in a transgenic plant or to particular stages in its development. Thus, for example seed-specific, root-specific, leaf-specific, flower-specific etc promoters may be used. Seed-specific promoters include those described by Dalta et al (Biotechnology Ann. Rev. (1997), 3, pp.269-296). Particular examples of seed-specific promoters are napin promoters (EP-A-0 255, 378), phaseolin promoters, glutenine promoters, helianthene promoters (WO92/17580), albumin promoters (WO98/45460), oleosin promoters (WO98/45461) and ATS1 and ATS3 promoters (WO99/20775).

**[0180]** The cell may be in any form. For example, it may be an isolated cell, e.g. a protoplast, or it may be part of a plant tissue, e.g. a callus, or a tissue excised from a plant, or it may be part of a whole plant. The cell may be of any type (e.g. of any type of plant part). For example, an undifferentiated cell, such as a callus cell; or a differentiated cell, such as a cell of a type found in embryos, pollen, roots, shoots or leaves. Plant parts include roots; shoots; leaves; and parts involved in reproduction, such as pollen, ova, stamens, anthers, petals, sepals and other flower parts.

**[0181]** The invention provides a method of obtaining a transgenic plant cell comprising transforming a plant cell with a polynucleotide or vector of the invention to give a transgenic plant cell. Any suitable transformation method may be used (in the case of wheat the techniques disclosed in Vasil V et al, Biotechnology 10, 667-674 (1992) may be used). Preferred transformation techniques include electroporation of plant protoplasts and particle bombardment. Transformation may thus give rise to a chimeric tissue or plant in which some cells are transgenic and some are not.

**[0182]** The cell of the invention or thus obtained cell may be regenerated into a transgenic plant by techniques known in the art. These may involve the use of plant growth substances such as auxins, gibberellins and/or cytokinins to stimulate the growth and/or division of the transgenic cell. Similarly, techniques such as somatic embryogenesis and meristem culture may be used. Regeneration techniques are well known in the art and examples can be found in, e.g. US 4,459,355, US 4,536,475, US 5,464,763, US 5, 177,010, US 5, 187,073, EP 267,159, EP 604, 662, EP 672, 752, US 4,945,050, US 5,036,006, US 5,100,792, US 5,371,014, US 5,478,744, US 5,179,022, US 5,565,346, US 5,484,956, US 5,508,468, US 5,538,877, US 5,554,798, US 5,489,520, US 5,510,318, US 5,204,253, US 5,405,765, EP 442,174, EP 486,233, EP 486,234, EP 539,563, EP 674,725, WO91/02071 and WO 95/06128.

**[0183]** In many such techniques, one step is the formation of a callus, i.e. a plant tissue comprising expanding and/or dividing cells. Such calli are a further aspect of the invention as are other types of plant cell cultures and plant parts. Thus, for example, the invention provides transgenic plant tissues and parts, including embryos, meristems, seeds, shoots, roots, stems, leaves and flower parts. These may be chimeric in the sense that some of their cells are cells of the invention and some are not. Transgenic plant parts and tissues, plants and seeds of the invention may be of any of the plant species mentioned herein.

**[0184]** Regeneration procedures will typically involve the selection of transformed cells by means of marker genes.

**[0185]** The regeneration step gives rise to a first generation transgenic plant. The invention also provides methods of obtaining transgenic plants of further generations from this first generation plant. These are known as progeny transgenic plants. Progeny plants of second, third, fourth, fifth, sixth and further generations may be obtained from the first generation transgenic plant by any means known in the art.

**[0186]** Thus, the invention provides a method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant of the invention, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

**[0187]** Progeny plants may be produced from their predecessors of earlier generations by any known technique. In particular, progeny plants may be produced by: (a) obtaining a transgenic seed from a transgenic plant of the invention belonging to a previous generation, then obtaining a transgenic progeny plant of the invention belonging to a new generation by growing up the transgenic seed; and/or (b) propagating clonally a transgenic plant of the invention belonging to a previous generation to give a transgenic progeny plant of the invention belonging to a new generation; and/or (c) crossing a first-generation transgenic plant of the invention belonging to a previous generation with another compatible plant to give a transgenic progeny plant of the invention belonging to a new generation; and optionally (d) obtaining transgenic progeny plants of one or more further generations from the progeny plant thus obtained.

**[0188]** These techniques may be used in any combination. For example, clonal propagation and sexual propagation may be used at different points in a process that gives rise to a transgenic plant suitable for cultivation. In particular, repetitive back-crossing with a plant taxon with agronomically desirable characteristics may be undertaken. Further steps of removing cells from a plant and regenerating new plants therefrom may also be carried out.

**[0189]** Also, further desirable characteristics may be introduced by transforming the cells, plant tissues, plants or seeds, at any suitable stage in the above process, to introduce desirable coding sequences other than the polynucleotides of the invention. This may be carried out by the techniques described herein for the introduction of polynucleotides of the invention.

**[0190]** For example, further transgenes may be selected from those coding for other herbicide resistance traits, e.g. tolerance to: Glyphosate (e.g. using an EPSP synthase gene (e.g. EP-A-0,293,358) or a glyphosate oxidoreductase

(WO 92/00377) gene); or tolerance to fosametin; a dihalobenzonitrile; glufosinate, e.g. using a phosphinothrycin acetyl transferase (PAT) or glutamine synthase gene (cf. EP-A-0,242,236); asulam, e.g. using a dihydropteroate synthase gene (EP-A-0,369,367); or a sulphonylurea, e.g. using an ALS gene); diphenyl ethers such as acifluorfen or oxyfluorfen, e.g. using a protoporphyrin oxidase gene); an oxadiazole such as oxadiazon; a cyclic imide such as chlorophthalim; a phenyl pyrazole such as TNP, or a phenopylate or carbamate analogue thereof.

[0191] Similarly, genes for beneficial properties other than herbicide tolerance may be introduced. For example, genes for insect resistance may be introduced, notably genes encoding *Bacillus thuringiensis* (Bt) toxins. Likewise, genes for disease resistance may be introduced, e.g. as in WO91/02701 or WO95/06128.

[0192] Typically, a protein of the invention is expressed in a plant of the invention. Depending on the promoter used, this expression may be constitutive or inducible. Similarly, it may be tissue- or stage-specific, i.e. directed towards a particular plant tissue (such as any of the tissues mentioned herein) or stage in plant development.

[0193] The invention also provides methods of obtaining crop products by harvesting, and optionally processing further, transgenic plants of the invention. By crop product is meant any useful product obtainable from a crop plant.

### **Products that contain mutant gluten proteins or proteins that comprise sequence capable of acting as an antagonist**

[0194] The invention provides a product that comprises the mutant gluten proteins or protein that comprises sequence capable of acting as an antagonist. This is typically derived from or comprise plant parts from plants mentioned herein which express such proteins. Such a product may be obtainable directly by harvesting or indirectly, by harvesting and further processing the plant of the invention. Directly obtainable products include grains. Alternatively, such a product may be obtainable indirectly, by harvesting and further processing. Examples of products obtainable by further processing are flour or distilled alcoholic beverages; food products made from directly obtained or further processed material, e.g. baked products (e.g. bread) made from flour. Typically such food products, which are ingestible and digestible (i.e. non-toxic and of nutrient value) by human individuals.

[0195] In the case of food products that comprise the protein which comprises an antagonist sequence the food product may also comprise the wild-type gluten protein, but preferably the antagonist is able to cause a reduction (e.g. completely) in the coeliac disease symptoms after such food is ingested.

### **Deamidation**

[0196] Where a sequence described herein includes a Gln residue, the invention also provides that sequence where the Gln residue has been deamidated to a Glu residue. One or more (e.g., 1, 2, 3, 4, 5, etc.) Gln residue(s) per sequence may be deamidated, but when there is more than one Gln residue, not all of them must be deamidated. Preferably, the Gln residues that are deamidated are those susceptible to deamidation by transglutaminase.

[0197] Examples where Gln may be deamidated are given in the sequence listing. For example, residue 4 of SEQ ID NO:1 can be a Gln residue or a Glu residue, residue 6 of SEQ ID NO:2 can be a Gln residue or a Glu residue, residues 4 and 7 of SEQ ID NO:6 can each independently be Gln or Glu residues, etc. The Gln residues that are susceptible to deamidation, and their deamidated Glu counterparts, are referred to as "Glx" residues.

[0198] Where the agent includes more than one Glx residue, these may be arranged in any configuration. For example, the Glx residues may be consecutive residues, and/or may be separated by one or more (e.g., 1,2,3,4,5,6, 7, 8, etc.) other residues. As mentioned above, for HLA-DQ8 epitopes, the agent preferably comprises a Glx residue that is separated by seven residues from another Glx residue.

[0199] Preferred agents of the invention are deamidated agents, i.e., the agent comprises the one or more Glx residues in the Glu form. This can be achieved in various ways, e.g., by including Glu residues during production, or by converting Gln residues to Glu by deamidation. Conversion of Gln to Glu can be achieved by treating an agent that contains Gln residues that are susceptible to deamidation with a deamidating agent. The one or more Gln residues are preferably deamidated to Glu by transglutaminase, for example as described in the examples.

[0200] The skilled person will be able to determine which particular Gln residues in the agent are susceptible to deamidation and thus which residues should be Glu residues arising from deamidation of a Gln residue. For example, Gln-containing sequences susceptible to deamidation by transglutaminase generally conform to a motif: e.g., QXPX, QXP(Y), QXX (FYMLVW), QXP(Y), QXX (FY), PQ (QL) P (FY)P. For example, the sequence PQ (QL) P (FY)P facilitates deamidation of the underlined Q at position 2 by transglutaminase.

[0201] In particular, agents comprising the deamidated versions of SEQ ID NOs: 1-1927 are preferred (where such sequences are not already deamidated). Most preferably, the agents of the invention comprise the transglutaminase-deamidated versions of SEQ ID NOs: 1-1927 (again, where not already deamidated). Analogues and equivalents of these agents, as defined herein, are also encompassed within the scope of the invention.

## EXAMPLES

[0202] The invention is illustrated by the following nonlimiting Examples:

5 ***Initial gliadin epitope screening library***

[0203] In initial experiments involving 29 HLA-DQ2+ individuals with coeliac disease on long-term gluten free diet, interferon-gamma ELISPOT assays were used to screen a previous Pepset (described in WO 03/104273, which is incorporated herein by reference) initially as pools of peptides and then in 15 subjects as individual peptides with and without deamidation by tTG. This Pepset library consisted of 652 20mer gliadin peptides spanning all unique 12mers contained within all Genbank entries described as wheat gliadins found in September 2001. This Pepset library was designed "manually" from gene-derived protein sequences aligned using ClustalW software (MegAlign) arranged into phylogenetic groupings.

10 [0204] Approximately 0.6 micromole of each of 652 of the 20mers was provided. Two marker 20mer peptides were included in each set of 96 (VLQQHNIAHGSSQVLQESTY - peptide 161, and IKDFHVVYFRESRDALWKGPG) and were characterized by reverse phase-HPLC and amino acid sequence analysis. Average purities of these marker peptides were 19% and 50%, respectively. Peptides were initially dissolved in acetonitrile (10%) and Hepes 100mM to 10mg/ml. The final concentration of individual peptides incubated with PBMC for the IFN $\gamma$  ELISpot assays was 20 mcg/ml. These peptides were deamidated by incubation with guinea pig tissue tTG (Sigma T5398) in the ratio 100:32 mcg/ml for two hours at 37°C. Peptides solutions were stored at -20°C and freshly thawed prior to use. These studies were conducted in Oxford, UK. ELISpot assays were performed as described for those conducted in Melbourne, Australia (all other studies described herein). "Oxford" data regarding subject responses to individual peptides was pooled with "Melbourne" data for subsequent "minimal" epitope analysis in the "EM algorithm" (see below).

25 ***Second round gliadin epitope screening library***

[0205] A second round gliadin epitope library was designed according the bioactive sequences identified from the initial gliadin epitope screening library of 652 20mers. Gliadin 20mers with mean bioactivity equivalent to >5% of the most potent gliadin 20mer (91: PQQFPPQLPYPQQLPYPQP) in 15 HLA-DQ2+ subjects assessed with all 652 deamidated 20mers were defined. Since earlier studies (see WO 03/104273) indicated that deamidated pools of this Pepset were more potent than without deamidation, glutamine residues within bioactive 20mers potentially deamidated by tTG were identified according to the motif QXPX, QXZ (FYWILVM) where X is any amino acid except proline, and P is proline, Z is any amino acid, and FYWILVM represent hydrophobic amino acids (consistent with the motifs for tTG-mediated deamidation published by Vader W. et al J Exp Med 2002 J. Exp. Med. 195:643-649, PCT WO 03/066079, and Fleckenstein B. 2002. J Biol Chem 277:34109-16).

30 [0206] 12mer peptides were then identified in which each potential deamidation site could be in position 4, 6 or 7 in the 9mer located within HLA-DQ2 binding groove (HLA-DQ2 anchors at these positions show a preference for glutamate). Candidate 12mer core epitope sequences were then flanked with glycine followed by the N-terminal residue present in the parent gliadin polypeptide and at the C-terminal by the C-terminal residue present in the parent gliadin polypeptide followed by glycine (i.e. GXXXXXXXXXXXXXXXXG).

35 [0207] Peptides were synthesised with glutamine or glutamate in position 9. Peptides (100mcg/ml) (+/- deamidation by tTG) were then assessed in interferon gamma ELISPOT assays using PBMC from 15 HLA-DQ2+ coeliac volunteers after gluten challenge. Results of these assays were analysed according to the EM algorithm (see below). In addition, the most potent distinct peptides were synthesised and purified to >80% (Mimotopes) and assessed in interferon gamma ELISPOT assays using PBMC from 15 HLA-DQ2+ coeliac volunteers after wheat gluten challenge.

45 ***Complete gluten epitope screening library***

[0208] To make practical the design of a substantially larger peptide library spanning all wheat gliadin and glutenin, rye, barley, and oat gluten-like proteins (prolamines), and to confirm data from the previous gliadin peptide library, an iterative algorithm was developed to automate design of a minimal set of 20mers including all unique 12mers (excluding signal peptide sequences) in gluten proteins. The ScanSet algorithm is shown in Figure 1.

50 [0209] The method tests for all possible peptide epitopes from a group of proteins whether they are potential antigens in a range of patients. T-cell epitopes range in size between 9 and 15 AA. To test all possible 12mers in a set of proteins, becomes quickly unfeasible because of the high numbers.

55 [0210] Here we use the fact that, for example, a 20mer peptide can cover up to 9 different 12mers. We therefore developed a combinatorial approach to cover all possible 12mers represented in a family of proteins.

[0211] 20 amino acid (20mer) long peptides are generated that are tested as antigens, and that cover all 12mer peptide

sequences that exist in the group of proteins. We define the length of peptides to generate as  $L$  (e.g. 20) and the length of the epitopes we want to cover as  $S$ . We developed a computer program that generates all uniquely occurring  $L$ mers from a set of proteins. Further, we generate all uniquely occurring  $S$ mers from this set of proteins. Next we select a set of  $N$   $L$ mers that contains all sequences of  $L$ mers. Figure 1 outlines how this algorithm works.

**[0212]** On 16 June 2003, Genbank contained accession numbers for 53 alpha/beta, 53 gamma and 2 omega gliadins, and 77 LMW and 55 HMW glutenins from *T. aestivum*, 59 hordeins, 14 secalins, and 20 avenins (see Figure 2). In total, ScanSet identified 18117 unique 12mers contained in the 225 gluten gene products.

**[0213]** All unique gluten 12mers could be subsumed in 2922 20mers. These 20mers were synthesised in a Pepset peptide library (Mimotopes Inc., Melbourne, Australia). Pepset peptides were synthesized in batches of 96 (Mimotopes Inc., Melbourne Australia). Approximately 0.7 to 1.3 micromole of each of 2922 20mers was provided. Two marker 20mer peptides were included in each set of 96 (one representative peptide from the 94 other peptides on each particular plate, and IKDFHVFRESRDALWKGPG) and were characterized by reverse phase-HPLC and mass spectroscopy. Average purities of these marker peptides were 36% (range: 5-68%) and 64% (range:55-71 %), respectively.

**[0214]** Peptides were initially dissolved in aqueous acetonitrile (50%). Peptides in aqueous acetonitrile were transferred to sterile 96-well plates and diluted in sterile PBS with 1mM calcium (250 mcg/ml) and then incubated with tTG (25 mcg/ml) (Sigma T5398) for 6h 37°C and then stored frozen (-20°C) until use.

**[0215]** Subjects all had biopsy-proven coeliac disease and had followed a strict gluten free diet for at least 6 months. All subjects possessed *HLA-DQB1\*02* (HLA-DQ2) alone (n=100) or *HLA-DQA1\*03* and *HLA-DQB1\*0302* (HLA-DQ8) alone (n=5). In all cases, tTG-IgA was assessed before gluten challenge and was in the normal range (30% of initial volunteers were found to have elevated tTG-IgA and were excluded since chronic gluten exposure is associated with failure to induce peripheral blood gluten-specific T-cells by short-term gluten challenge). Volunteers consumed Baker's Delight "white bread block loaf" (200g daily for three days) or Uncle Toby's oats (100g daily for three days). All but three subjects completed the three day challenge (one withdrew after first mouthful of bread, and the other two vomited after initial two slices of bread. Data from the latter two were included in subsequent analysis). Blood (300ml) was drawn six days after commencing gluten challenge. Gluten peptide-specific IFN $\gamma$  ELISpot responses have not been found in our previous studies, and so "pre-challenge" blood was not assessed in this set of experiments (Anderson, RP et al 2000. Nat. Med. 6:337-342., WO 01/25793, WO 03/104273).

**[0216]** IFN $\gamma$  ELISpot assays (Mabtech, Sweden) were performed in 96-well plates (MAIP S-45, Millipore) in which each well contained 25 $\mu$ l of peptide solution and 100 $\mu$ l of PBMC (2-8x10<sup>5</sup>/well) in RPMI containing 10% heat inactivated human AB serum. After development and drying, IFN $\gamma$  ELISpot plates were assessed using the MAIP automated ELISpot plate counter. Data was then analysed according to a novel algorithm (Expectation Maximization: EM) to define and quantify interferon-gamma responses to 9mer sequences contained within the peptide library (see Figure 3 and below). 9mer peptides were then rationalised according to an algorithm that assumes redundancy in T-cell recognition, the "IterativeCluster" algorithm (see Figure 4 and below), by allowing groups of amino acids with similar chemical properties at any one position in the 9mer, or for glutamate to replace glutamine at any position (assuming deamidation may have occurred).

**[0217]** Since there were data sets from only two HLA-DQ8+ individuals who were not also HLA-DQ2+, and these were utilizing only the 721 wheat gliadin 20mers from the "Complete gluten epitope screening library", bioactive peptides were identified by taking the average rank of peptide-specific IFN $\gamma$  ELISPOT responses in the two subjects. For prediction of likely HLA-DQ8-restricted gliadin epitopes, it was assumed that a glutamine residue susceptible to tTG-mediated deamidation occupied either position 1 or 9 in potential 9mer core regions of epitopes, consistent with the HLA-DQ8 binding motif and the findings of van de Wal et al (van de Wal, Y. et al 1998. J. Immunol. 161(4):1585-1588).

#### ***Expectation Maximization (EM) algorithm to analyze data from ELISpot:***

**[0218]** Figure 3 shows an algorithm to analyze data coming from an assay using the ELISpot. T-cell responses to different peptides are measured in 96 well plates using T-cell assays. Assays are performed on many patients using many different peptide antigens. The result of the T-cell assays can be summarized in a table where the rows represent peptides and the columns patients and the individual measurements (counts) are in the table (e.g., see Figure 3B). The purpose of the EM algorithm is to differentiate between response and non response of a patient to a peptide and to estimate a mean rate of response and a proportion of people responding for each peptide.

**[0219]** Responses are measured for a number of different patients ( $i$  will be used to indicate the patient) and for many different peptides ( $j$  will be used to indicate the peptide). Each measurement ( $y_{ij}$ ) represents a count of T-cells from patient  $i$  responding to peptide  $j$ . In order to estimate, whether a measurement for a certain peptide in a patient can be called a response or whether it is more likely to be coming from a background distribution, we propose a model for an incomplete data problem, with  $y_{ij}$  being the observed count of spots and  $z_{ij}$  an unobserved indicator, whether person  $i$  responds to peptide  $j$ .

**[0220]** The observed number of counts  $y_{ij}$  are modelled to come from independent Poisson distributions:  $\text{poisson}(\alpha_i$ ,

$\lambda_j$ ), if patient  $i$  is responding to peptide  $j$ , i.e.  $z_{ij} = 1$ , and  $\text{poisson}(\alpha_i, \lambda_0)$ , if patient  $i$  is not responding to peptide  $j$ , i.e.  $z_{ij} = 0$ .

- Complete data:  $y_{ij}$  (observed counts),  $z_{ij}$  (response indicator, not observed).
- Parameters:  $\theta = (\alpha_i, \lambda_j, \lambda_0, p_j)$
- $\alpha_i$ : Patients overall responsiveness.
- $\lambda_j$ : Peptide induced rate of response.
- $\lambda_0$ : Background rate of response.
- $p_j$ : Proportion of people responding to peptide  $j$ .

EM algorithm:

#### [0221]

- Set variables initially to random values
- E-step: compute likelihood
- M-step: maximize likelihood function
- Iterate E- and M-step

#### *Iterative procedure to find minimal set of responsive epitopes*

[0222] A program to compute a minimal set of peptides for use in a vaccine based on the T-cell responses estimated in the EM algorithm was developed. We measured T-Cell responses to Lmers from a group of proteins. The peptides were generated to cover all possible Smers. We estimated the following parameters for the response by an EM algorithm: rate of response, number of people responding, proportion of people responding. The proportion of people responding multiplied with the estimated rate of response is used as a criterion to define epitopes which are good antigens. Many of the measured Lmers contain the same Smer epitopes. In order to find the epitopes (Smers) which can explain all the responses in Lmers we select the Smer which is contained in Lmers that in the mean have the highest responses. Then we remove all Lmers that contain this Smer from our measurements. Next we select the Smer with the highest responses in the remaining Lmers. We iterate this procedure until no Smers with responses higher than a specified cutoff exist. We use several iterations with different cutoffs. This process is sketched in Figure 4. The such defined list of clustered Lmers can be used as a basis to define the optimal epitopes and select peptides that function as good antigens.

#### *HLA-DQ2 epitopes in wheat gluten*

[0223] HLA-DQ2 epitopes in wheat gliadins and glutenins were identified using PBMC collected on day 6 after commencing gluten challenge in a total of 76 HLA-DQ2+ individuals in gamma-interferon ELISPOT assays (Initial gliadin epitope library: n=15, Second round gliadin epitope screening library: n=15, Complete gluten epitope screening library: n= 46). All data relating to individual peptide responses in coeliac subjects was pooled and analysed by the EM algorithm.

[0224] A series of 9mer sequences were identified and ordered according to the intensity of gamma-interferon responses and the proportion of individuals responding (see Figure 5). Many of the sequences identified could be grouped in "superfamilies" allowing for several different amino acids with similar chemical properties to be present at any one position in the putative epitope (see Figure 6). For example, in "Sequence 1" of Figure 6 (SEQ ID NO: 1555) P (QR) P (QE) LP (FY) PQ, glutamine (Q) or arginine (R) are both accepted at position 2 except that Q generates a substantially more bioactive epitope.

[0225] By reviewing the 110 most "active" 9mer sequences identified by the EM algorithm, the "list" of 9mer motifs could be condensed to 41 9mers, many of which overlapped (for example "Sequence 1" and "2" (SEQ ID NOS: 1555 and 1558 respectively) overlap by 7 residues and are both present in A-gliadin 57-73 QE65). In selected cases, high-grade peptides were synthesised and confirmed the bioactivity of peptides identified by the EM algorithm (see Figure 7).

#### *HLA-DQ2 epitopes in oats avenins*

[0226] Avenin peptides were assessed after challenge with oats (n=30 subjects) or after wheat bread (n=8) in HLA-DQ2+ coeliac subjects. ELISPOT responses were found for the peptides found in Figure 8. One of the reactive avenin peptides was homologous to a sequence in wheat gluten (SEQ ID NO: 1590).

#### *Oats (avenin) high quality peptide studies*

[0227] High grade avenin peptides were assessed 3 days after completing oats challenge with pure wheat-free oats,

## EP 2 412 380 A1

100g/d for 3 days ("day 6" PBMC interferon gamma ELISPOT responses). These peptides were designed upon peptides previously defined using the screening grade ("first round") avenin peptide library and on potential deamidation sites. There were 25 peptides (as 16mers) with purity verified by HPLC as >80%, and sequences confirmed by mass spectroscopy.

5 **[0228]** Interferon gamma ELISPOT responses to the high grade avenin peptides following deamidation by tTG were compared in 18 subjects with DQ2+ coeliac disease.

**[0229]** The dominant (>70% maximal response) peptides after oats challenge included: EQQFGQNIFSGFVSQQL (SEQ ID NO: 1764) (11/18 subjects), QLRCPAIHSVVQAAIL (SEQ ID NO: 1765) (4/18 subjects), and QYQPYPEQEQPILQQQ (SEQ ID NO: 1766) (3/18 subjects). 2/18 subjects did not have avenin specific responses (defined by SFU (spot forming units) > 3 X blank) and 6/18 subjects mean maximal SFU were less than 10. Two additional peptides elicited positive responses: QIPEQLRCPAIHSVVQ (SEQ ID NO: 1767) (3/18 subjects) and EQYQPEQQPFMQPL (SEQ ID NO: 1768) (>40% maximal peptide response in 5/18 subjects). The panel of 25 peptides included several peptides similar to peptide 1490 (SEQYQPYPEQQEPFVQ) reported in Arentz-Hansen, PLoS Medicine (Oct. 2004, vol. 1, issue 1 (84-92), however, that peptide induced a strong positive response in only one subject, and far weaker response in 5 subjects.

15 **[0230]** Interferon gamma ELISPOT responses to high grade avenin peptides were absent prior to gluten challenge, and were blocked by pre-treatment of PBMC with anti-HLA DQ but not anti-HLA DR antibody.

### *Rye and barley screening peptide libraries*

20 **[0231]** Secalin and hordein 20mer first round peptide libraries were assessed 3 days after completing rye (bread, 100g/d for 3 days) or barley (boiled, 100g/d for 3 days) challenge ("day 6" PBMC interferon gamma ELISPOT responses). Although iterative analysis using 2nd and 3rd round peptide libraries to define epitopes has not yet been performed, the 20mers pre-treated with tTG found to induce "potent" responses shared substantial structural similarity to the bioactive peptides identified after wheat challenge. However, the dominant peptide sequences after rye or barley challenge did not include peptides with the PQPQLPY sequence found to be dominant after wheat challenge. The dominant (>70% maximal response) 20mer after rye challenge was usually PQLFLPQQPFPPQPQQPFP (SEQ ID NO: 1769) (8/14 subjects), or occasionally QFPFPQQPTPIQPQQPFPQ (SEQ ID NO: 1770) (4/14), QQPQLFPQTQQSSPQQPQQ (SEQ ID NO: 1771) (1/14), PQTQQPQQPFPPQPQQQLF (SEQ ID NO: 1772) (1/14) and/or QEQREGV-QILLPQSHQQLVG (SEQ ID NO: 1773) (1/14). Additional peptides noted for greater than 40% maximal response in at least 1 subject include:

35 FPQQPQQPFPQPQQQLPLQP (SEQ ID NO: 1774) (3/14, 2 > 70%)  
PQQPFPQQPEQI IPQQPQQP (SEQ ID NO: 1775) (5/14, 3 > 70%)  
QQLPLQPQQPFPQPQQPIQ (SEQ ID NO: 1776) (6/14, 2 > 70%)  
40 QQPQQPFPQPQQPVPQQPQ (SEQ ID NO: 1777) (3/14, 1 > 70%)  
SIPQPQQPFPQPQQPFPQSQ (SEQ ID NO: 1778) (4/14, 1 > 70%)  
QTQQSIPQPQQPFPQPQQPF (SEQ ID NO: 1779) (3/14, 1 > 70%)  
NMQVGPSPQVWPQQQLPQ (SEQ ID NO: 1780) (2/14, 1 > 70%)  
VGPSGQVSWPQQQLPQPQQ (SEQ ID NO: 1781) (2/14, 2 > 70%)  
45 QQPFLQPQQPFSQPQQPFL (SEQ ID NO: 1782) (1/14, 1 > 70%)  
FPLQPQQPFPQQPEQI ISQQ (SEQ ID NO: 1783) (5/14, 1 > 70%)  
PQQPQRPFPAQQPEQI ISQQP (SEQ ID NO: 1784) (3/14, 1 > 70%)  
SPQQPQLPFPQPQQPFVVVV (SEQ ID NO: 1785) (4/14, 1 > 70%)  
QQPSIQLSLQQQLNPCKNVL (SEQ ID NO: 1786) (1/14, 1 > 70%)

**[0232]** Typically, the dominant peptides after barley challenge included one of six peptide motifs, or were one of eight other individual 20mers "dominant" in only one of 17 subjects after barley challenge. The six motifs identified:

50 QQPIPQQPQPY (SEQ ID NO: 1787)  
PFPQPQQPFPW (SEQ ID NO: 1788)  
LQPQQPFPQ (SEQ ID NO: 1789)  
PQPQQASPL (SEQ ID NO: 1790)  
I I PQQPQQPF (SEQ ID NO: 1791)  
55 YPEQPQQPF (SEQ ID NO: 1792)

**[0233]** The barley hordein peptides showing at least 40% maximal peptide response in at least one subject include the following, wherein an asterisk indicates the eight individual peptides showing maximal response in a single individual:

## EP 2 412 380 A1

QQQPFQIPQQPYPYQQ (SEQ ID NO: 1793) (8/17, 2 > 70%)  
QQPQFSQQIPQQPYPYQ (SEQ ID NO: 1794) (9/17, 8 > 70%)  
PQQVPQQPYPYQQPFP (SEQ ID NO: 1795) (5/17, 1 > 70%)  
5 PQQPQIPQQPYPYQQP (SEQ ID NO: 1796) (6/17, 2 > 70%)  
YPQQPFPQQIPQQPYPY (SEQ ID NO: 1797) (6/17, 2 > 70%)  
QPYPQQPYPYQQPFPQ (SEQ ID NO: 1798) (7/17, 2 > 70%)  
QPQQPFPQQPVPQQPYPY (SEQ ID NO: 1799) (5/17, 2 > 70%)  
PQYPQQPFPQQPFCQQ (SEQ ID NO: 1800) (1/17, 1 > 70%)\*  
10 QFPQQPFPWQQPFPQ (SEQ ID NO: 1801) (10/17, 2 > 70%)  
PFPQQPFPQQPFRQQ (SEQ ID NO: 1802) (6/17, 3 > 70%)  
WQQPFPQQPFLQPQQ (SEQ ID NO: 1803) (9/17, 5 > 70%)\*  
PWQQPFPQPEIPQQPQ (SEQ ID NO: 1804) (1/17, 1 > 70%)  
QQPFPQQPIYQPQPFN (SEQ ID NO: 1805) (5/17, 1 > 70%)  
15 PQQPFPQQPFSWQPQ (SEQ ID NO: 1806) (6/17, 2 > 70%)\*  
QPQQPFPQQPIYQPQQP (SEQ ID NO: 1807) (4/17, 1 > 70%)\*  
QSQQPFPQQPFPQQP (SEQ ID NO: 1808) (1/17, 0 > 70%)  
PFPQQPFSWQQPFLQP (SEQ ID NO: 1809) (1/17, 0 > 70%)  
FPQPEFPQQPFPFLQP (SEQ ID NO: 1810) (1/17, 0 > 70%)  
20 PFPQQPFWQQPFPQ (SEQ ID NO: 1811) (6/17, 0 > 70%)  
FPQYQIPTLPQQPFPQQP (SEQ ID NO: 1812) (2/17, 1 > 70%)  
FPLQQPFPQQPFPQQ (SEQ ID NO: 1813) (1/17, 0 > 70%)  
QQPFLQPQQPFPQ (SEQ ID NO: 1814) (1/17, 0 > 70%)  
SPLQQPFPQSEQI IPQQ (SEQ ID NO: 1815) (1/17, 0 > 70%)  
PQASPLQPQQASPLQPQ (SEQ ID NO: 1816) (1/17, 1 > 70%)  
25 PQQPFWQQPFPQQPFL (SEQ ID NO: 1817) (1/17, 1 > 70%)\*  
PVLSQQPCTQDQTPLLQEQ (SEQ ID NO: 1818) (1/17, 1 > 70%)  
RQLPKYI IPQQPFPFLQP (SEQ ID NO: 1819) (1/17, 1 > 70%)  
QGSEQIIPQQPFPPLQPH (SEQ ID NO: 1820) (7/17, 3 > 70%)\*  
PQGSEQIIPQQPFPPLQPF (SEQ ID NO: 1821) (2/17, 1 > 70%)  
30 QPFPFPQFFPYPQQTFPP (SEQ ID NO: 1822) (4/17, 1 > 70%)  
PFPQQQKYEQPFPFW (SEQ ID NO: 1823) (1/17, 1 > 70%)  
QKYPEQQPFPWQQPTIQL (SEQ ID NO: 1824) (1/17, 1 > 70%)  
FQQPQSYVPQQPFPQ (SEQ ID NO: 1825) (3/17, 1 > 70%)  
QIPYVHPSILQLNPKVFL (SEQ ID NO: 1826) (1/17, 1 > 70%)  
35 LAAQLPAMCRLEGGGGLLAS (SEQ ID NO: 1827) (1/17, 1 > 70%)  
PYLPEELSPYQIPTLPQPQ (SEQ ID NO: 1828) (1/17, 1 > 70%)\*  
VSPHPGQTTVSPHQGQTT (SEQ ID NO: 1829) (1/17, 1 > 70%)\*

### ***Second and third round wheat glutenin and gliadin peptide libraries***

40 **[0234]** The second round wheat gliadin and glutenin library was designed upon the sequences of 20mer wheat gliadin and glutenin peptides that induced at least 5% of the response (interferon gamma ELISPOT) stimulated by the most active transglutaminase (tTG) pre-treated (enzymatically deamidated) 20mer peptide in any subject. All 2nd round 16mer peptides were assessed in at least 18 subjects. The 2nd round library generated from the "Oxford" gliadin 20mer library had been assessed in ten subjects - this data was merged with data generated from the 18 subjects used to assess the new 2nd round (expanded) gliadin/glutenin library. Hence, individual 16mer peptides pre-treated with transglutaminase were assessed in either 18 (novel gliadin/glutenin sequences based on "Melbourne" 20mer library) or 28 subjects (gliadin sequences based on "Oxford" 20mer library). All 16mers identified for the second round Oxford library also fulfilled the selection criteria for the Melbourne second round library.

50 **[0235]** The second round peptide library data was analysed according to the "dominance" of peptide responses in the interferon gamma ELISPOT in individual subjects i.e. the percent response of an individual's PBMC to a specific peptide normalized against that individual's maximal peptide-induced response. Sequences of peptides that stimulated at least 40% of the maximal peptide-specific response in at least one subject are shown in Table I below. The dataset supports the consistency and "dominance" of peptides conforming to the sequences identified using the first round 20mer peptide library using the Expectation Maximization (EM) algorithm described above.

55

EP 2 412 380 A1

Table 1: Peptides confirmed in Second Round Library as at least 40% as active as the peptide with maximal activity in any one subject: Ranked according to potency of peptide family

Peptide	SEQ ID NO:	>70%	40-70%	10-40%	<10%
G- <b>QLPYPQPQLPYPQP-G</b>	1830	18/28	4/28	3/28	3/28
G-LQPFPQPQLPYPQP-G	1831	14/28	8/28	Nil	6/28
G-LQPFPQPQLPFPQP-G	1832	4/28	8/28	5/28	10/28
G-LQPFPQPQLPYLQP-G	1833	1/28	1/28	12/28	14/28
G-LQPFPQPQLPYSQP-G	1834	2/28	3/28	12/28	11/28
G-LQPFPQPQLSYSQP-G	1835	Nil	1/28	2/28	25/28
G- <b>QQPFPQPQQPFPWQ-G</b>	1837	9/28	8/28	5/28	6/28
G-QQPFPQPQQPIPVQ-G	1838	8/28	5/28	7/28	8/28
G-QQPFPQPQQPFSQQ-G	1839	4/28	7/28	8/28	9/28
G-QQPFPQPQQPFCQQ-G	1840	2/28	2/28	13/28	11/28
G- <b>GLERPWQQQLPPQ-G</b>	1841	2/18	1/18	Nil	15/18
G- <b>QTFPHQPQQAFPQP-G</b>	1842	1/28	2/28	Nil	25/28
<b>LQQQCSPVAMPQRLAR</b>	1843	1/28	1/28	11/28	15/28
<b>QGQQGYYPISPQQSGQ</b>	1844	1/18	1/18	1/18	15/18
PGQGQSGYYPTSPQQS	1845	1/18	1/18	Nil	16/18
QGQPGYYPTSPQQIGQ	1846	1/18	1/18	1/18	15/18
GQGQSGYYPTSPQQSG	1847	1/18	Nil	2/18	15/18
QQGYPTSPQQSGGQ	1848	Nil	1/18	Nil	17/
QGQQGYPTSPQQPPQ	1849	Nil	1/18	Nil	Nil
QQGYYPISPQQLGQGQ	1850	Nil	1/18	Nil	Nil
<b>YVPPDCSTINVPYANI</b>	1851	1/18	1/18	1/18	15/18
<b>IIMQQEQQEQRQGVQI</b>	1852	1/28	Nil	8/28	19/28
VAHAIIIMHQQQQQQQE	1853	Nil	1/28	2/28	25/28
G- <b>QPIPQQPQPFPLQ-G</b>	1854	1/28	Nil	5/28	
G- <b>FPQLQQPQQPFPQQ-G</b>	1855	1/28	Nil	1/28	26/28
G-FPQTQQPQQPFPQQ-G	1856	Nil	1/28	2/28	25/28
G-QPLSQPQQTFPQQ-G	1857	Nil	1/28	Nil	27/28
G-QQPQQPQQPFPQQ-G	1858	Nil	1/28	5/28	22/28
G-FPQPQQPQQPFPQQ-G	1859	Nil	1/28	3/28	25/28

EP 2 412 380 A1

(continued)

	Peptide	SEQ ID NO:	>70%	40-70%	10-40%	<10%
5	G-FPQPQQPQQSFPQQ-G	1860	Nil	1/28	1/28	26/28
	G- <b>QPQQTFPQQPQLPF</b> -G	1861	1/18	Nil	2/18	15/18
10	G- <b>MQVDPSGQVQWPQQ</b> -G	1862	1/18	Nil	Nil	17/18
	G-IQVDPSGQVQWPQQ-G	1863	1/18	Nil	Nil	17/18
15	G- MQADPSGQVQWPQQ-G	1864	1/18	Nil	Nil	17/18
	G-MQVDPSGQVQWPQQ-G	1865	1/18	Nil	Nil	17/18
	<b>G-QQEQQILQQILQQQ</b> -G	1866	1/18	Nil	Nil	17/18
20	<b>VPLYRTTTSVPGVGT</b>	1867	1/18	Nil	Nil	17/18
	<b>LQTLPSMCNVYIPPYC</b>	1868	1/18	Nil	Nil	17/18
	LALQTLPAMCNVYIPP	1869	1/18	Nil	Nil	17/18
25	<b>DAIRAIYSIVLQEQQ</b>	1870	1/18	Nil	Nil	17/18
	G- <b>QQQFSQPQQQFPQP</b> -G	1871	Nil	5/28	7/28	16/28
	G-FFPQPQQQFPQPQQ-G	1872	Nil	1/28	10/28	17/28
30	G-FPQPQQQFPQPQQ-G	1873	Nil	1/28	Nil	27/28
	G-QQFPQPQQQFPQP-G	1874	Nil	1/28	12/28	15/28
35	G- <b>QPQPFLPQLPYPQP</b> -G	1875	Nil	4/28	9/28	15/28
	G- <b>QQPFPQPQQQLPQP</b> -G	1876	Nil	3/28	6/28	19/28
40	G-LPFPQPQQPLPQP-G	1877	Nil	2/18	4/18	12/18
	G- <b>QQAFPQPQQTFPHQ</b> -G	1878	Nil	3/28	8/28	17/28
45	G-QQPFTQPQQPTPIQ-G	1879	Nil	1/28	4/28	23/28
	G-QQIFPQPQQTFPHQ-G	1880	Nil	1/28	10/28	17/28
	G- <b>QQQFIQPQQPFPQQ</b> -G	1881	Nil	2/28	11/28	15/28
50	G-QPFPLQPQQPFPQQ-G	1882	Nil	2/28	7/28	19/28
	G-QPFPWQPQQPFPQQ-G	1883	Nil	2/28	8/28	18/28
55	G-QPTPIQPQQPFPQQ-G	1884	Nil	2/28	5/28	21/28
	G- <b>QVSFQQPQQQYPSP</b> -G	1885	Nil	2/28	4/28	22/28

EP 2 412 380 A1

(continued)

Peptide	SEQ ID NO:	>70%	40-70%	10-40%	<10%
G-FFQQPQQQYPSSQQ-G	1886	Nil	1/28	1/28	26/28
G-GKSQVLQQSTYQLL-G	1887	Nil	2/18	1/18	15/18
GQVVNNHGQTVFNDIG	1888	Nil	1/18	4/18	
G-QPQLPFPQQPQQQF-G	1889	Nil	1/28	2/28	25/28
G-QPFPQPQAQLPFP-G	1890	Nil	1/28	2/28	25/28
G-HQQPGQRQQGYYPT-G	1891	Nil	1/18	1/18	16/18
G-HQQFPQQIPVVQP-G	1892	Nil	1/18	1/18	16/18
LEAVTSIALRTLPTMC	1893	Nil	1/18	1/18	
G-QQPQFSQQQIPVI-G	1894	Nil	1/18	Nil	17/18

[0236] The third round peptide library consisted of 74 peptides based upon structurally distinct sequences in the second round library found to induce at least 10% of the maximal response to any peptide in any subject. These peptides corresponded to wild-type (non-deamidated) sequences virtually identical to those used in the second round library. The distinct feature of this library was that it consisted of peptides with purity verified by HPLC as >80%, and with sequences confirmed by mass spectroscopy.

[0237] Interferon gamma ELSIPOT responses to the 3rd round library peptides following deamidation by tTG were compared in 14 subjects. Once again, sequences including the PQPQLPY motif were "dominant" in 9/14 subjects. However PFPQPQQPFPW (SEQ ID NO: 1895) stimulated >70% of maximal response in 1/14 subjects, PFPQQPQQPFPQ (SEQ ID NO: 1896) in 1/14, PQPFLPQLPYPQP (SEQ ID NO: 1897) in 1/14, QPFPQPQQPQQP (SEQ ID NO: 1898) in 4/14 (including 3 subjects in whom PQPQLPY peptides were not potent epitopes) SGQGVSSQSQSQSQ (SEQ ID NO: 1899) in 2/14 (including one in which PQPQLPY peptides were not potent), QYEVIRSLVLRTPNM (SEQ ID NO: 1900) and GLARSQMLQQSICHVG (SEQ ID NO: 1901) each in one (the same) subject in whom PQPQLPY peptides were not potent epitopes, RTTTSVPFGVGTGVGA (SEQ ID NO: 1902) in 1/14 subjects and AIHTVIHSI IMQQEQQ (SEQ ID NO: 1903) in 1/14 subjects.

[0238] Many of the sequences tested in third round were structurally related and individual subject's responses were present or absent according to the "relatedness" of certain sequences, suggesting redundancy of peptides recognized by gluten specific T cells induced by in vivo gluten challenge.

[0239] Interferon gamma ELISPOT responses to 3rd round peptides were absent before gluten challenge, and were blocked by pre-treatment of PBMC with anti-HLA DQ but not HLA DR antibody.

**Combitopes**

[0240] The issue of epitope redundancy and the potential utility in diagnostics and therapeutics of peptides designed to combine "unique" dominant epitopes was addressed by comparing interferon gamma ELISPOT responses after wheat (n=16 HLA DQ2 coeliac disease subjects), rye (n=17) or barley (n=13) challenge to the sequences: QLQPF-PQPELPYPQPQL (SEQ ID NO: 1904) ("P04724E"), QPEQPFPQPEQPFPWQP (SEQ ID NO: 1905) ("626fEE"), and QLQPF-PQPELPYPQPFPQQPEQPFPQPEQPFPWQP (SEQ ID NO: 1906) ("Combitope"). After rye and barley challenge the sum of the median ELISPOT responses (spot forming units) to P04724E and 626fEE were almost identical (99%, and 102%, respectively) to the response to a similar (optimal) concentration of the Combitope. However, after wheat challenge (n=16 subjects), median P04724E response was 89% of that to Combitope, and median 626fEE responses was 70% of the response to Combitope. These findings would be consistent with substantial redundancy of these related epitope sequences, P04724E and 626fEE, after wheat challenge but not after rye or barley, and that combining dominant epitope sequences within longer peptides does not reduce their biological availability. Hence, combitopes derived from selected potent epitopes may be efficient delivery devices for T cell epitope-based therapeutics and diagnostics in coeliac disease.

**Epitopes in wheat gluten associated with HLA-DQ8+ coeliac disease**

[0241] Epitopes in wheat gliadins were identified using PBMC after gluten challenge in two individuals, one HLA-DQ8 homozygous, and one HLA-DQ8 heterozygote. Induced T-cell responses in other HLA-DQ8 (not DQ2) coeliac individuals responded weakly to gluten challenge and their data did not allow detailed analysis.

[0242] Deamidated 20mers including the core sequence: QGSFQPSQQ (SEQ ID NO: 1907), corresponding to the known HLA-DQ8-restricted alpha-gliadin epitope (in which Q1 and Q9 are deamidated by tTG for optimal activity), induced moderately strong peptide responses. However, a series of "core" peptides were associated with more potent responses in 20mers derived from gamma and omega gliadins (see Figure 9). The most potent peptides possessed glutamine in a sequence that would suggest susceptibility to deamidation separated by seven residues from a second glutamine also susceptible to deamidation (as found in QGSFQPSQQ (SEQ ID NO: 1907)) suggesting that these deamidated sequences would become high affinity binders for HLA-DQ8 following deamidation by tTG. (The binding motif for HLA-DQ8 favours glutamate at positions I and 9.) A further group of 20mers possessed glutamine residues susceptible to deamidation but not separated by seven residues from a second glutamine susceptible to tTG-mediated deamidation.

**HLA DQ8 coeliac disease gliadin and glutenin epitopes**

[0243] Five subjects with coeliac disease that possess HLA DQ2 and HLA DQ8 alleles underwent wheat gluten challenge. PBMC from two subjects initially challenged were used to screen the first round "Melbourne" wheat gliadin 20mer library. The 20mer sequences identified using PBMC from these two HLA DQ8 CD subjects were dissected further by screening, in five HLA DQ8+ DQ2- CD subjects including the two original subjects, a second round library based on reactive 20mers in the 1<sup>st</sup> round library. The 2<sup>nd</sup> round library consisted of *screening grade* overlapping 16mers, and 13mers predicted to correspond to tTG-mediated deamidation products of epitopes with the potential for deamidation of glutamine at position 1 and/or position 9 (consistent with the HLA DQ8 peptide binding motif). In addition, the 1400 glutenin (HMW and LMW) tTG-pretreated 20mers in the "Melbourne" wheat gluten library were also screened in these five subjects.

[0244] The most potent and consistently dominant gliadin 16mers were the related sequences VYIPPYCTIAPFGIFG (SEQ ID NO: 1908) (3/5 subjects >70% response to maximal gliadin 16mer) and AMCNVYIPPYCAMAPF (SEQ ID NO: 1908) also dominant in 3/5 subjects (4/5 subjects produced dominant responses to one or both of these peptides). In addition, a series of peptides derived from previously identified bioactive 20mers whose responses in the ELISPOT were enhanced or permissive to specific glutamine residues being deamidated were identified: (QE) QPTPIQP (QE) (SEQ ID NO: 1909), (QE) QPFPLQP (QE) (SEQ ID NO: 1910), (QE)QPIPVQP(QE) (SEQ ID NO: 1911), (QE) QPQQPFP (QE) (SEQ ID NO: 1912), (QE) QP (QE) LP FP (QE) (SEQ ID NO: 1913), (QE) GS FQPSQ (QE) (SEQ ID NO: 1914) (previously published HLA DQ8 epitope, van der Wal 1998), (QE) LPFP (QE) QP (QE) (SEQ ID NO: 1915), and (QE) QP FP (QE) QP (QE) (SEQ ID NO: 1916).

[0245] Screening the glutenin 20mer library identified a further series of sequences that were dominant in at least one of the five subjects. Dominant 20mer peptides shared the motifs or had the sequences: PQQQQQLVQQQ (SEQ ID NO: 1917), QGIFLQPH (LQ) I (AS) QLEV (SEQ ID NO: 1918), QPGQGQQG (HY) Y (SEQ ID NO: 1919), QSRYEAIRAI (FY) S (SEQ ID NO: 1920), RTTTSVPFD (SEQ ID NO: 1921), QPPFWRQQP (SEQ ID NO: 1922), Q (PS) (PS) (FI) (PS) QQQQ (SEQ ID NO: 1923), (QPLR) GYYPTSPQ (SEQ ID NO: 1924) (previously identified HLA DQ8 epitope, van der Wal 2001), QGSYYPGQASPQ (SEQ ID NO: 1925), GYYPTSSLQPEQGQQGYPT (SEQ ID NO: 1926), and QGQQLAQQGQQQAQVQQG (SEQ ID NO: 1927). Glutenin peptides were assessed after pre-treatment with transglutaminase. Hence, the requirement for deamidation for these epitopes is not known.

[0246] A comprehensive library of "uncharacterised" screening grade peptides including all unique 12mer sequences encoded by genes present in Genbank defined as (bread making) wheat (*Triticum aestivum*), rye, barley, or oats gluten, gliadin, glutenin, secalin, hordein, or avenin have been assessed using T cells from HLA DQ2+ (and in some cases HLA DQ8+) coeliac disease volunteers six days after commencing in vivo gluten challenge. A relatively consistent pattern of epitope hierarchy has been identified in HLA DQ2 coeliac disease that is similar to but not identical after consumption of other grains toxic in coeliac disease. Peptides with the sequence PQPQLPY are dominant after wheat challenge in at least two thirds of HLA DQ2+ coeliac disease, but other epitopes are occasionally dominant while PQLPY peptides are essentially inactive in fewer than one in six HLA DQ2+ subjects with coeliac disease. The contribution of rare dominant epitopes will be better assessed after screening large numbers (e.g. >30) subjects (in progress). Epitope hierarchy after rye and barley consumption is similar to that after wheat with the exception that deamidated peptides similar to the gliadin/hordein/secalin sequences PQPQQPFP or PFPQQPQQP are usually dominant rather than PQPQLPY (a sequence unique to wheat alpha-gliadins). Combitepes that comprise serial and partially overlapping gluten epitopes are as active or more active than single epitopes alone and offer a means of efficiently delivering multiple gluten epitopes for T cell recognition. Such combitepes are therefore useful in design and delivery of peptide therapies in coeliac disease that target multiple unique T cell epitopes.

## REFERENCES

## [0247]

- 5 1. Molberg O, et al. Nature Med. 4, 713-717 (1998).
2. Quarsten H, et al. Eur. J. Immunol. 29, 2506-2514 (1999).
3. Greenberg CS et al. FASEB 5, 3071-3077 (1991).
4. Mantzaris G, Jewell D. Scand. J. Gastroenterol. 26, 392-398 (1991).
- 10 5. Mauri L, et al. Scand. J. Gastroenterol. 31, 247-253 (1996).
6. Bunce M, et al. Tissue Antigens 46, 355-367 (1995).
7. Olerup O, et al. Tissue antigens 41, 119-134 (1993).
8. Mullighan CG, et al. Tissue-Antigens. 50, 688-92 (1997).
9. Plebanski M et al. Eur. J. Immunol. 28, 4345-4355 (1998).
- 15 10. Anderson DO, Greene FC. The alpha-gliadin gene family. II. DNA and protein sequence variation, subfamily structure, and origins of pseudogenes. Theor Appl Genet (1997) 95:59-65.
11. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Van der Wal Y, Kooy YMC, Lundin KEA, Koning F, Roepstorff P, Sollid LM, McAdam SN. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med. 2000; 191:603-12.
- 20 12. Vader LW, de Ru A, van der Wal, Kooy YMC, Benckhuijsen W, Mearin ML, Drijfhout JW, van Veelen P, Koning F. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 2002; 195:643-649.
13. van der Wal Y, Kooy Y, van Veelen P, Pena S, Mearin L, Papadopoulos G, Koning F. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol. 1998; 161:1585-8.
14. van der Wal Y, Kooy Y, van Veelen P, Pena S, Mearin L, Molberg O, Lundin KEA, Sollid L, Mutis T, Benckhuijsen WE, Drijfhout JW, Koning F. Proc Natl Acad Sci USA 1998; 95:10050-10054.
- 25 15. Vader W, Kooy Y, Van Veelen P et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002, 122:1729-37 16. Arentz-Hansen H, McAdam SN, Molberg O, et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadin rich in proline residues. Gastroenterology 2002, 123:803-809.

30 **[0248]** Each of the PCT publications, U.S. patents, other patents, journal references, and any other publications cited or referred to herein is incorporated herein by reference in their entirety.

## Claims

- 35 1. A composition for use in a method of preventing, treating, or diagnosing coeliac disease, comprising at least one agent selected from:
  - 40 (a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of transglutaminase-deamidated SEQ ID NOs: 1787, 1793, 1794, 1796 and 1797; or
  - (b) a peptide which is capable of being recognised by a T cell receptor that recognises the peptide of (a) and which is not more than 50 amino acids in length.
- 45 2. A composition according to claim 1, wherein the agent is HLA-DQ2-restricted.
3. A composition according to claim 1, wherein the agent is HLA-DQ8-restricted.
4. A composition according to claim 1, wherein the agent comprises a barley epitope.
- 50 5. A composition according to claim 1, wherein the agent comprises a wheat epitope.
6. A pharmaceutical composition for use in a method of preventing, treating, or diagnosing coeliac disease, comprising an agent as defined in claim 1 and a pharmaceutically acceptable carrier or diluent.
- 55 7. A composition comprising an agent as defined in claim 1, for use in a method of preventing or treating coeliac disease by tolerising T cells which recognise the agent.
8. A composition comprising an agent as defined in claim 1, for use in a method of preventing or treating coeliac

disease by suppressing the production of an antibody which recognises the agent.

- 5
9. A composition comprising an agent as defined in claim 1, for use in a method of diagnosing coeliac disease, wherein the method comprises administering the agent to the skin of an individual and measuring the occurrence of inflammation at the site of administration.
10. A composition according to claim 1, comprising multiple agents comprising a combination of a wheat epitope, an oat epitope, a rye epitope, or a barley epitope.
- 10
11. A composition according to claim 10, comprising at least 2, 5, 10 or 20 agents.
12. A composition according to claim 11, wherein the agents comprise epitopes from 2, 3, 4 or more species selected from the panel of species consisting of wheat, rye, barley, oats, or triticale.
- 15
13. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:
- (a) contacting a sample from the individual with an agent as defined in claim 1; and
- (b) determining in vitro whether T cells in the sample recognise the agent, recognition by the T cells indicating that the individual has or is susceptible to coeliac disease.
- 20
14. A method according to claim 13, wherein the sample is a blood sample.
15. A method according to claim 13 or claim 14, wherein the T cells are not restimulated in an antigen specific manner in vitro before the said determining.
- 25
16. A method according to any one of claims 13 to 15, wherein the recognition of the agent by the T cells is determined by detecting the secretion of a cytokine from the T cells.
17. A method according to claim 16, wherein the cytokine is IFN- $\gamma$ .
- 30
18. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:
- (a) contacting a sample from the individual with an agent as defined in claim 1; and
- (b) determining in vitro whether an antibody in the sample binds to the peptide, such binding indicating that the individual has or is susceptible to coeliac disease.
- 35
19. A method of determining whether a food is capable of causing coeliac disease, comprising detecting the presence of an amino acid sequence which is capable of being modified by a transglutaminase to an agent as defined in claim 1, the presence of the amino acid sequence indicating that the food is capable of causing coeliac disease.
- 40
20. A method according to claim 19, wherein the amino acid sequence is detected by a binding assay in which the food is contacted with an antibody which specifically binds to the amino acid sequence.
21. An antibody for use in the method of claim 20, which specifically binds to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1787, 1793, 1794, 1796 and 1797.
- 45
22. A polynucleotide that comprises a coding sequence which encodes an agent as defined in claim 1.
23. A polynucleotide according to claim 22 that additionally comprises one or more regulatory sequences operably linked to the coding sequence, which regulatory sequences are capable of securing the expression of the coding sequence in a cell.
- 50
24. A transgenic non-human mammal which expresses a T cell receptor that recognises an agent as defined in claim 1.
- 55
25. A method of identifying a product which is therapeutic for coeliac disease, comprising administering a candidate substance to a mammal as defined in claim 24, which has or which is susceptible to coeliac disease, and determining whether the substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product.

**EP 2 412 380 A1**

**26.** A mutant gluten protein whose wild-type sequence can be modified by a transglutaminase to a sequence which is an agent as defined in claim 1, which mutant gluten protein comprises a mutation which prevents its modification by a transglutaminase to a sequence which is an agent as defined in claim 1; or a fragment of such a mutant gluten protein which is at least 7 amino acids long and which comprises the mutation.

5

**27.** A polynucleotide that comprises a coding sequence that encodes a protein or fragment as defined in claim 26.

**28.** A cell comprising a polynucleotide as defined in claim 27, or which has been transformed with such a polynucleotide.

10

**29.** A transgenic plant or plant seed comprising a plant cell according to claim 28.

**30.** A food that comprises a protein as defined in claim 26.

15

20

25

30

35

40

45

50

55

**Figure 1**




Figure 2

Alpha/beta gliadins (n=53)	Gamma gliadins (n=53)	LMW glutenins (n=77)	HMW glutenins (n=55)	Hordeins (n=59)	Secalins (n=14)	Avenins (n=20)
S07361	AAA34272	AAB35353	A03353	A24095.1	A23277	S29209
P18573	S07398	AAB48474	A24266	A25677	AAB37403	S29208
P04728	PS0094	AAB48475	A30843	AAA32942	AAB37404	S29207
P04727	P21292	AAB48476	AAA62315	AAA32943	AAB37405	S06455
P04726	P08453	AAB48477	AAB02788	AAA32944	AAB37406	P80356
P04725	P08079	AAB48478	AAB23624	AAA32955	AAB37407	P27919
P04724	P06659	AAB48479	AAB23625	AAA32967	AAB58403	P14812
P04723	P04730	BAA22613	AAB23626	AAA92333	AAG35598	JQ1048
P04722	P04729	BAA22614	AAB23627	AAB28161	CAA26449	JQ1047
P04721	JS0402	BAA23162	AAB23628	AAB71678	S18235	JQ1046
P02863	JA0153	BAB78737	AAD32223	AAB71679	S18236	JG0015
EEWTA	EEWTG	BAB78738	AAF23506	B24095	S70327	B36433
E22364	CAC94871	BAB78739	AAF23507	B25677	S70328	AAB32025
D22364	CAC94870	BAB78740	B30843	BAA11642	S70329	AAB23365
CAB76964	CAC94869	BAB78741	CAA26847	CAA25509		AAA32716
CAB76963	CAC94868	BAB78742	CAA27052	CAA25912		AAA32715
CAB76962	CAC11089	BAB78743	CAA31395	CAA25913		AAA32714
CAB76961	CAC11088	BAB78744	CAA31396	CAA25914		AAA32713
CAB76960	CAC11087	BAB78745	CAA32115	CAA26889		1502200A
CAB76959	CAC11080	BAB78746	CAA43331	CAA31861		1411172A
CAB76958	CAC11079	BAB78747	CAA43361	CAA37729		
CAB76957	CAC11078	BAB78748	CAA59340	CAA42642		
CAB76956	CAC11065	BAB78749	CAC40684	CAA48209		
CAB76955	CAC11064	BAB78750	CAC40685	CAA51204		
CAB76954	CAC11057	BAB78751	CAC40686	CAA59104		
CAA35238	CAC11056	BAB78752	CAC40687	CAA60681		
CAA26385	CAC11055	BAB78753	CAC83002	P02864		
CAA26384	CAB75404	BAB78754	CAC83003	P06470		
CAA26383	BAA11251	BAB78755	CAC83018	P06471		
CAA10257	AAN32705	BAB78756	CAC84118	P06472		
C22364	AAK84880	BAB78757	CAC84119	P17990		
BAA12318	AAK84780	BAB78758	CAC84120	P17991		
B22364	AAK84779	BAB78759	CAC84121	P17992		
AAN32704	AAK84778	BAB78760	CAC84122	P80198		
AAB23109	AAK84777	BAB78761	EEWTHW	S07189		
AAB23108	AAK84776	BAB78762	JC2099	S07365		
AAA96525	AAK84775	BAB78763	JC4966	S07975		
AAA96524	AAK84774	BAB78764	JN0689	S07976		
AAA96523	AAK84773	CAA30570	JN0690	S08312		
AAA96522	AAK84772	CAA31685	P02861	S18350		
AAA96276	AAF42989	CAA59313	P02862	S20519		
AAA34283	AAD30556	CAA59338	P08488	S52390.1		
AAA34282	AAD30440	CAA59339	P08489	T04369		
AAA34281	AAB31090	CAA59340	P10387	T04473		
AAA34280	AAA34289	CAA76890	P10388	T04474		
AAA34279	AAA34288	EEWT1	S02262	T05718		
AAA34278	AAA34287	P10385	S04832	T05737		
AAA34277	AAA34286	P10386	S15720	T06211		
AAA34276	AAA34285	P16315	S18733	1103203A		

AAA17741	AAA34274	S01992	S29176	1103203B		
A27319	1802407A	S04325	S29177	1103203C		
A22364	1507333A	S57645	S29178	1210226A		
1307187B	1209306A	S57654	S29179	1307151A		
	<b>Omega gliadins (n=2)</b>					
		S57655	AAN78346	1307151B		
	A59156	S57656	AAO74630	1604464A		
	AAG17702	T05910		A24095.2		
		T05923		AAP31051		
		T06505.1		CAA48209.2		
		T06505.2		S52390.2		
		T06506				
		T06508				
		T06980				
		T06981				
		T06982				
		AAP44992				
		AAP44991				
		AAP44989				
		AAO53259				
		CAD58622				
		CAD58619				
		CAD58621				
		A03353				
		AAO53264				
		AAO53265				
		AAO53266				
		AAO53267				
		CAA76890				
TOTAL:	All gliadins					
20mers	721	645	786	416	155	199
12mers	4465	3945	4799	2672	957	1279
9mers	3739	3164	3630	2413	811	1207

**FIGURE 3****Figure 3A****M-Step:**

$$\begin{aligned} \frac{dQ(\theta, \theta^{(c)})}{dp_j^{(c)}} = 0 & \rightarrow p_j^{(c+1)} = \frac{\sum_i \hat{z}_{ij}^{(c)}}{n} \\ \frac{dQ(\theta, \theta^{(c)})}{d\alpha_i^{(c)}} = 0 & \rightarrow \alpha_i^{(c+1)} = \frac{\sum_j [\hat{z}_{ij}^{(c)} y_{ij} + (1 - \hat{z}_{ij}^{(c)}) y_{ij}]}{\sum_j [\lambda_j^{(c)} \hat{z}_{ij}^{(c)} + \lambda_0^{(c)} (1 - \hat{z}_{ij}^{(c)})]} \\ \frac{dQ(\theta, \theta^{(c)})}{d\lambda_j^{(c)}} = 0 & \rightarrow \lambda_j^{(c+1)} = \frac{\sum_i \hat{z}_{ij}^{(c)} y_{ij}}{\sum_i \alpha_i^{(c)} \hat{z}_{ij}^{(c)}} \\ \frac{dQ(\theta, \theta^{(c)})}{d\lambda_0^{(c)}} = 0 & \rightarrow \lambda_0^{(c+1)} = \frac{\sum_{ij} (1 - \hat{z}_{ij}^{(c)}) y_{ij}}{\sum_{ij} \alpha_i^{(c)} (1 - \hat{z}_{ij}^{(c)})} \end{aligned}$$

**E-Step:**

$$\hat{z}_{ij}^{(c+1)} = E(z_{ij} | y_{ij}) = pr(z_{ij} = 1 | y_{ij}) = \frac{p_j^{(c)} pr(y_{ij} | \alpha_i \lambda_j^{(c)})}{p_j^{(c)} pr(y_{ij} | \alpha_i \lambda_j^{(c)}) + (1 - p_j^{(c)}) pr(y_{ij} | \alpha_i \lambda_0^{(c)})}$$

**Compute:**

$$\begin{aligned} Q(\theta, \theta^{(c)}) = \sum_{ij} \{ & \hat{z}_{ij}^{(c)} \log p_j + (1 - \hat{z}_{ij}^{(c)}) \log(1 - p_j) + y_{ij} \hat{z}_{ij}^{(c)} \log(\alpha_i \lambda_j) \\ & + y_{ij} (1 - \hat{z}_{ij}^{(c)}) \log(\alpha_i \lambda_0) - \hat{z}_{ij}^{(c)} \alpha_i \lambda_j - (1 - \hat{z}_{ij}^{(c)}) \alpha_i \lambda_0 \} \end{aligned}$$

**Figure 3B**

Patient:  $i = 1 \dots 29$   
 Peptide:  $j = 1 \dots 652$   
 Plate:  $m = 1 \dots 7$





Figure 4




Figure 5

Group	Consensus	SEQ ID NO:	Sequence	SEQ ID NO:
1	gEIpFpEpE	1	gqlypypape lpyppqg	200
			gqlypypaqalpyppqg	201
2	EIpFpEpEI	2	ylqlapfpapqlypypaqal p	202
			papfppqlypypaqalpyppq	203
			pymqlapfpapqlypypaqal	204
			qlapfpapqlypypaqal	205
			gqlypypape lpyppqg	206
			gqlypypaqalpyppqg	207
			papfppqlypypaqalpyppq	208
			mqlapfpapqlypypaqalpy	209
			qlapfpape lpyppaqal	210
			pqlypypaqalpyppaqalpypp	211
			pqlypypaqalpyppaqalpypp	212
			lqpfppape lpyppape lpypp	213
			lqlapfpapqlypypaqalpy	214
			papfppqlypypaqalpyppq	215
			3	EEpFpFEpE
pqqpqqpfpapqapfpwqapq	217			
qpfppaqapfpwqapqpfppq	218			
qpfppaqapfpwqapqpfppq	219			
5	FpEpEEpIp	4	qapfpqqpqqpfpapqapip	220
			pqqpqqpfpapqapipvqpq	221
			pqqpqqpfpapqapipvqpq	222
			gqapfpapeqapipvqg	223
			gqapfpapqapipvqg	224
			pqqpqqpfpapqapipvqpq	225
6	FpEpEEpFp	5	qpfppaqapfpwqapqpfppq	226
			pqqpqqpfpapqapipvqpq	227
			pqqpqqpfpapqapipvqpq	228
			qpfppaqapfpwqapqpfppq	229
			gqapfpapeqapipvqg	230
			gqapfpapqapipvqg	231
			pqqpqqpfpapqapipvqpq	232
			qpfppaqapfpwqapqpfppq	233
			qppqpfpapeqapipwqp	234
			qpeqpfpapeqapipwqp	235
			qppqpfpapeqapipwqp	236
qpeqpfpapeqapipwqp	237			
7	EpEIpFpEp	6	ylqlapfpapqlypypaqal p	238
			papfppqlypypaqalpyppq	239
			pymqlapfpapqlypypaqal	240
			qlapfpapqlypypaqal	241
			gqlypypape lpyppqg	242
			qlapfpape lpyppqg	243
			lqlapfpapqlypypaqalpypp	244
			qlapfpape lpyppqg	245

			gqllpvecpqllpypcpq	246
			pqplpqpqlpvecpqllpypcpq	247
			lqlqpfppqqlpypcpq qpf r	248
			lqlqpfppqqlpypcpqelqvecpqllpypcpqpf	249
			mqllqpfppqqlpypcpqelqve	250
			glqpfppqqlpypcpq g	251
			qlqpfppqqlpypcpqql	252
			pqlqvecpqllpypcpqelqve	253
			qlqpfppqqlpypcpq qp	254
			glqpfppqqlpypcpq g	255
			pqlqvecpqllpypcpqelqve	256
			lqlqpfppqqlpypcpqelqve	257
			lqlqpfppqqlpypcpqelqve	258
			glqpfppqqlpypcpq g	259
			pqlqvecpqllpypcpqelqve	260
			ypqqlpypcpq qpf r p q q s y	261
			gsgqqlpypcpq gsg	262
			lqlqpfppqqlpypcpqelqvecpqllpypcpqpf	263
8	EEpFpEpEI	7	qapqapfpqql pfpqqseq	264
			fpqapqapfpqql pfpqqq	265
9	pEEpFSEEG	8	gqapfpqpeapfsqgg	266
			gqapfpqppapfsqgg	267
10	gFpEpEIpF	9	gs gfpqel pypgsg	268
11	pEEEpEEpF	10	qpqlpfpqppqppqppf pq	269
			gqapqppapfp pqqg	270
			gqapqppapfp pqqg	271
12	IEEpEEpFp	11	lqapqppfp qppqqlpqqg	272
			lqapqppfp qppqqlpqqg	273
			qpqppfpqlqapqppfp qpq	274
			pfpqlqapqppfp qppqqlp	275
			gfpqlqapqppfp qgg	276
			gfpqlqapqppfp qgg	277
13	pEpEpFIpE	12	lqpfppqppflpqlpypqppq	278
			lqlqpfppqppflpqlpypq	279
14	EEISpcmdI	13	lqqilqqqltpcmdv vlqqh	280
			ilqqilqqqltpcmdv vlqq	281
15	FEEdpFpEE	14	qspqqsfsyqqapfpqppyp	282
			yqqapfpqppypqppypsqq	283
			pqqqsfsyqqapfpqppypq	284
16	EpFpEpEIp	15	ylqlqpfppqppflpqlpypqppq	285
			pymqlqpfppqppflpqlpypqppq	286
			qlqpfppqppflpqlpypqppq	287
			glqpfppqppflpqlpypqppq	288
			lqlqpfppqppflpqlpypqppf r	289
			qlqpfppqppflpqlpypqppq	290
			lqlqpfppqppflpqlpypqppf r	291
			lqlqpfppqppflpqlpypqppflpqlpypqppf	292
			mqllqpfppqppflpqlpypqppq	293
			glqpfppqppflpqlpypqppq	294

			gl qpfppqelp ypqqql	295
			gl qpfppqqlp ypqqqp	296
			gl qpfppqqlp ypqqg	297
			gl qpfppqelp ypqqelpypf	298
			qqq qpfppqqlp fpqqseq	299
			lql qpfppqqlp ypqqqlpy	300
			fpqqq qpfppqqlp fpqqq	301
			gl qpfppqqlp fpqqg	302
			gl qpfppqelp ylqqg	303
			pylql qpfppqqlp ysqqqp	304
			gl qpfppqelp ysqqg	305
			lql qpfppqqlp ylqqqpfr	306
			lql qpfppqqlp ylqqqpfr	307
			lql qpfppqqlp ysqqqpfr	308
			gsg qpfppqelp gsg	309
			gl qpfppqqlp ypqqqlpypqqqpf	310
			gl qpfppqqlp ysqqg	311
			qpfppqqlp ysqqqfrrpqq	312
			lql qpfppqqlp ysqqqfrr	313
			gl qpfppqqlp ylqqg	314
			qfpsqlpylql qpfppqqlp	315
			pfpsqqpymql qpfppqqlp	316
			pfpsqlpylql qpfppqqlp	317
			pfpsqqpylql qpfppqqlp	318
			pfpsqqpylql qpfppqqlp	319
17	pEEpEEEEfp	16	pqqpf pqqppqqf qpqqp	320
			gqpf pqqppqqf qpq	321
			qqppqpf pqqppqqf qpqq	322
			gqpf pqqppqqf qpq	323
			gf pqqppqqf qpqqg	324
			ppqqf pqqppqqf qpqqg	325
			gf pqqppqqf qpqqg	326
			gqpf pqqppqqf qpq	327
			qqppqpf pqqppqqf qpqq	328
			ppqqppqpf pqqppqqf qpq	329
			gf pqqppqqf qpqqg	330
18	pFSEEEEpI	17	qpp pfsqqqqv lpqg	331
			lqqp pfsqqqqv lpqqqp	332
			pfsqqqp pfsqqqqv lpq	333
			qqqpilsqqp pfsqqqqv l	334
			qp pfsqqqqv lpqqspfsq	335
			qqqlpqqp pfsqqqqv ll	336
			qqqpilsqqp pfsqqqqv l	337
			qqqp pfsqqqqi lpqqppf	338
			pfsqqqp pfsqqqqi lpqq	339
			qqqpilpql pfsqqqqv lp	340
			qpp pfsqqqqv lpqqspfs	341
			qpp pfsqqqqv lpqg	342
			qs pfsqqqqv lpqqqpvi	343
			qp pfsqqqqv lpqqspfsq	344
			qqqp pfsqqqqv ipqqpsf	345

EP 2 412 380 A1

			lppfsqqllppfsqqqqpv lp	346
			qqqqppfsqqqqpv lpqqsp	347
			sqqqpilsqqppfsqqqqpv	348
			pfsqqqqpv llqqqipfvhp	349
19	pEEpSpIEp	18	ftqppqtpiqp qppfpqqp	350
			pftqppqtpiqp qppfpqq	351
			fpeqsqqpftqppqtpiqp	352
20	EpEEpIpIE	19	pppppppppppppppppppppp	353
			pppppppppppppppppppppp	354
			pppppppppppppppppppppp	355
			pppppppppppppppppppppp	356
			pppppppppppppppppppppp	357
			p qppqppipvpqqqsfpqqsq	358
			qppqppipvpqqqsfpqqsq	359
21	EpEEpEIpF	20	qppfp qppqppqppf pqqppq	360
			qppqppqppfp qppqppqppf p	361
			qppqppfp qppqppqppf pqq	362
			qppqppfp qppqppqppf pqq	363
			p qppqppqppf pqqppqppfpq	364
			pqqppfp qppqppqppf pqqppq	365
			gqqppfp qppqppqppf g	366
			qppfp qppqppqppf pqqppq	367
			gqqppfp qppqppqppf g	368
			gfp qppqppqppf pqqg	369
			gfp qppqppqppf pqqg	370
22	EpEIpFpEg	21	gsqp qppqppqppf pqqg	371
23	FpEpEIpFg	22	gsqp fpqppqppf pqqg	372
24	pEEpFcEEg	23	gqqppfpqppqppf pqqg	373
			gqqppfpqppqppf pqqg	374
25	FpEpEEEEp	24	gf fpqppqppf pqqg	375
			gqqp fpqppqppf pqqg	376
			sqqppqpp fpqppqppf pqqg	377
			gqqp fpqppqppf pqqg	378
			sqqppqpp fpqppqppf pqqg	379
			qp fpqppqppf pqqppqppf	380
			gf fpqppqppf pqqg	381
			sqqppqpp fpqppqppf pqqg	382
			gf fpqppqppf pqqg	383
			gqqp fpqppqppf pqqg	384
26	gEpSpIEpE	25	gqptpi qpp qppfpqqg	385
			gqptpi qpp qppfpqqg	386
27	FIpEIpFpE	26	flpqlpypqppqsfpqqppyp	387
			flpqlpypqppqsfpqqppyp	388
			gqqpp flpqlpypqppg	389
			pqp flpqlpypqppqsfpqq	390
			pqp flpqlpypqppqsfpqq	391
			gqqpp flpqlpypqppg	392
			flpqlpypqppqsfpqqppg	393
28	FIEEEcSRI	27	svlqqllnpckv flqqqcsHV	394
			kv flqqqcsHV amsqrlarp	395
29	pFpEpEEpF	28	qppqppqppf pppqppfpq	396

			pgqppqppfppqppf pwqpp	397
			pqqppqppqppfppqppf pw	398
			ppfppqppqppf pwqppqppfpa	399
			qqppfppqppqppf pwqpp	400
			qqppfppqppqppf pwqpp	401
			pqqppqppqppfppqppf pw	402
			ppfppqppqppf pwqppqppfpa	403
			ppqppfppqppqppf pwqpp	404
			ppqppfppqppqppf pwqpp	405
			ppqppfppqppqppf sqqpp	406
			qqppfppqppqppf sqqpp	407
			qqppfppqppqppf sqqpp	408
			gqvqwpqqppfppqppqppf ce	409
			pqqppqppfppqppqppf sqqppqpp	410
			wppqppfppqppqppf cqppqpp	411
			psgqvqwpqqppfppqppqppf	412
			qqppfppqppqppf sqqpp	413
			pqqppfppqppqppf ceppqpprt	414
			ppqppfppqppqppf pwqpp	415
			ppqppfppqppqppf pwqpp	416
			qqppfppqppqppf cqppqpprti	417
			qqppqppfppqppqppf sqqppqppi	418
			qqppfppqppqppf ceppqpprti	419
30	FIEpEEpFp	29	qqflqppqppfpp qppqppypq	420
			gqqqfiqppqppfpp qpp	421
			pqqqfiqppqppfpp qppqppyt	422
			gqqqfiqppqppfpp qpp	423
			qqqfiqppqppfpp qppqppyt	424
			fsqppqppqppfiqppqppfpp q	425
			pqqqfiqppqppfpp qppqppyt	426
			pqqpflqppqppfpp qppqppf	427
			pqqqflqppqppfpp qpprppyt	428
			pqqqflqppqppfpp qppqppyt	429
31	pEEEEIaRg	30	qqppqppqpplahgtflqpphki	430
			qqppqppqpplahgtflqpphia	431
32	EpEEpFpEp	31	ppqppqppfppqpp qppfppwppq	432
			pqqppqppqppfppqpp qppfppw	433
			qqppfppqppqppfppqpp qppfpp	434
			ppqppqppfppqpp qppfppvqppq	435
			ppqppqppfppqpp qppfppvqppq	436
			ppqppqppqppfppqpp qppfppw	437
			qqppqppfppqpp qppfppqppseq	438
			ppqppfppqpp eqppfppwppq	439
			lqqppqppfppqpp qqpplppqppq	440
			ppqppfppqpp eqppfppwppq	441
			fppqppqppfppqpp qppfppqppseq	442
			ppqppqppfppqpp qppfppvqppq	443
			plqppqppfppqppqppqppfppqpp q	444
			sqppqppfppqpp qqppfppqppqpp	445
			sqppqppfppqpp qqppfppqppqpp	446
			pqqppfppqppqppqppfppqpp qpp	447

			qlpfpq <del>qpqqpfpqp</del> qppqq	448
			hqpqqqfpqtq <del>qpqqpfpqp</del>	449
			pqtq <del>qpqqpfpqp</del> qqt fpqq	450
			<del>qpqqpfpqp qpqqpfpqp</del>	451
			pqqpfpqqp <del>qpqqpfpqp</del> q	452
			<del>qpqqpfpqp qpqqpfpqp</del>	453
			sq <del>qpqqpfpqp</del> qppqqs fpq	454
			qqqqpfpqqp <del>qpqqpfpqp</del> q	455
			<del>qpqqpfpqp qpqqpfpqp</del>	456
			pq <del>qpqqpfpqp</del> qqaqlpfpq	457
			<del>qpqqpfpqp qpqqpfpqp</del>	458
			qpqqpfpqsq <del>qpqqpfpqp</del> q	459
			<del>qpqqpfpqp qpqqpfpqp</del>	460
			<del>qpqqpfpqp qpqqpfpqp</del>	461
			sk <del>qpqqpfpqp</del> qppqqs fpq	462
			<del>qpqqpfpqp qpqqpfpqp</del>	463
			<del>qpqqpfpqp qpqqpfpqp</del>	464
			<del>qpqqpfpqp qpqqpfpqp</del>	465
			qsk <del>qpqqpfpqp</del> qppqqs fp	466
			fplqpqqpfpq <del>qpqqpfpqp</del>	467
			qppqqqfpqqp <del>qpqqpfpqp</del>	468
			qpqqpfpqsq <del>qpqqpfpqp</del> q	469
			qpqqpfpqsk <del>qpqqpfpqp</del> q	470
			p1qpqqpfpq <del>qpqqpfpqp</del> q	471
			qqfpqtq <del>qpqqpfpqp</del> qqt f	472
			qppqqpfpqsk <del>qpqqpfpqp</del>	473
33	pFpIEpEEp	32	pqqpqqpfplqpqqp fpqqp	474
			gqpfplqpqqp fpqqg	475
			pqqpqqpfplqpqqp fpqqp	476
			gqpfplqpqqp fpqqg	477
			pqq1qqpfplqpqqp fpqqp	478
			pqqpqqpfplqpqqp fpqqp	479
			seqi1pqq1qqpfplqpqqp	480
34	EpEEaFpEp	33	gqt fph qpqqafpqp g	481
			qt fph qpqqafpqp qqt fph	482
			gqt fph qpqqafpqp g	483
			pqqt fph qpqqafpqp qqt f	484
35	pEFpSEIpF	34	ppqqypqppqfpsqlpy lql	485
			qqypqppqfpsqlpy lqlqp	486
36	pFpEpEEEEI	35	<del>lqqqqpfpqqqq1pqqq</del>	487
			gqqpfpqqqq1pqqg	488
			<del>lqqqqpfpqqqq1pqqq</del>	489
			<del>pqq1qpqqqpfpqqqq1p</del>	490
			gqqpfpqqqq1pqqg	491
			qpfppqqqq1pqqppqqsf	492
37	ppEIpFpEp	36	<del>pqqfppq1pypqpqlpypqp</del>	493
			<del>pqqfppq1pypqpqlpypqp</del>	494
			qpfppq1pypqp qpfppqqp	495
			<del>pqqfppq1pypqpqlpypqp</del>	496
			pqqfppq1pypqp qpfppqq	497
			pqqfppq1pypqp pppfspqq	498

			pqp f ppqlpypqp qsfppqq	499
			gqpqp f ppel pypqp g	500
			gqpqp f ppqlpypqp g	501
			pfpqpqp f ppqlpypqp pff	502
			gsg ppel pypqp gsg	503
			pfpqpqp f ppqlpypqp qsf	504
			pqp f ppqlpypqp pffspqq	505
38	mEIEpFpEp	37	py mqlqpfppq qipypqpq	506
			mqlqpfppq qipypqpq	507
			mqlqpfppq qpfppqlpypq	508
			pfpsqqpymqlqpfppq qpf	509
			pfpsqqpymqlqpfppq qip	510
			pfpsqqpymqlqpfppq qpf	511
39	EESScRI mE	38	pqlarsqmw qqsschvmq q	512
			qqlarsqml qqsschvmq qq	513
			pqlarsqmw qqsschvmq q	514
			rlarsqml qqsschvmq qqc	515
			rpqmw qqsschvmq qqccqq	516
			mw qqsschvmq qqccqqlqq	517
			sqml qqsschvmq qqccqql	518
			qqsschvmq qqccqqlqqip	519
			qqsschvmq qqccqqlqqip	520
			rlarsqmw qqsschvmq qqc	521
			arsqml qqsschvmq qqccq	522
40	EEFSEpEEE	39	gq qqfsqpqqe fpqpq	523
			gq qqfsqpqqq fpqpq	524
			gq qqfsqpqqq fpqpq	525
			sqqpq qqfsqpqqq fpqpq	526
			sqqpq qqfsqpqqq fpqpq	527
			qqfsqpqqe fpqpq	528
			qsqpq qqfsqpqqq fpqpq	529
			qpq qqfsqpqqq fpqpqqp	530
41	pEEEEpEpE	40	gf fpa pqqefpqpq qg	531
			sqqpqqefpqpqqqfpqpq	532
			sqqpqqefpqpqqqfpqpq	533
			ppqpfpqpqqqfpqpq	534
			ppqpfpqpqqqfpqpqq	535
			qpfpqpqqqfpqpqqpqqsf	536
			qpfpqpqqqfpqpqqpqpq	537
			gf fpa pqqefpqpq qg	538
			sqqpqqefpqpqqqfpqpq	539
			gf fpa pqqefpqpq qg	540
			qpqpqqqfpqpqqpqpq	541
			gf fpa pqqefpqpq qg	542
			ppqpfpqpqqqfpqpqq	543
			gf fpa pqqefpqpq qg	544
			ppqpqqqfpqpqqpqpqq	545
			gf fpa pqqefpqpq qg	546
			sqqpqqqfsqpqqqfpqpq	547
			sqqpqqqfsqpqqqfpqpq	548
			qqfsqpqqefpqpq q	549

EP 2 412 380 A1

			qsqqpqqqfsqppqqqfpqqq	550
			ppqqqfpqqqppqqqfpqqq	551
			ppqqqfsqppqqqfpqqq	552
			qqqqqfpqqqppqqqfpqqq	553
			ppqqqppfpqqqppqqqfpqqq	554
			qffsqppqqqfpqqq	555
			tfphqppqqqfpqqqppqqqf	556
			qtfphqppqqqfpqqqppqqq	557
			qfpqqppqqqfpqqq	558
			sppqqqfpqqqppqqqfpqqq	559
			qtcphqppqqqfpqqqppqqq	560
42	pIpEIEpRn	41	pvpqlqpknpqqqqpqqv	561
			avrvpvpqlqpknpqqqqp	562
43	SScISgIER	42	metscisglerpwqqqplpp	563
44	FEEEpIppE	43	pwqqqplppqqsfsqqppfs	564
			pwqqqplppqqsfsqqppfs	565
			erpwqqqplppqhtlfpqqq	566
			etrcipglerpwqqqplppq	567
			shipglerpwqqqplppq	568
			mrcipglerpwqqqplppq	569
			scisglerpwqqqplppq	570
			pwqqqplppqgtlfpqqqpf	571
			erpwqqqplppqqsfsqqpp	572
			scisglerpwqqqplppq	573
			rpwqqqplppqgtlfpqqqpf	574
			pwqqqplppqhtlfpqqqpf	575
			ekpwqqqplppqpppcsq	576
			pwqqqplppqqsfsqqppfs	577
			etscipglerpwqqqplppq	578
45	EpIpEEpSF	44	sqpppfsqqqqqplppqpsf	579
			qplppqpsfsqqpppfsqqq	580
			qqqqqplppqpsfsqqppp	581
			ppfsqqqqqplppqpsfsqq	582
			qplppqpsfsqqpppfsqqq	583
			sqpppfsqqqqqplppqpsf	584
			qqqqqplppqpsfsppg	585
			qqqqqplppqpsfsqqppp	586
			qqqqqplppqpsfsppg	587
46	IIFSSIIEE	45	qqsryearairivystilqe	588
			aivystilqeqqvqgsiq	589
47	EpIISEEpp	46	fsqqpppfsqqqplppqpsf	590
			fsqqpppfsqqqplppqpsf	591
			fsqqpppfsqqqplppqpsf	592
			fsqqpppfsqqqplppqpsf	593
			fsqqpppfsqqqplppqpsf	594
			fsqqpppfsqqqplppqpsf	595
			fsqqpppfsqqqplppqpsf	596
48	EgIEIIRpI	47	vmqqeqqgqilrplfqlv	597
			qqqqgqilrplfqlvqq	598
49	pFSSIIagI	48	csiikapfssvagi ggqyr	599
			csiikapfssvagi ggq	600

EP 2 412 380 A1

50	FcSSSIapI	49	yippy <del>c</del> sttiapv gifgtn	601
			vyippy <del>c</del> sttiapv gifgtn	602
51	RIamSERIa	50	qqcshvamsqrla r <del>s</del> qmwqq	603
			kvflqqcshvamsqrla r <del>p</del>	604
			q <del>c</del> shvamsqrla r <del>p</del> qmwqq <del>s</del>	605
52	EpESFppEE	51	flpqlpyp <del>q</del> q <del>s</del> fppq <del>p</del> yp	606
			pqpflpqlpyp <del>q</del> q <del>s</del> fppq <del>q</del>	607
			pqpflpqlpyp <del>q</del> q <del>s</del> fppq <del>q</del>	608
			pqpfp <del>p</del> qlpyp <del>q</del> q <del>s</del> fppq <del>q</del>	609
			g <del>q</del> q <del>s</del> f <del>p</del> pe <del>q</del> pypq <del>q</del>	610
			lpqlpyp <del>q</del> q <del>s</del> fppq <del>q</del> pypq	611
			g <del>q</del> q <del>s</del> fppq <del>q</del> pypq <del>q</del>	612
53	siilqEqqq	52	rydaicaity <del>s</del> iilq <del>e</del> qqq <del>q</del>	613
			airaiiys <del>i</del> iilq <del>e</del> qqq <del>q</del> gf <del>v</del> q	614
			iraivys <del>i</del> iilq <del>e</del> qqq <del>q</del> gf <del>v</del> q <del>p</del>	615
			iiys <del>i</del> iilq <del>e</del> qqq <del>q</del> g <del>q</del> gsves <del>q</del>	616
			airaiiys <del>i</del> iilq <del>e</del> qqq <del>q</del> v <del>q</del> gs	617
			aiiys <del>i</del> iilq <del>e</del> qqq <del>q</del> gf <del>v</del> q <del>p</del> q <del>q</del>	618
			ryeairaiivys <del>i</del> iilq <del>e</del> qqq <del>q</del> v	619
			iraitys <del>i</del> iilq <del>e</del> qqq <del>q</del> gf <del>v</del> q <del>a</del>	620
			vy <del>s</del> iilq <del>q</del> q <del>q</del> q <del>q</del> q <del>q</del> q <del>q</del> q <del>q</del> q <del>s</del>	621
			aiiys <del>i</del> iilq <del>e</del> qqq <del>q</del> v <del>q</del> gsiq <del>s</del>	622
			siraivys <del>i</del> iilq <del>q</del> q <del>q</del> q <del>q</del> q <del>q</del> q	623
			aiiys <del>i</del> iilq <del>e</del> qqq <del>q</del> v <del>q</del> gsiq <del>s</del>	624
			aiif <del>s</del> iilq <del>e</del> qqq <del>q</del> gf <del>v</del> q <del>p</del> q <del>q</del>	625
			<del>s</del> iilq <del>e</del> qqq <del>q</del> g <del>q</del> gsves <del>q</del> e <del>q</del> q	626
			rhesiraiiys <del>i</del> iilq <del>q</del> q <del>q</del> q <del>q</del> q	627
			y <del>s</del> iilq <del>e</del> qqq <del>q</del> gf <del>v</del> q <del>p</del> q <del>q</del> q <del>q</del> p	628
			airaiiys <del>i</del> iilq <del>e</del> qqq <del>q</del> v <del>q</del> gs	629
			yeairaiiys <del>i</del> iilq <del>e</del> qqq <del>q</del> gf	630
54	ESEEpEEpF	53	hqpqqq <del>f</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del>	631
			p <del>q</del> t <del>q</del> q <del>p</del> q <del>q</del> p <del>f</del> p <del>q</del> p <del>q</del> t <del>f</del> p <del>q</del> q	632
			q <del>p</del> f <del>p</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> q <del>q</del>	633
			q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> q <del>p</del> q <del>p</del> f <del>p</del> q <del>t</del>	634
			q <del>p</del> q <del>p</del> f <del>p</del> q <del>s</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> p <del>q</del>	635
			g <del>f</del> p <del>q</del> t <del>q</del> q <del>p</del> e <del>q</del> p <del>f</del> p <del>q</del> q <del>q</del>	636
			g <del>f</del> p <del>q</del> s <del>q</del> q <del>p</del> e <del>q</del> p <del>f</del> p <del>q</del> q <del>q</del>	637
			p <del>q</del> q <del>p</del> q <del>p</del> f <del>p</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del>	638
			q <del>p</del> f <del>p</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> l <del>q</del> p	639
			q <del>p</del> q <del>p</del> f <del>p</del> q <del>s</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> p <del>q</del>	640
			q <del>p</del> q <del>p</del> f <del>p</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> p	641
			p <del>q</del> t <del>q</del> q <del>p</del> q <del>p</del> f <del>p</del> q <del>s</del> q <del>q</del> p <del>q</del> p <del>f</del>	642
			q <del>q</del> f <del>p</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> p <del>q</del> t <del>f</del>	643
			q <del>q</del> p <del>f</del> p <del>q</del> s <del>q</del> p <del>q</del> p <del>f</del> g	644
			q <del>p</del> f <del>p</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> p <del>q</del> q	645
			g <del>f</del> p <del>q</del> s <del>q</del> q <del>p</del> q <del>p</del> f <del>p</del> q <del>q</del>	646
			q <del>p</del> f <del>p</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> s <del>k</del> q <del>p</del>	647
			q <del>p</del> f <del>p</del> q <del>t</del> q <del>q</del> p <del>q</del> p <del>f</del> p <del>q</del> s <del>q</del> q <del>p</del>	648
			g <del>f</del> p <del>q</del> t <del>q</del> q <del>p</del> q <del>p</del> f <del>p</del> q <del>q</del>	649
			q <del>q</del> p <del>f</del> p <del>q</del> s <del>e</del> q <del>p</del> q <del>p</del> f <del>g</del>	650
			q <del>q</del> p <del>f</del> p <del>q</del> t <del>q</del> q <del>p</del> q <del>p</del> f <del>g</del>	651

EP 2 412 380 A1

			gqqpfpqtqapqapf g	652
			pfpqtaqapqapf pqlqapqa	653
55	EIEEpEEpI	54	qpfpqalqapqapf pqpqapq	654
			gfpqalqapqapf pqqq	655
			qppqapfpqalqapqapf pqpq	656
			gfpqalqapqapf pqqq	657
56	IpEEpEEpF	55	gqpiqapqapf plqg	658
			fpelqapipqapqapf plqg	659
			fpelqapipqapqapf plqg	660
			gqpiqapqapf plqg	661
			gqlqapipqapqapf g	662
			gqlqapipqapqapf g	663
57	FpEEpEEpF	56	gqpfqapqapf pqpqapip	664
			fpqapqapf pqpqapip	665
			gqpfqapqapf pqpqapip	666
			fpqapqapf pqpqapip	667
			gqpfqapqapf pqpqapip	668
			tqppqapfpqapqapf pqt g	669
			qtqppqapfpqapqapf pqt	670
			pqpqapqapf pqpqapqapf pqt	671
			qapfpqapqapf pqtqppqg	672
			qapypqapqapf pqtqppqg	673
			gqpfqapqapf pqqq	674
			fpelqapipqapqapf pqpq	675
			pqpqapfpqapqapf pqpq	676
			plqppqapfpqapqapf pqpq	677
			gqppqapfpqapqapf g	678
			gqpyqapqapf pqqq	679
			gqpfqapqapf pqqq	680
			ypqapfpqapqapf pqqppf	681
			qqt fpqapqalpfpqapqapf	682
			pqpqapfpqapqapf pqpq	683
			fpqapqapf pqpqapip	684
			gqppqapfpqapqapf g	685
			rqpfpqapqapypqapqapf	686
			gqpyqapqapf pqqq	687
			qapfpqapqapypqapqapf	688
			qppqapfpqapqapf pqt qap	689
			fpqapqapypqapqapf pqt	690
			fpqapqapypqapqapf pqt	691
			pfpqapqapypqapqapf	692
			pfpqapqapf pqpqapqapf pqpq	693
			gqppqalpfpqapqapf g	694
			gqppqalpfpqapqapf g	695
			pqpqapqapf pqpqapqapf pqpq	696
			qapqapqapf pqpqapqapf pqpq	697
			lqppqapfpqapqapypqapqapf	698
			pqpqapfpqapqapypqapqapf	699
			pqpqapfpqapqapypqapqapf	700
58	SpIEpEEpF	57	gqptpqpqapf pqpq	701
			ftqppqaptpqpqapf pqpq	702

EP 2 412 380 A1

			pftqppqp tpiqqppf pqq	703
			tpiqqppf pqqppppf	704
			gqp tpiqqppf pqq	705
59	pFSEEpEEI	58	gqpfqqpqi fpqqg	706
			qqpfqqpqi fpqqqt fp	707
			qqqp fpqqpfsqqpqi	708
			hqpfqqpqi fpqqqt fp	709
			gqpfqqpqi fpqqg	710
			pflqhqpfqqpqi fpqp	711
			gqpqqpfseqpqi fg	712
			qqpflqhqpfqqpqi f	713
			qpqqpfqqpqi fpqqqt	714
			gqpqqpfqqpqi fg	715
60	gEEIFpEpE	59	gqqi fpqpe qt fphgg	716
			gqqi fpqqqt fphgg	717
61	EpEEpEEpF	60	pqqppppf pqqppfw	718
			pqqppppf pqqppfw	719
			pqqfp pqqppf pqq	720
			pqqfp pqqppf pqq	721
			ppppppf pqqpppfp	722
			ppppfp pqqppf pqq	723
			ppppfp pqqppf pqq	724
			tpiqqppfp pqqppf	725
			piqqppfp pqqppf p	726
			qfp pqqppf pqqpp	727
			gqpfp pqqppf g	728
			ppppfp pqqppf pqp	729
			lqqpplp pqqppf p	730
			gfp pqqppf pqqg	731
			gfp pqqppf pqqg	732
			qfp pqqppf pqlqq	733
			pqqfp pqqppf pqq	734
			ppppppf pqqppliqp	735
			ppppfp pqqppf pqlqq	736
			gqpfp pqqppf g	737
			gqplp pqqppf g	738
			p pqqppf pqqppliqp	739
			qfp pqqppf pqsqq	740
			tfhqppppvp pqqppf	741
			gqfp pqqppf g	742
			gqplp pqqppf g	743
			tfhqppppfp pqqppf	744
			qplp pqqppf pqsqq	745
			gqfp pqqppf g	746
			qvp pqqppf lqqppf	747
			qplp pqqppf pqsqq	748
			qvp pqqppf lqqppf	749
62	FpEEpEEpI	61	pqqqplp fpqqppl pqp	750
			qqplp fpqqppl pqp	751
63	pSSEppFp	62	qqpfpqqpppssqqppfp	752
			qqqqpssqqppfp qqqqfp	753

EP 2 412 380 A1

			ppfsqqqqpssqppfp qqh	754
64	FpEEpEIpF	63	pqqpfpqqqt fpqqqlpf	755
			fpqqqt fpqqqlpf pqqp	756
			qqt fpqqqlpf pqqpqqpf	757
			pqqpfpqqqt fpqqqlpf	758
65	pFpFEpEEp	64	qpfppqqqpfppqqp fpq	759
			qpfppqqqpfppqqp fpq	760
			qpfppqqqpfppqqp fpq	761
			qqpfppqqp fpqqq	762
			ppfwppqqp fpqtqqsfplq	763
			qqpfppqqp fpqqq	764
66	pEESFpREg	65	qqqifppqqtfphgg	765
			qqqafppqqtfphgg	766
			qqqifppqqtfphgg	767
			qqqtfpqqtfphgg	768
			qqqafppqqtfphgg	769
			qqqtfpqqtfphgg	770
67	SFpREpEEa	66	qqi fpqqqt fphppqqa fp	771
			qq fphppqqa fpqq	772
			q fphppqqa fpqqqt fph	773
			qq fphppqqa fpqq	774
			ppq fphppqqa fpqqqt f	775
68	FSEEEpSFS	67	pqqqppfsqqqpsfs qqpp	776
69	aFpEpEESF	68	qqqafppqqtf phgg	777
			qafppqqtf phppqqqfpq	778
			qafppqqtf phppqqqfpq	779
			qqqafppqqtf phgg	780
			qt fphppqqa fppqqtf ph	781
			qqafppqqtf phppqqqfp	782
			ppqt fphppqqa fppqqtf	783
70	SEEpFSEpE	69	qqfpeqsqppftppq qptpi	784
			fpqsqppftppq qptpi q	785
71	IEpFpEpEp	70	lqpppppp lpppppp	786
			lqlpppppp fppqlyppq	787
			lqlpppppp fppqlyppq	788
			lqlpppppp fppqlyppq	789
			lqlpppppp fppqlyppq	790
			ppfsqqpymqlpppppp f	791
			fpsqqpylqlpppppp fl	792
			ppfsqqpylqlpppppp f	793
			sqppylqlpppppp fppq	794
			ppfsqqpymqlpppppp f	795
72	pFpRpEIpF	71	qqpylqlpppppppyppq	796
			qlpppppppyppq	797
			lqlpppppppyppqppfr	798
			qlpppppppyppq	799
73	EEIFpEpEE	72	qqqifppqqtfphgg	800
			qqqifppqqtfphgg	801
			qqifppqqtfphppqqa fp	802
			ppqifppqqtfphppqqqf	803
			qqifppqqtfphppqqqfp	804

EP 2 412 380 A1

			qqpfsqqpqqifpqqqtfp	805
			hqpfsqqpqqifpqqqtfp	806
			qpqqpfsqqpqqifpqqqt	807
74	EpEESpER	73	pqqqfiqqpqqpqqtyppq	808
			qpqqqfiqqpqqpqqtyppq	809
			qpfpqppqqtyppqpqqp	810
			pqqpfpqppqqtyppqpqqp	811
			pqqqfiqqpqqpqqtyppq	812
			qppfpqppqqtyppqpqqp	813
			qppfpqppqqtyppqpqqp	814
75	FpERpEEpF	74	qqtppqrppqpfpqtaqqp	815
			qpfppqqpqqtyppqrppqpf	816
			qqtppqrppqpfpqtg	817
			qqtppqrppqpfpqtg	818
			qppfpqqpqqtyppqrppqpf	819
			qppfpqqpqqtyppqrppqpf	820
			qqtppqrppqpfpqtaqqp	821
			qtppqrppqpfpqtaqqp	822
76	IEpFpEpEI	75	ylqlappfpapqlpypapqlp	823
			pymqlappfpapqlpypapql	824
			qlappfpapqlpypapql	825
			glappfpapqlpypapql	826
			lqlappfpapqlpypapql	827
			qlappfpapqlpypapql	828
			lqlappfpapqlpypapql	829
			lqlappfpapqlpypapqlpypapqlpypapql	830
			mqlappfpapqlpypapqlpyp	831
			glappfpapqlpypapql	832
			glappfpapqlpypapql	833
			glappfpapqlpypapql	834
			glappfpapqlpypapql	835
			lappfpapqlpypapqlpypf	836
			lqlappfpapqlpypapqlpyp	837
			glappfpapqlpypapql	838
			glappfpapqlpypapql	839
			pylqlappfpapqlpypapql	840
			glappfpapqlpypapql	841
			lqlappfpapqlpypapqlpyp	842
			lqlappfpapqlpypapqlpyp	843
			lqlappfpapqlpypapqlpyp	844
			lqlappfpapqlpypapqlpypapqlpypapqlpypapql	845
			glappfpapqlpypapql	846
			lqlappfpapqlpypapqlpyp	847
			glappfpapqlpypapql	848
			glappfpapqlpypapql	849
			qfppsqpypylqlappfpapqlp	850
			lqlappfpapqlpypapqlpyp	851
			lqlappfpapqlpypapqlpyp	852
			gsglappfpapqlpypapql	853
			pfpqqpypmqlappfpapqlp	854
			glappfpapqlpypapqlpyp	855

EP 2 412 380 A1

			pfpqpylqlapfpapql p	856
			pfpqpylqlapfpapql p	857
			pfpqpylqlapfpapql p	858
77	EpFpESEES	76	pfpwapaqapfpataqs fplq	859
			qpfqatqqs fplqqaqpfq	860
			fwpapaqapfpataqs fplq	861
78	ESScIpgIE	77	metscipgle rpwqqaplqq	862
			etscipgle rpwqqaplppq	863
79	pIIPRgppF	78	sqqqpilprgppf sqqtqpv	864
80	EpEEEEpEp	79	gffpapeqefpqp qqq	865
			gqapfpapeqefpqp q	866
			sqqqpfpapeqefpqp q	867
			gqapfpapeqefpqp q	868
			sqqqpfpapeqefpqp q	869
			pqqapfpapeqefpqp q	870
			qpfqapeqefpqp qqqqqs f	871
			gqapfpapeqefpqp q	872
			sqqqpfpapeqefpqp q	873
			gqapfpapeqefpqp q	874
			gffpapeqefpqp qqq	875
			sqqqpfpapeqefpqp q	876
			gffpapeqefpqp qqq	877
			sqqqpfpapeqefpqp q	878
			gqapfpapeqefpqp q	879
			sqqqpfpapeqefpqp q	880
			gqapfpapeqefpqp q	881
			gqt fph qpeqefpqp g	882
			gffpapeqefpqp qqq	883
			sqqqpfpapeqefpqp q	884
			gqapfpapeqefpqp q	885
			gffpapeqefpqp qqq	886
			sqqqpfpapeqefpqp q	887
			gqapfpapeqefpqp q	888
			sqqqpfpapeqefpqp q	889
			gqapfpapeqefpqp q	890
			gffpapeqefpqp qqq	891
			sqqqpfpapeqefpqp q	892
			gqapfpapeqefpqp q	893
			gqapfpapeqefpqp q	894
			sqqqpfpapeqefpqp q	895
			gqapfpapeqefpqp q	896
			t fppqqatcph qpeqefpqp	897
			gffpapeqefpqp qqq	898
			t fph qpeqefpqp qqqqq f	899
			qt fph qpeqefpqp qqqqq	900
			gffpapeqefpqp qqq	901
			sqqqpfpapeqefpqp q	902
			qt cph qpeqefpqp qqqqq	903
			gqt fph qpeqefpqp g	904
81	nmEadpSgE	80	nmqadpsgq vqwpqqqflq	905
			ata nmqadpsgq vqwpqqq	906

EP 2 412 380 A1

82	gaIcSSISn	81	fdeeknstgalcsslsnqas	907
83	EFpEEElpI	82	qppfpqqhqqfpqqqpvvq	908
			qqplfpqqhqqfpqqqpvv	909
			qfpqqqpvvqpsvlqqlnp	910
84	EEEpIIIEE	83	sqqqqpfpq qqaplllqqpp	911
			qqqqp illqqppfsqhqqpv	912
			qqqpfpaqqaplllqqppfs	913
			qqqqppfsqqqqapillqqp	914
			pfsqqqqpvlqqqipfvhp	915
			qqqpfpaqqaplllqqppfs	916
85	SEEpEESFp	84	qqplsqqqqatfpqqatfp	917
			hqpf sqqqqatfpqqatfp	918
			qpfpqphqpf sqqqqatfpq	919
			qqplsqqqqatfpqqg	920
			pvpqphqpf sqqqqatfpqp	921
			qqplsqqqqatfpqqg	922
			qqlvqlqqplsqqqqatfp	923
			pqlqqplsqqqqatfpqqg	924
86	FRREpEESF	85	phqt fhhqqqatfpqqqaty	925
			qt fhhqqqatfpqqqatyph	926
			qt fhhqqqatfpqqqatyph	927
			qrtipqphqt fhhqqqatfp	928
87	RFFFpSSpR	86	sgqqghwyyptspklsgqqg	929
88	REpEEEFSE	87	tfhqppqqqfsqppqqqqf	930
			qtfhqppqqqfsqppqqqq	931
89	SIEEIIIEE	88	qqqtlqqilqqq lipcrdv	932
			tlqqilqqq lipcrdvvlqq	933
			qqqqqqqqtlqqilqqq lip	934
90	IEEpIppEE	89	pwlqqplppqqtlpqqllqq	935
			sniiisflkpwllqqplppqq	936
91	pISpEESgE	90	qqqqyyypisppqsgqqqqp	937
92	pEpFpEpEp	91	pypqppfpqqpp fppqly	938
			pfpqqppypqppfpqqpp f	939
			ppppppfpqqpp fppqlyppq	940
93	EpEpFpEpE	92	pypqqppfpqqpp fppqly	941
			qqpfpqqppypqqppfpqqp	942
			pfpqqppypqqppfpqqppf	943
			ppppppfpqqpp fppqlyppq	944
94	FpEEpEESF	93	ppqqflqqqqfpqqppqaty	945
			qqqflqqqqfpqqppqatyp	946
			ppqqflqqqqfpqqppqaty	947
			ppppppfpqqppqqsfpqqp	948
			qqpfpqqppqqsfpqqg	949
			qpfpqqppqatyppppqqpp	950
			qqppppfpqqppqqsfg	951
			qqppppfpqqppqqsfg	952
			ppppfpqqppqqsfpqqpppp	953
			ppppfpqqppqatyppppqqpp	954
			qqpfpqqppqqsfpqqg	955
			qqppppfpqqppqatfg	956
			pfpqqppppfpqqppqqsfpq	957

EP 2 412 380 A1

			gqppqp fpqppqqt f g	958
			qap fpqppqqt y pqrppqp f	959
			qap fpqppqqt y pqrppqp f	960
95	EESFSEpp	94	pwqqqplpp qqsfsqpp fs	961
			pwqqqplpp qqsfsqpp fs	962
			erpwqqqplpp qqsfsqpp	963
			p qqsfsqpp fsqqqqqplp	964
			qqsfsqpp fsqqqqqplp q	965
			qplpp qqsfsqpp fsqqqq	966
			pwqqqplpp qqsfsqpp fs	967
96	FpEEpFpEE	95	ypqppfpqpp qppfpqpp f	968
			yqqpp fpqppypq pypsqq	969
			lpqpyaqpylp yppqppfpq	970
			pqqsfsyqqppfpqppypq	971
			p fpqppypq pypsqppyp	972
			qelqspqal yppqppypq py	973
			yaqpylp yppqppfpqppq	974
			qap fpqppypq pypsqpp	975
97	EpSSEEpIS	96	qpssqppls qhqppfpqqi	976
			qpppfsqqq qpssqppls q	977
98	EpIEERESF	97	qlerpwqq qplqqk et f pqq	978
99	ISpEEIqEg	98	qggyp isppq lgg qsgq	979
100	EEEccERIp	99	qsschvm qqccqr lp qipe	980
101	agEgEEgFF	100	gqqagggggy ptspqqlg	981
102	EEEpFpEpE	101	gqvwp qppfpqp qppce	982
			gqvwp qppfpqp qppce	983
			gqvwp qppfpqp qppce	984
			gqvwp qppfpqp qppce	985
			gqvwp qppfpqp qppce	986
			gqvwp qppfpqp qppce	987
			gqvwp qppfpqp qppce	988
			psgqvwp qppfpqp qppce	989
			gqvwp qppfpqp qppce	990
			gqvwp qppfpqp qppce	991
			psgqvwp qppfpqp qppce	992
			gqvwp qppfpqp qppce	993
			vdpsgqvwp qppfpqp	994
103	EIEFpEEEE	102	psgqvwp qppfpqp	995
			niqvdp sg qvwp qppfp	996
			gqvwp qppfp qp qp qp qp	997
			psgqvwp qppfpqp	998
			ttaniquvdp sg qvwp qppfp	999
			vdpsgqvwp qppfpqp	1000
			qivfpsg qvwp qppfp	1001
			gqvwp qppfp qp qp qp	1002
			gqvwp qppfp qp qp qp	1003
104	EpIEEIccE	103	qstyqplqqlccqqlwqipe	1004
			qstyqplqqlccqqlwqipe	1005
			qstyqplqqlccqqlwqipe	1006
105	pFpEpEFpS	104	ppqppypqpp qppqpp q	1007
			gqqppfpqppypqpp q	1008

EP 2 412 380 A1

			qqpfppqqpypqpfps qlp	1009
			qqpypqpfps qlpylqlqp	1010
106	aIESIpSmc	105	feeirnlalqtllpsmcnvyi	1011
			rnlalqtllpsmcnvyippyc	1012
			eirnlalqtllpsmcnvyipp	1013
107	RIFEIpERI	106	elccqhlwqipekl qcqaih	1014
			elccqhlwqipekl qcqaih	1015
			glccqhlweipekl qq	1016
			glccqhlwqipekl qq	1017
			lccqhlwqipekl qcqaihn	1018
108	pFpESEESF	107	pfpwqppqpfqtqqsflq	1019
			qpfqtqqsflqppqppfq	1020
			fpwqppqpfqtqqsflqp	1021
			pfpqtqqsflqppqppfq	1022
109	EgFFEpSEE	108	gqgffqpsqqnpqaqgsfq	1023
			gqgffqpsqqnpqaqg	1024
			qqypsgqgffqpsqqnpqaq	1025
			qqypsgqgffqpsqqnpqaq	1026
			gqgffqpsqqnpqaqg	1027
			psgqgffqpsqqnpqaqgsf	1028
			qqypsgqgffqpsqqnpqaq	1029
110	ESIFESScR	109	arsqtlwqsschvmqqqccr	1030
111	ISSIFSIII	110	llqqckpvslvsslwsiilp	1031
			lvsslwsiilppsdccvmrq	1032
			lvsslwsiilppsdccvmrq	1033
112	ESFpEpEES	111	qqqtffqpeqt fphqg	1034
			qqqtffqpeqt fphqppqqfp	1035
			qqqtffqpeqt fphqg	1036
			qqpqtffqpeqt fphqppq	1037
			phqt fhhqppqtffqpeqt y	1038
			qqplsqppqqtffqpeqt fp	1039
			qtffqpeqt yphqppqqfpq	1040
			happfsqppqqtffqpeqt fp	1041
			qqqtffqpeqt fphqppqqvp	1042
			qtffqpeqt yphqppqqfpq	1043
			qt fhhqppqtffqpeqt yph	1044
			hhqppqtffqpeqt yphqppq	1045
			qqqtffqpeqt fphqppqqfs	1046
			qtffqpeqt yphqppqqfpq	1047
			qt fhhqppqtffqpeqt yph	1048
			hhqppqtffqpeqt yphqppq	1049
113	mEnSRIpqI	112	menshipgl erpsrqpplp	1050
			menshipgl erlsqqpplp	1051
			menshipgl egpsqqpplp	1052
114	EEcSpIaIp	113	kvflqqcspvaipyrlars	1053
115	pFSEEEIp	114	qppfsqqqqt pfsqqqqip v	1054
			sqqqpppfsqqqqip vihps	1055
			qqqqt pfsqqqqip vihpsv	1056
116	ESRcIpqIE	115	etrcipgle rpwqqqplpp	1057
			metrcipgle rpwqqqplpp	1058
117	IpSIERpIE	116	metshipslekplqqplpl	1059

EP 2 412 380 A1

			cashipslekplq qqplplq	1060
118	aEIpFpEEp	117	qqpfpqqqqaqlpfqqp qq	1061
			qqqaqlpfpqqp qqplpqqp	1062
			qaqlpfpqqp qqplpqqpqqp	1063
			qqpfpqqqqaqlpfqqp qq	1064
			qpfqqqqaqlpfqqp qq	1065
119	SIIRSIpn	118	qppaqyevir slvrltlnm	1066
			qyevir slvrltlnmcnvy	1067
			qyevir slvrltlnmcnvy	1068
120	aEIEgIRSI	119	qqqpaqlegirsl vlktlp	1069
			iiqqqpaqlegirsl vlkt	1070
121	EEpaEIEgI	120	qlaqqgiiqqppaqlegi	1071
			qqqqpaqlegirsl vlktlp	1072
			iiqqqqpaqlegirsl vlktlp	1073
122	SpIampERI	121	ckvflqqqc spvampqrl ar	1074
			lqqqc spvampqrl ar	1075
			vflqqc spvampqrl arsqm	1076
			qqqc spvampqrl arsqmwq	1077
			c spvampqrl arsqmwqss	1078
			qc spvampqrl arsqmwqqs	1079
			ckvflqqqc spvampqrl ar	1080
			qqqc spvampqrl arsqmwq	1081
			vflqqqc spvampqrl arsq	1082
			vflqqqc spvampqrl arsq	1083
			spvampqrl arsqmlqqssc	1084
123	EInpcRnFI	122	qqlnpcknfl lqqckpvsiv	1085
			slqqslqqqlnpcknfl lq	1086
			qpslqqqvnpcnfl lqqck	1087
			iqqslqqqlnpcknfl lqqc	1088
			iqpslqqqvnpcnfl lqqc	1089
			lqqqvnpcnfl lqqcklvs	1090
124	IEpEEIaEI	123	qgtflqqqvaql elmtsia	1091
125	EFSEEEIip	124	qqp qfsqqqqip vihpsvlq	1092
			qppfsqqqqp qfsqqqqip v	1093
126	FpEpEpFpp	125	lqlqpfpqpqpfpqqlpypq	1094
			qpfpsqqpypqpqpfpqqlp	1095
			lqypqpqpfpqpqpfpqqlpypq	1096
			lqlqpfpqpqpfpqqlpypq	1097
			mqqpqpfpqpqpfpqqlpypq	1098
			qpfpsqqpypqpqpfpqqlp	1099
			lqfpqpqpfpqqlpypqpqpfp	1100
			lqfpqpqpfpqqlpypqpqpqs	1101
			lqypqpqpfpqpqpfpqqlpypq	1102
			sqqpypqlqlqpfpqpqpfpqql	1103
			pfpssqqpypqpqpfpqqlpyp	1104
127	FpEpEEpFc	126	qqqpfpqpqpfpqqlpypq	1105
			qqvqwpqpqpfpqpqpfpqqlpyp	1106
			wqqpqpfpqpqpfpqqlpypq	1107
			qqqpfpqpqpfpqqlpypq	1108
			lqqpqpfpqpqpfpqqlpypq	1109
			qqqpfpqpqpfpqqlpypq	1110

			fpqpqppfc qppartipqph	1111
			qqqpfpqpqppfc eqpart i	1112
128	EEIpEIpEE	127	ccqqlpqipeq sryearai	1113
			sschvmqqqcc qqlpqipeq	1114
			qccqqlpqipeq sryqaira	1115
			qqccqqlpqipeq sryear	1116
			qccqqlpqipeq srseaira	1117
			qccqqlpqipeq sryqaira	1118
			hvmqqqcc qqlpqipeq sry	1119
			qqccqqlpqipeq srydair	1120
			qccqqlpqipeq srydvira	1121
			cqqlpqipeq sryearaii	1122
129	pEESEEIIP	128	fpqpqlpfpqqsqiip qql	1123
			pqqsqiip qqlqppfplqp	1124
			pqqsqiip qqlqppfplqp	1125
			fpqpqlpfpqqsqiip qql	1126
130	pnnnSpSnR	129	plnnnspnnspnh hns	1127
			nns pnnnspnh hns pnnn	1128
			plnnnspnnspnh hns	1129
			nns pnnnspnh hns pnn	1130
			nns pnnnspnh hns pnnn	1131
131	mEEEEEEER	130	ii mqqeqqeqr qgvqi	1132
			ivhsii mqqeqqeqr qgvqi	1133
			ivhsii mqqeqqeqr q	1134
			sivhsii mqqeqqeqr qgvq	1135
			ivhsii mqqeqqeqr qgvqi	1136
132	EEmpcRnF	131	qqmnpcknf llqqcnhvs lv	1137
			iqsflqqmnpcknf llqqc	1138
			qsflqqmnpcknf llqqcn	1139
			iqpylqqmnpckny llqqc	1140
			iqpylqqmnpckny llqqc	1141
			lqqmnpckny llqqcnpvs	1142
133	cnInIpIFR	132	tmcnvnvplyr ttrvpfgv	1143
			tsfalrtlptm cnvnvplyr	1144
134	IISIIIPRS	133	cnhsvlvss lvsii lprs dc	1145
			hsvlvss lvsii lprs dcqv	1146
			lvss lvsii lprs dcqvmqq	1147
135	EIaEIpEES	134	schvmqqqccqqlaqipeqs	1148
			qccqqlaqipeqs rheaira	1149
136	RpFIEEpIp	135	mesniisfl kpwllqqlpp	1150
			snliisfl kpwllqqlppqq	1151
137	pFpEpEEpE	136	qqpfpqpqpqpqlpfpqpqpq	1152
			ppqpfqpqpqpqpfpqpqpq	1153
			qlpfpqpqpqpqpfpqpqpq	1154
			qpqpqpqpqpfpqpqpqp	1155
			qpqpqpqpqpqpqpqpqp	1156
			spqpqpqpqpqpqpqpqp	1157
			qpqpqpqpqpqpqpqpqp	1158
			qpqpqpqpqpqpqpqpqp	1159
			ppqpfqpqpqpqpfpqpqpq	1160
			skqpqpqpqpqpqpqpqp	1161

			qskqpqqpfpapqapqasfg	1162
			gqqpfpapqapqlpfg	1163
			gqpfpapqapqlpfpqapq	1164
			gqqpfpapqapqapfg	1165
			gqqpfpapqapqlpfg	1166
			gqpfpapqapqapfpqapq	1167
			gqqpfpapqapqasfg	1168
			gqyqwpqggqgqpfpapqapq	1169
			pqqpfpapqapqapfpqlaq	1170
			gqqpfpapqapqapfg	1171
			gqqpfpapqapqasfg	1172
			gqpfpapqapqapfpqsgap	1173
			pfpapqapqasfpqqqapli	1174
138	FpEpEEpEE	137	pqqpfpapqapqapfpapqapq	1175
			qfpfpapqapqapfpapqapq	1176
			pqqpfpapqapqapfpapqapq	1177
			qfpfpapqapqapfpapqapq	1178
			sqqpqqapfpapqapqasfg	1179
			qfpfpapqapqapfpapqapq	1180
			skaqqapfpapqapqasfg	1181
			qqfpapqapqapqlpqqapf	1182
			qskapqggqfpapqapqasfg	1183
			qfpfpapqapqapfpapqapq	1184
			gqqpfpapqapqapfg	1185
			gfpapqapqasfpqqg	1186
			qfpfpapqapqapfpapqapq	1187
			gfpapqapqapfpapqapq	1188
			pqqpqqqfpapqapqasfg	1189
			gqqqfpapqapqasfg	1190
			gfpapqapqapfpapqapq	1191
			fpapqapqapqlpqrqpfq	1192
			qfpfpapqapqapfpapqapq	1193
			pqqpqqqfpapqapqapfpapqapq	1194
			gqqpfpapqapqasfg	1195
			qfpfpapqapqapfpapqapq	1196
			pqqpfpapqapqapfpapqapq	1197
			gqqpfpapqapqapfg	1198
			qfpfpapqapqasfg	1199
			qfpfpapqapqapfpqsgap	1200
			gfpapqapqasfpqqg	1201
			pfpapqapqasfpqqqapli	1202
			gqqqfpapqapqasfg	1203
			gqqqfpapqapqapfg	1204
			lfpnqqqqfpapqapqapfg	1205
			qlfpnqqqqfpapqapqapq	1206
			sqqqqfpapqapqasfg	1207
			qlcpnqqqqfpapqapqap	1208
			gqqqfpapqapqapfg	1209
			qqfpapqapqapqlpqrqpf	1210
			qqfpapqapqapqlpqqapf	1211
139	EEIEEiccE	138	lqqssyqqlqqlccqqlfqi	1212

EP 2 412 380 A1

			qssyqqlqqlccqqlfqipe	1213
140	pEESFpEES	139	ppqsfpqqs qqsqqpfaqq	1214
			ppqqqppipvqppqqsfpqqs q	1215
			ppqqqppipvqppqqsfpqqs qq	1216
			vqppqqsfpqqs qqsqqpfaq	1217
141	IFpEpEpEF	140	rpqqlypqpqpqy sqpqqpi	1218
			qpfrpqqlypqpqpqy sqp	1219
142	EEpFpEEpE	141	qqpfpqppq qppfpqppqpp	1220
			qqflqp qppfpqppq qpypp	1221
			plqp qppfpqppq qppfpqpp	1222
			ppqqfiqp qppfpqppq qty	1223
			p qppfpqppq qppfpqppq	1224
			ppqqfpqppq qppfpqppq	1225
			t qpp qppfpqppq qppfpqpp	1226
			p qppfpqppq qppfpqppq	1227
			qqpfpqt qpp qppfpqppq q	1228
			qt qpp qppfpqppq qppfpqt	1229
			qqp qppfpqppq qppfpqppq	1230
			qqpfpqppq qppfpqt qppq	1231
			tpiap qppfpqppq qppqppf	1232
			qqpyppqpp qppfpqt qppq	1233
			qqqfiqp qppfpqppq qtypp	1234
			plqp qppfpqppq qppqppf	1235
			ppqqfiqp qppfpqppq qty	1236
			qqpfpqppq qppfpqppq q	1237
			fplqp qppfpqppq qppfpqpp	1238
			ppqpflqp qppfpqppq qppf	1239
			plqp qppfpqppq qppfpqpp	1240
			qqp qppfpqppq qppfg	1241
			yp qppfpqppq qppfpqppf	1242
			ppqp qppfpqppq qsfqpp	1243
			p qppfpqppq qppfpqppq	1244
			qqpfpqppq qppssqppfpq	1245
			ppqqfiqp qppfpqppq qpy	1246
			plqp qppfpqppq qppfpqpp	1247
			ppqqfpqppq qppfpqppq	1248
			qqp qppfpqppq qppfg	1249
			rpfpqpp qppypqppq qppf	1250
			qqp qppfpqppq qsfq	1251
			qqp qppfpqppq qsfq	1252
			p qppfpqppq qsfqppqpp	1253
			qqpfpqppq qppypqppqppf	1254
			qp qppfpqppq qppfpqt qpp	1255
			qqpfpqt qpp qppfpqppq q	1256
			fpqpp qppypqppq qppfpqt	1257
			p qppfpqppq qtyppqppq	1258
			qqp qppfpqppq qppfpqppq	1259
			ppfpqpp qppypqppq	1260
			qqp qppfpqppq qtfq	1261
			ppfpqpp qppfpqppq qsfq	1262
			qqp qppfpqppq qtfq	1263

EP 2 412 380 A1

			yaqpylpyppqqfppqqpp	1264
			ppqqfpppppppppppppp	1265
			qqpqqqfpppppppp	1266
			pppppppppppppppppp	1267
			qqpqqqfpppppppp	1268
			pppppppppppppppppp	1269
			pppppppppppppppppp	1270
			pppppppppppppppppp	1271
			pppppppppppppppppp	1272
143	EIaEIEImS	142	ggtflqqqyvaqlmltsta	1273
			ppqqqqlahqiaqlevmtsi	1274
			qphqiaqlevmtsialrilp	1275
			phqiaqlevmtsfalrtlpt	1276
			hqiaqlevmtsialrilptm	1277
			gtllqphqiaqlevmtsial	1278
			qiaqlevmtsfalrtlptmc	1279
			tllqphqiaqlelmtsialr	1280
			flqphqiaqlevmtsiaprt	1281
			qgtflqphqiaqlevmtsia	1282
			qiaqlevmtsialrilptmc	1283
144	FEIpEESEc	143	elccqhlwqipeqsqcqhah	1284
			hlwqipeqsqcqhahqnvvha	1285
			qhlwqipeqsqcqhahkvvh	1286
			elccqhlwqipeqsqcqhah	1287
145	EEEEEEEEIg	144	qsgqqlsqsqqsqqqlgqc	1288
			qsdqgvsqsqqqsqqqlgqc	1289
			qgvsqsqqqsqqqlgqcsfq	1290
			filsvsqppqqqsqqqlgqq	1291
			qcvsqpqqqsqqqlgqqppq	1292
			qqsgqgvsqsqqqsqqqlgq	1293
			cvsqpqqqsqqqlgqqppqq	1294
			yqpqqqsqqqlgqcsfqppq	1295
			qsqqqsqqqlgqcsfqppqq	1296
			qpqqqsqqqlgqqppppppq	1297
			qlgqcvsqpqqqsqqqlgqq	1298
			qlgqcvsqpqqqsqqqlgqq	1299
146	SIIEpSIIE	145	isivqpsilqqlnpckvflq	1300
			ppqqiisivqpsvlqqlnpck	1301
			qqqlppqqiisivqpsilqql	1302
147	FSaSSSIRF	146	plysattsvrfgvgtgvgay	1303
			vplysattsvrfgvgtgvga	1304
148	REEEEEEEI	147	aiimhqqqqqqqqqqqqqqq	1305
			gqmhqqqqqqqqqqqqqqq	1306
			hqqqqqqqqqqqqqqqqqqq	1307
			iimhqqqqqqqqqqqqqqqqq	1308
			gqmhqqqqqqqqqqqqqqq	1309
149	IIEEEISpc	148	lqqilqqqltpcmdvvlqqh	1310
			qqqqqqqilqqilqqqltpc	1311
			lqqilqqqltpcmdvvlqq	1312
150	EElIpEEEE	149	qqvlpqqqpfvhpasilqql	1313
			qlppfsqqqqqvlpqqqpf	1314

EP 2 412 380 A1

151	FSEEEEpFp	150	fsqqqqpqsfsqqqqpfpqqq	1315
			fsqqqqpqsfsqqqqpfpqqq	1316
			ppfsqqqqpqsfsqqqqpfpq	1317
152	cIpgIERpF	151	metscipglerpwqqqplqq	1318
			etrqipglerpwqqqplppq	1319
			mrcqipglerpwqqqplppq	1320
			metrcqipglerpwqqqplpp	1321
			mdtscqipglerpwqqqplpp	1322
			etsqipglerpwqqqplppq	1323
153	EEEcIpIam	152	mvflqqqcipvamqrclars	1324
			lnpckvflqqqcipvamqrc	1325
154	EIaEIpREI	153	vmqqqcccqlaqiprqlqca	1326
			qccqqlaqiprqlqcaaihs	1327
			mqqqcccqlaqiprqlqcaa	1328
			qlaqiprqlqcaaihsvvhs	1329
155	EEpREFpEE	154	hhqqqpiqqqphqfpqqqpc	1330
156	RpmFIEpEE	155	ypqqrpmqlpqqqpisqqqa	1331
			sfppqqpypqqrpmqlpqqq	1332
			ypqqrpmqlpqqqpisqqqa	1333
157	IEEEmpcR	156	iqsflqqqmpcknyllqqc	1334
			qsflqqqmpcknyllqqcn	1335
			iqpylqqqmpcknyllqqc	1336
			pqqqqpaiqsflqqqmpck	1337
			iqpylqqqmpcknyllqqc	1338
			lqqqmpcknyllqqcnpvs	1339
158	SRIISpRgR	157	srllsprgkelhtpqeqfpq	1340
			srllsprgkelhtpqeqfpq	1341
159	REEEEEEEp	158	iilhqqqqqqqssqvslqq	1342
160	dcEIImEEEc	159	ilprsdccvmqqqcqqqlaq	1343
			smilprsdccvmqqqcqqql	1344
			vsiilprsdccvmqqqcqqq	1345
161	SEpEIpFSE	160	qpylqlqpfsqpqlpysqpq	1346
			lqlqpfsqpqlpysqpqpf	1347
			sqpylqlqpfsqpqlpysq	1348
			lqlqpfsqpqlpysqpqpf	1349
162	EIpFSEEEE	161	qqqplpqlpfsqqqqpvlp	1350
			plisqqqqlpfsqqqqpqls	1351
			psflqqqplpqlpfsqqqq	1352
163	EEpFpIEpE	162	qqqppfplpqqpfpqqp	1353
			qqqppfplpqqpfpqqp	1354
			qqqlppfplpqqpfpqqp	1355
			qqqppfplpqqpfpqqp	1356
			ppppfplpqqpfpqqp	1357
			seqllpqqqlppfplpqqp	1358
			ppppfplpqqpfpqqp	1359
164	RFdaIRaII	163	pripeqsrzdairaiiysiv	1360
			qsryzdairaiiysivlqeqq	1361
			qsryzdairaiiysivlqeqq	1362
			pripeqsrzdairaiiysiv	1363
165	ESRFdaIRa	164	pripeqsrzdairaiiysiv	1364
			qsryzdairaiiysivlqeqq	1365

EP 2 412 380 A1

			peqsrydairaitypiilqe	1366
			qccqqlpripeqsrydaira	1367
			eqsrydairaitysiilqeq	1368
			qccqqlpripeqsrydaira	1369
			qsrydairaitysiylqeqq	1370
			pripeqsrydairaitysiylv	1371
166	EpSpEpEEI	165	flqqpqqpspqqqv vqiis	1372
			sqppflqqpqqpspqqqv v	1373
			pqqpspqqqv vqiispatp	1374
167	SIREEpIIp	166	qppfslhqppvlpqqqipyv	1375
			qppfslhqppvlpqqqipyv	1376
			qpilpqqppfslhqppvlpq	1377
			qpilpqqppfslhqppvlpq	1378
168	ppFSIREEp	167	qqqqqpilpqqppfslhqpp	1379
			qppfslhqppvlpqqqipyv	1380
			qppfslhqppvlpqqqipyv	1381
			qpilpqqppfslhqppvlpq	1382
			qpilpqqppfslhqppvlpq	1383
169	FpIIIEEEE	168	dairaitypiilqeqqqgfv	1384
170	FSEEEppF	169	psqqqqppfsqqqqpvlpq	1385
			qppfsqqqqppfsqqplis	1386
			qpsfsqqqqppfsqqqppfs	1387
			qqqqpftqqqqppfsqqppi	1388
			ppfsqqqqpsfsqqqqppfs	1389
			qqqqppfsqqqqppfsqqqq	1390
			sqqqqappfsqqqqppfsqq	1391
			fsqqqqpfsqqqqppfsqq	1392
			psfsqqqqppftqqqqppf	1393
			vlpqqppfsqqqqppfsrst	1394
			isqqqqappfsqqqqppfsq	1395
			ppfsqqqqppfsqqqqppfs	1396
			fsqqqqppfsrsthssqqpp	1397
			isqqqqppfsqqqqppfsq	1398
			qppysqqqqppfsqqqqppf	1399
			qrqlppfsqqqqppfsqqqq	1400
			fsqqqqppfsqqqqppfsqq	1401
			eqappfsqqqqppfsqqqqp	1402
			pfsqqqqppfsqhqqppvlpq	1403
			ysqqqqppfsqqqqppfsqq	1404
			qqqqqqppftqqqqppfsq	1405
			fsqqqqppfsqqqqppftq	1406
			qqqqppfsqqqqppfsqqqq	1407
			ftqqqqppfsqqspisqqqq	1408
			niqqqqppfsqqqqppfsqq	1409
			qqqqpftqqqqppfsqqspi	1410
171	EREEpIIpE	170	sqhqppvlpqqqipsvqpsi	1411
			qqplfsqkqppvlpqqpafs	1412
			plfsqkqppvlpqqppfsqq	1413
			sqqqppfsqhqqppvlpqq	1414
			psfsqqqqppfsqhqqppvlpq	1415
172	EEppFSEES	171	fsqqppfsqqppvlpqq	1416

EP 2 412 380 A1

			ftqqqppfsqqspisqqqq	1417
			qqqppftqqqppfsqqspi	1418
173	EEEEEEEEp	172	qqqqqqqqqqqqqqqqqqqq	1419
			qqqqqqqqqqqqqqqqqqqq	1420
			pfsqqqqqqqqqqqqqqqq	1421
			gsgqqqqqqqqqqqqqqqq	1422
			ppfsqqqqqqqqqqqqqq	1423
			qqqqspfsqqqqqqqqqq	1424
			spisqqqqqqqqqqqqqq	1425
			sqqqqqqqqqqqqqqqqqq	1426
			qqqqqqqqqqqqqqqqqq	1427
			qqqqqqqqqqqqqqqqqq	1428
			qqqqppftqqqqqqqqqq	1429
			qqqqqqqqqqqqqqqqqq	1430
			qqqqqqqqqqqqqqqqqq	1431
			qqqqqqqqqqqqqqqqqq	1432
			qqppfsqqqqqqqqqqqq	1433
			qqqqqqqqqqqqqqqqqq	1434
			qqqqqqqqqqqqqqqqqq	1435
			ilhqqhqqqqqqqqqqqq	1436
			qqppfsqqqqqqqqqqqq	1437
			qqqqqqqqqqqqqqqqqq	1438
			hhhqqqqqqqqqqqqqq	1439
			aiilhqqqqqqqqqqqq	1440
174	EEEEppFS	173	pfsqqqqqqqqqqqqqq	1441
			sqqqqppfsqqqqqqqq	1442
			isqqqqqqppfsqqqqqq	1443
			psfsqqqqppftqqqqpp	1444
			fsqqqqppfsqqqqppft	1445
			qqppfsqqqqqqqqqqpp	1446
175	pSIEpSIE	174	qipsvqpsilqqlnpcklfl	1447
			pvlppqqqipsvqpsilqqln	1448
176	pEEElqEEp	175	qqqlgqcsfqppqqqlgqqp	1449
			qlssqvsfqppqqqlgqqp	1450
			sfqqppqqqlgqqpqqqqqq	1451
			qqqqqlgqqpqqqqqqqvlq	1452
			sfqqppqqqlgqqpqqqqqq	1453
			qqqlgqcsfqppqqqlgqqp	1454
			csfqppqqqlgqqpqqqqqq	1455
177	cSFEpEEE	176	qqqlgqcsfqppqqqlgqqp	1456
			lgqcsfqppqqqlgqqpqq	1457
			sqqqllgqcsfqppqqqlgqq	1458
			qsqqqlgqcsfqppqqqlgq	1459
			qqqlgqcsfqppqqqlgqqp	1460
			csfqppqqqlgqqpqqqqqq	1461
178	REIccERIF	177	gplrelccqhlwqipg	1462
			qstyqllrelccqhlwqipe	1463
			qstyqllrelccqhlwqipe	1464
			gplrelccehlwqipg	1465
			qstyqllrelccqhlwqipe	1466
179	IEEEpIIE	178	peppfsqqqqpvlqqspfs	1467

EP 2 412 380 A1

			qqpilpeppfs lqqqvlpq	1468
			psflqqqpilpq lpfsgqqq	1469
			pfsqqqpsflqqqpilpq lp	1470
180	ERppFSEEE	179	qrppfsqqq qqpvlqqppf	1471
			lqqppfsqqrppfsqqq qqp	1472
			qrppfsqqq qqpvlqqppf	1473
			lqqppfsqqrppfsqqq qqp	1474
181	mIFIEEEcI	180	svlqqlnpcmvflqqqci pv	1475
			mvflqqqci pvamqrclars	1476
182	EEERpFIEp	181	qqsfpqqqrpfiaq slqqql	1477
			qpqqppqsfpqqqrpfiaq s	1478
			fpqqqrpfiaq slqqqlnpc	1479
183	SFpEIpgEI	182	gyyp tfpqlpgql qpaqqq	1480
184	IEEEIIPeI	183	ggqvqwlqeqlvpql g	1481
			psgvqwlqqqlvpql qpl	1482
			ggqvqwlqeqlvpql g	1483
			ggqvqwlqqqlvpql g	1484
			psgvqwlqqqlvpql qpl	1485
185	ppFIEpSIE	184	fpqqppfiqpslq qqvnpq	1486
			pqqppfiqpslq qqvnpck	1487
			qqppqsfpqqppfiqpslq	1488
186	IIPeEpaFS	185	qqpl tsgkqpvlqqpafs	1489
			kqpvlqqpafs qqqt vl	1490
			qqqt vlqqpafs qqhqql	1491
187	pEpEEElpE	186	lqqppqpl pqpqqql pqpqq	1492
			qqpp pqpqqql pqpqq	1493
			lqqppqpl pqpqqql pqpqq	1494
			qqpp pqpqqql pqpqq	1495
			qp pqpqqql pqpqqqs f	1496
			pqpqqql pqpqqqs fpqq	1497
188	gSanmEIdp	187	gtanmqvdp ssqvqwpqqqp	1498
			gtanmqvdp ssqvqwpqqqp	1499
			gtanmqvdp ssqvqwpqqqp	1500
189	EEEgmRIFI	188	qqqqqqqqqgmhifl plsqq	1501
			imqqqqqqqqqqgmhifl pl	1502
			qqqqgmhifl plsqqqqvgq	1503
190	RIIRaIIIR	189	caihkvvhailhqqkqq	1504
			caihkvvhailhqqkqqq	1505
191	IpIFgSSSS	190	lrtlpmcsvgv vpvvgttts	1506
			lptmcgvn vplygttts vpf	1507
			vpvygttts vpfvgvtqvgq	1508
			csvn vpvvgttts vpfvgvt	1509
192	pEEIgEEpE	191	pqpqqqlqqqpqqevpqvaf	1510
			qcsfqppqpqqqlqqqpqqe	1511
193	ESgEEElIE	192	qgvsqpqqqsgqqqlvq csf	1512
			qsgqqqlvq csfqppqpqqql	1513
194	FppEIpFpE	193	pqp fppqlpypqqlpypqp	1514
			pqp fppqlpypqqlpypqp	1515
			qp fppqlpypqqlpypqp	1516
			pqp fppqlpypqqlpypqp	1517
			lqlqpfpqpqp fppqlpypq	1518

			ppq fppqlpyppqppfrpqq	1519
			ppq fppqlpyppqpppfsppq	1520
			lqlqpfppqpp fppqlpyppq	1521
			ppq fppqlpyppqpsfppqq	1522
			mqlqpfppqpp fppqlpyppq	1523
			qqppq fppqlpyppqg	1524
			qqppq fppqlpyppqg	1525
			ppppqpp fppqlpyppqppf	1526
			ppppqpp fppqlpyppqpsf	1527
			ppppqpp fppqlpyppq	1528
			ppq fppqlpyppqpppfsppq	1529
			gsg fppqlpyppq gsg	1530
			ppppq fppqlpyppqtppfpp	1531
			ppq fppqlpyppqtppfppqq	1532
			qp fppqlpyppqtppfppqqp	1533
195	cSpIampER	194	ckvflqqq cspvampqr lar	1534
			lqqq cspvampqr lar	1535
			vflqq cspvampqr larsqm	1536
			lnpckvflqqq cspvampqr	1537
			qqq cspvampqr larsqmwq	1538
			csqvampqr larsqmwqgss	1539
			q cspvampqh larsqmwqgss	1540
			ckvflqqq cspvampqr lar	1541
			qlnpckvflqqq cspvampqr	1542
			qqq cspvampqr larsqmwq	1543
			vflqqq cspvampqh larsq	1544
			vflqqq cspvampqr larsq	1545
196	dEESqEqEE	195	sqrrqqdqsgqqppgrrq	1546
197	EIEESIIFg	196	tppqqlqqsilwgipallr	1547
198	pFSEEEIpI	197	qqppfsqqelpi lpqqppfs	1548
			qqppppfsqqppfsqqelpi	1549
			fsqqppfsqqelpi lpqqp	1550
199	SSRIpgIER	198	me tshipglekpsqqplpl	1551
			me tsrvpglekpwqqplpp	1552
200	SIaIRSIpm	199	lmt sialrtlpmmcsvnpv	1553
			hlevmt sialrtlpmmcsvn	1554

**Figure 6**

- Sequence 1: P(QR)P(QE)LP(FY)PQ (SEQ ID NO: 1555)  
 Optimal responding peptide: PQLPYQPQLPYQPQPFRP (SEQ ID NO: 1556)  
 High grade peptide: QLQPFPPQPELPYPQPQP (SEQ ID NO: 1557)  
 Groups included: 1,2,7,8,10,16,22,23,72
- Sequence 2: P(FY)P(QR)P(QE)LP(FY) (SEQ ID NO: 1558)  
 Optimal responding peptide: PQLPYQPQLPYQPQPFRP (SEQ ID NO: 1559)  
 High grade peptide: QLQPFPPQPELPYPQPQP (SEQ ID NO: 1560)  
 Groups included: 1,2,7,8,10,16,22,23,72, 76 PART
- Sequence 3: (PIAT)FPQ(PT)(QE)Q(PTS)(FITY) (SEQ ID NO: 1561)  
 Optimal responding peptide: QPFPQPQPFPWQPQPFPQ (SEQ ID NO: 1562)  
 High grade peptides: GQQPFPQPEQFPWQG (SEQ ID NO: 1563)  
 GQQPFPQPEQFIPVQG (SEQ ID NO: 1564)  
 Groups included:  
 3,5,6,9,20,24,29,60,69,70,73,74,77,102PT,108,112
- Sequence 4: PQ(PT)(QE)Q(PTS)(FIY)(PS)(VWHQL) (SEQ ID NO: 1565)  
 Optimal responding peptide: QPFPQPQPFPWQPQPFPQ (SEQ ID NO: 1566)  
 High grade peptide: GQQPFPQPEQFPWQG (SEQ ID NO: 1567)  
 GQQPFPQPEQFIPVQG (SEQ ID NO: 1568)  
 Groups included: 3,5,6,9,20,60,66,69,73,74,77,PART 86  
 (3 AND 4 OVERLAP)  
 Status: Similar to Sequence 3
- Sequence 5: (KQW)(QR)P(QE)Q(SPIT)(FLY)PQ (SEQ ID NO: 1569)  
 Optimal responding peptide: QPQLPFPQPQPQPFPQ (SEQ ID NO: 1570)  
 High grade peptide: GFPQTQQPEQFPQQG (SEQ ID NO: 1571)  
 Groups included: 11,12,32,54,55,56,59,61,62,65
- Sequence 6: P(FIYL)(PS)(QE)(QR)P(QE)Q(PT) (SEQ ID NO: 1572)  
 Optimal responding peptide: PLQPQPFPQPQPFPQPQ (SEQ ID NO: 1573)  
 High grade peptide: QPFPPEQPQPFPQQG (SEQ ID NO: 1574)  
 Groups included: 32PT,54,55,56,57,61,62,63PT,75,85.94PT
- Sequence 7: FLP(QE)LPYPQ (SEQ ID NO: 1575)  
 Optimal responding peptide: LQLQPFPPQPFLPQLPYPQ (SEQ ID NO: 1576)  
 High grade peptide: PQQPFLPELPYPQPQS (SEQ ID NO: 1577)  
 Groups included: 13,27,71 PART
- Sequence 8: LQQIL(QE)QQL (SEQ ID NO: 1578)  
 Optimal responding peptide: LQQILQQQLTPCMDVVLQQH (SEQ ID NO: 1579)  
 High grade peptide: NO  
 Groups included: 14,89
- Sequence 9: FSYQ(EQ)QFPQ (SEQ ID NO: 1580)  
 Optimal responding peptide: PQQSF'SYQQPFPQPYPQ (SEQ ID NO: 1581)  
 High grade peptide: NO  
 Groups included: 15,96PT
- Sequence 10: FPS(QE)(LQ)PY(LM)Q (SEQ ID NO: 1582)  
 Optimal responding peptide: PFPSQQPYLQLQPFPPQLP (SEQ ID NO: 1583)  
 High grade peptide: NO  
 Groups included: 16PT,35,38,71PT, 76PT,92PT,93PT
- Sequence 11: (PQSH)QP(QE)Q(QE)(LF)(PS)Q (SEQ ID NO: 1584)  
 Optimal responding peptide: QQPQPFPQPQPFPQ (SEQ ID NO: 1585)  
 High grade peptide: GFFPQPEQEFPQQG (SEQ ID NO: 1586)

## EP 2 412 380 A1

Groups included: 17,25,36,40,41,80,88

- Sequence 12: P(FW)(SP)(EQ)Q(EQT)QP(VILSF) (SEQ ID NO: 1587)  
Optimal responding peptide: QQQQPPFSQQQPVLQQSP (SEQ ID NO: 1588)  
(similar to but more active than PFSQQQSF in WO 02/083722)  
PSGQVQWPQQQPPFPQQP (SEQ ID NO: 1589)  
High grade peptide: GQPPFSEQEQPVLPPQ (SEQ ID NO: 1590)  
Groups included: 18,79,84PT,97,102PT,103PT,115
- Sequence 13: (IL)QP(QE)QPFQ (SEQ ID NO: 1591)  
Optimal responding peptide: FTQPQQPTPIQPQQPFPQQP (SEQ ID NO: 1592)  
(similar to but more active than IIQPQQPAQ in WO 02/083722)  
High grade peptide: GQQQFIQPEQPFPQQG (SEQ ID NO: 1593)  
Groups included: 19 (PART),26,30,58
- Sequence 14: QQP(EQ)LFPQ (SEQ ID NO: 1594)  
Optimal responding peptide: QQPQQPFPQPQQPQLFPQ (SEQ ID NO: 1595)  
High grade peptide: NO  
Groups included: 21,64
- Sequence 15: QPQP(EQ)LPF (SEQ ID NO: 1596)  
Optimal responding peptide: QQPQQPFPQPQQPQLFPQ (SEQ ID NO: 1597)  
High grade peptide: NO  
Groups included: 21
- Sequence 16: PQP(EQ)QP(EQ)LP (SEQ ID NO: 1598)  
Optimal responding peptide: QQPQQPFPQPQQPQLFPQ (SEQ ID NO: 1599)  
High grade peptide: NO  
Groups included: 21
- Sequence 17: VFLQQCSPV (SEQ ID NO: 1600)  
Optimal responding peptides:  
GROUP 28: SVLQQLNPCKVFLQQCQSHV (SEQ ID NO: 1601)  
GROUP 122: CKVFLQQCSPVAMPQRLAR (SEQ ID NO: 1602)  
GROUP 114: KVFLQQCSPVAIPYRLARS (SEQ ID NO: 1603)  
High grade peptide: NO  
Groups included: 28,114,122
- Sequence 18: (M)(WL)(QW)QSSCHVMQ (SEQ ID NO: 1604)  
Optimal responding peptides:  
GROUP 39: PQLARSQMWWQSSCHVMQQ (SEQ ID NO: 1605)  
GROUP 110: ARSOTLWQSSCHVMQCCR (SEQ ID NO: 1606)  
High grade peptide: NO  
Groups included: 39,110
- Sequence 19: QPQQQLAH (SEQ ID NO: 1607)  
Optimal responding peptide: QQPQQQLAHGTFLOPHQIA (SEQ ID NO: 1608)  
High grade peptide: NO  
Groups included: 31
- Sequence 20: FPLQPQP(FL)PQ (SEQ ID NO: 1609)  
Optimal responding peptide: PQLQPPFLQPQQPFPQQP (SEQ ID NO: 1610)  
High grade peptide: NO  
Groups included: 33
- Sequence 21: FPP(QE)(LQ)PYPQ (SEQ ID NO: 1611)  
Optimal responding peptide: PPFPPPELPPYPQPFRPQQ (SEQ ID NO: 1612)  
High grade peptide: PQQPFPPLPYPQPQS, (SEQ ID NO: 1613)  
GQQPFPPEQPYPQQG (SEQ ID NO: 1614)  
Groups included: 37,52,71,92PT,93PT,105

## EP 2 412 380 A1

- Sequence 22: LCC(QE)(HQR)L(PW)(QE)IP (SEQ ID NO: 1615)  
Optimal responding peptide: QSTYQPLQLCCQQLWQIPE (SEQ ID NO: 1616)  
High grade peptide: NO  
Groups included: 39PT,100,104,107,178
- Sequence 23: P(WLS)(QL)(QE)QPL(PQ)(PQ) (SEQ ID NO: 1617)  
Optimal responding peptide: ERPWQEQPLPPQHTLFPQQQ (SEQ ID NO: 1618)  
High grade peptide: NO  
Groups included: 44,78,90,95PT,98,116,117,113
- Sequence 24: QPLP(QE)QPSF (SEQ ID NO: 1619)  
Optimal responding peptide: PPFSQQQQPLPQQPSFSQQ (SEQ ID NO: 1620)  
High grade peptide: NO  
Groups included: 45,95PT
- Sequence 25: PF(SP)QQQQP(LVI) (SEQ ID NO: 1621)  
Optimal responding peptide: PPFSQQQQPLPQQPSFSQQ (SEQ ID NO: 1622)  
High grade peptide: NO  
Groups included: 45 PART
- Sequence 26: IVYSTILQE (SEQ ID NO: 1623)  
Optimal responding peptide: QQSRYEAIRIVYSTILQEQ (SEQ ID NO: 1624)  
High grade peptide: NO  
Groups included: 46
- Sequence 27: PFSQ(QE)QP(IS)(LF)S (SEQ ID NO: 1625)  
Optimal responding peptide: FSQQPPFSQQQPILSQQPP (SEQ ID NO: 1626)  
High grade peptide: NO  
Groups included: 47 PART,68
- Sequence 28: QGIQILRPL (SEQ ID NO: 1627)  
Optimal responding peptide: QEQQQGIQILRPLFQLVQGG (SEQ ID NO: 1628)  
High grade peptide: NO  
Groups included: 48
- Sequence 29: PFSSVAGI (SEQ ID NO: 1629)  
Optimal responding peptide: CSIIKAPFSSVAGIGGQYR (SEQ ID NO: 1630)  
High grade peptide: NO  
Groups included: 49
- Sequence 30: YCSTTIAPV (SEQ ID NO: 1631)  
Optimal responding peptide: YIPPYCSTTIAPVGIFGTN (SEQ ID NO: 1632)  
High grade peptide: NO  
Groups included: 50
- Sequence 31: HVAMSQRLA (SEQ ID NO: 1633)  
Optimal responding peptides: QQCSHVAMSQRLARSQMWWQ (SEQ ID NO: 1634)  
High grade peptide: NO  
Groups included: 51
- Sequence 32: YSIIILQ(QE)(QE)(QE)QGF (SEQ ID NO: 1635)  
Optimal responding peptide: RYDAICAITYSIIILQEQQQG (SEQ ID NO: 1636)  
High grade peptide: NO  
Groups included: 53
- Sequence 33: FPHQPQEQAFPQ (SEQ ID NO: 1637)  
Optimal responding peptide: QQIFPQPQQTFPHQPQQAFFP (SEQ ID NO: 1638)  
High grade peptide: GQTFPHQPEQAFFQPG (SEQ ID NO: 1639)  
Groups included: 67

EP 2 412 380 A1

- Sequence 34: PS(GS)(QE)V(QE)WPQ (SEQ ID NO: 1640)  
Optimal responding peptide: ATANMQADPSGQVQWPQQQP (SEQ ID NO: 1641)  
High grade peptide: NO  
Groups included: 81,102PT
- Sequence 35: GALCSSLSN (SEQ ID NO: 1642)  
Optimal responding peptide: FDEEKNSTGALCSSLSNQAS (SEQ ID NO: 1643)  
High grade peptide: NO  
Groups included: 82
- Sequence 36: QFP(QE)Q(QE)IPV (SEQ ID NO: 1644)  
Optimal responding peptide: QPPFPQQHQFPQQIPVVQ (SEQ ID NO: 1645)  
High grade peptide: NO  
Groups included: 83
- Sequence 37: P(FY)P(QE)QP(YF)PQ (SEQ ID NO: 1646)  
Optimal responding peptide: QQPFPQQPYPQQPYPSQQPY (SEQ ID NO: 1647)  
High grade peptide: NO  
Groups included: 96
- Sequence 38: QAGQG(QE)(QE)GY (SEQ ID NO: 1648)  
Optimal responding peptide: GQQAGQGQQGYPTSPQQLG (SEQ ID NO: 1649)  
High grade peptide: NO  
Groups included: 101
- Sequence 39: TLPSMCNVY (SEQ ID NO: 1650)  
Optimal responding peptide: FEEIRNLALQTLPSMCNVYI (SEQ ID NO: 1651)  
High grade peptide: NO  
Groups included: 106
- Sequence 40: FQPSQ(QE)NPQ (SEQ ID NO: 1652)  
Optimal responding peptide: QQYPSGQGFFQPSQQNPQAQ (SEQ ID NO: 1653)  
High grade peptide: NO  
Groups included: 109
- Sequence 41: IRSLVLKTL (SEQ ID NO: 1654)  
Optimal responding peptide: QPQQPAQLEGIRSLVLKTL (SEQ ID NO: 1655)  
High grade peptide: NO  
Groups included: 119,120,121

**Figure 7**

Gliadin Sequence	SEQ ID NO:	High quality peptide	A	B	C	D	E	F	G	H	I	J
1,2	1656	QLQPFPPQLPYQPQP	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3,4	1657	GQQPFPPQPEQFPWQG	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3,4	1658	GQQPFPPQPEQPIPVQG	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
3,4	1659	GQQPFPPQPEQFPWQG	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
5	1660	GFPQTQQPEQFPQQG		Y	Y				Y	Y		Y
5	1661	GFPQTQQPEQFPQQG		Y	Y				Y	Y		Y
6	1662	GQPFPEQPQQFPQQG								Y		
7	1663	PQPQFLPQLPYQPQS	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
11	1664	GFFPQPEQEFPQQG		Y	Y	Y	Y		Y			Y
11	1665	GFFPQPEQEFPQQG		Y	Y	Y	Y		Y			Y
12	1666	GQPPFSEQEQVLPQG					Y		Y		Y	
12	1667	GQPPFSEQEQVLPQG					Y		Y		Y	
13	1668	GQQQFIQPEQFPQQG		Y	Y	Y		Y	Y	Y		Y
21	1669	PQPQFPQLPYQPQS	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
21	1670	GQQQFPPEQYPQQG		Y	Y						Y	Y
33	1671	GQTFPHQPEQAFFQPG		Y	Y				Y		Y	Y

**Figure 8**

Avenin 20mer	SEQ ID NO:	Predicted core sequence(s)	SEQ ID NO:	Lambda	Proportion
TTTVQYDPSEQYQPYPEQQQ	1672	DPSEQYQPY	1684	33.58	0.145
QFDPSEQYQPYPEQQQPILQ	1673	PYPEQQQPI DPSEQYQPY	1685 1686	122.34	0.103
*VQYDPSEQYQPYPEQQQPFV	1674	PYPEQQQPF DPSEQYQPY	1687 1688	122.34	0.105
TVQYNPSEQYQPYPEQQQEPF	1675	PYPEQQQEPF DPSEQYQPY	1689 1690	146.42	0.051
YQPYPEQQQPILQQQMLLQ	1676	PYPEQQQPI	1691	52.56	0.126
EQYQPYPEQQQPFVQQQPPF	1677	PYPEQQQPF	1692	90.39	0.053
SEQYQPYPEQQQPFMQPLLQ	1678	PYPEQQQPFM	1693	19.07	0.226
*CRRLEQIPEQLRCPAIHSVV	1679	RRLEQIPEQ	1694	61.47	0.069
*QIPEQLRCPAIHSVVQAIL	1680			94.84	0.033
*NNKREQQFGQNI FSGFSVQL	1681			104.78	0.077
*QILRQAICQVTRQCCRLA	1682			34.01	0.055
*VPFLRSQILRQSTCHVMRRQ	1683			92.47	0.067

Sequence 1: PYPEQ(QE)QP(IF)(VLM) (SEQ ID NO:1695)  
 Optimal responding peptide: QFDPSEQYQPYPEQQQPILQ (SEQ ID NO:1696)  
 High grade peptide: NO  
 POTENCY: 6/30 RESPONDERS, RESPONSE RATE 122.3  
 (HOMOLOGOUS TO WHEAT Sequence 12: GQPPFSEQEQPVLPQG (SEQ ID NO:1590))

Sequence 2: CRRLEQIPEQLRCPAIHSVV (SEQ ID NO:1697)

Sequence 3: QFGQNI FSGFSVQLLSEALG (SEQ ID NO:1698)  
 POTENCY: 12/30 RESPONDERS, RESPONSE RATE 11.2

**Figure 10**

VRVPVPQLQP QNPSQQQPQE QVPLVQQQQF PGQQQQFPPQ  
 QPYPQPQPF SQQPYLQLQP FPQPQLPYPO PQSFPPQOPY  
 PQPQPQYSQP QQPISQQQAQ QQQQQQQQQQ QQQILQQILQ  
 QQLIPCMDVV LQQHNIAHAR SQVLOQSTYQ LLQELCCQHL  
 WQIPEQSQCQ AIHNVVHAI LHQQQKQQQQ PSSQVSFQQP  
 LQQYPLGQGS FRPSQQNPQA QGSVQPQQLP QFEEIRNLAL  
 QTLPAMCNVY IAPYCTIAPF GIFGTN (SEQ ID NO: 1928)

Figure 9

Group	Predicted epitope "core(s)"	SEQ ID NO:	Sequences	SEQ ID NO:	Response (SFC)	
					A	B
1	QQPTPIQPQ	1699	PFTQPQQPTPIQPQQPFQ	1722	70	18
2	QQPFPQQPQ or QQPFPWQPQ or QQPFPQSQQ	1700 1701 1702	QQQFIQPQQPFPQQPQQTYP	1723	57	21
			PFQQQPQQPFPQQPQQSFPQ	1724	53	23
			TPIQPQQPFPQQPQQPQQPF	1725	64	16
			QTQQPQQPFPQQPQQPFPQT	1726	52	17
			QQFLQPQQPFPQQPQQPYPQ	1727	44	16
			PQQPFPQQPQQPQQPFPQ	1728	51	14
			QQPFPQQPQQPFPQQPQQPI	1729	81	10
			PQQPFLQPQQPFPQQPQQPF	1730	45	9
			QPFQPPQQPFPWQPQQPFPQ	1731	19	8
			QPQQPFPQSQQPQQPFPQ	1732	41	15
			PQTQQPQQPFPQSQQPQQPF	1733	36	9
3	QQPFLQPQ or QQPFPQLQQ	1703 1704	SEQIIPQQLQQPFPFLQPQQP	1734	12	3
			PFPQTQQPQQPFPQLQQPQQ	1735	25	13
4	QQPIPVPQPQ or QQPIPQQPQ or QQPYPQQPQ	1705 1706 1707	QPQQPIPVQPQSFQQSQQ	1736	60	12
			FPELQQPIPQQPQQPFPFLQP	1737	22	7
			FQQPQQPYPQQPQQPFPQT	1738	19	4
			PRQPFQQPQQPYPQQPQQP	1739	19	13
5	PQQPQSFQQQ or PQQPQQPFPQQ	1708 1709	PFPQPQQPQSFQQQQPLI	1740	29	15
			LPQQPQQPQSFQQQRPFIQ	1741	37	12
			QPQQPQQPFPQQQPLIQPY	1742	49	17
6	QGSFQPSQQ	1710	QPQQQYPSGQGSFQPSQQNP	1743	54	5
			QYPSSQGSFQPSQQNPQAQG	1744	32	7
			GQGFFQPSQQNPQAQGSFQP	1745	7	3
7	PQQPFPQPQ or PQQPFPQTQ or	1711 1712	PQTQQPQQPFPQPQQTFPQQ	1746	21	9
			QQPQQPFPQPQLPFPQQSEQ	1747	15	2
			FWPQPQQPFPQTQSFPLQP	1748	25	7
8	QQPQQPFPQ or QQPQQPYPQ	1713 1714	PFPQTQQPQQPFPQLQQPQQ	1749	25	13
			QQPLPQPQQPQQPFPQSQQP	1750	54	20
			PFPQLQQPQQPFPQPQQQLP	1751	36	5
			PRQPFQQPQQPYPQQPQQP	1752	19	13
9	PFPQPQQPQ or PFPQSQQPQ or PFPQPQQAQ or QFPQTQQPQ	1715 1716 1717 1718	PQQPFPQPQQPQQPFPQLQQ	1753	37	8
			PQTQQPQQPFPQSQQPQQPF	1754	36	9
			QPQQPFPQSQQPQQPFPQPQ	1755	41	15
			PQQPQQPFPQPQQQAQLPFPQ	1756	16	7
			HQPQQQFPQTQQPQQPFPQP	1757	30	14
10	PQQQFIQPQ	1719	FSQPQQPQQQFIQPQQPFPQ	1758	45	8
11	QQPQLPFPQ or LQPQQPFPQ	1720 1721	PQPQQPQLPFPQQPQQPFPQ	1759	79	7
			PQQQFLQPQQPFPQQPQQPY	1760	35	14
12			QTLPAMCNVYIIPHCSTTIA	1761	35	7
13			NPSQQQPQEQVPLVQEQQFQ	1762	5	16
14			HHFRSNSNHFFHSNNNQFYR	1763	14	3



## EUROPEAN SEARCH REPORT

 Application Number  
 EP 10 17 1494

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X,D	WO 01/25793 A (ISIS INNOVATION LIMITED; ANDERSON, ROBERT, PAUL; HILL, ADRIAN, VIVIAN,) 12 April 2001 (2001-04-12) * page 6, line 10 - page 11, line 31; claims *	1-30	INV. A61K38/16 A61P1/00
X,D	WO 03/104273 A (ISIS INNOVATION LIMITED; ANDERSON, ROBERT, PAUL; HILL, ADRIAN, VIVIAN,) 18 December 2003 (2003-12-18) * page 11, line 20 - page 17, line 23; claims *	1-30	
X,D	WO 02/083722 A (ACADEMISCH ZIEKENHUIS LEIDEN; DRIJFHOUT, JAN, WOUTER; KONING, FRITS; M) 24 October 2002 (2002-10-24) * claims; examples *	1-30	
X,D	EP 1 332 760 A1 (ACADEMISCH ZIEKENHUIS LEIDEN; DRIJFHOUT, JAN, WOUTER; VAN VEELEN, PETR) 6 August 2003 (2003-08-06) * claims 1, 2,33; sequence 337 *	1-30	
X	WO 03/096979 A2 (UNIV LELAND STANFORD JUNIOR [US]; KHOSLA CHAITAN [US]; HAUSCH FELIX [C]) 27 November 2003 (2003-11-27) * page 8, line 32; claims *	26-30	TECHNICAL FIELDS SEARCHED (IPC) A61K A61P
Y	US 2003/215438 A1 (HAUSCH FELIX [DE] ET AL) 20 November 2003 (2003-11-20) * claims; sequence 25 *	1-30	
Y	FRASER J S ET AL: "Coeliac disease: In vivo toxicity of the putative immunodominant epitope.", GUT, vol. 52, no. 12, December 2003 (2003-12), pages 1698-1702, XP002363983, ISSN: 0017-5749 * abstract *	1-30	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 28 December 2011	Examiner Winger, Rudolf
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 10 17 1494

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-12-2011

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0125793	A	12-04-2001	AT 319091 T	15-03-2006
			AT 449965 T	15-12-2009
			AU 782262 B2	14-07-2005
			AU 7539400 A	10-05-2001
			CA 2386089 A1	12-04-2001
			DE 60026332 T2	10-08-2006
			DK 1218751 T3	03-07-2006
			DK 1672368 T3	04-01-2010
			EP 1218751 A2	03-07-2002
			EP 1672368 A1	21-06-2006
			ES 2256042 T3	16-07-2006
			ES 2335895 T3	06-04-2010
			HK 1088068 A1	09-04-2010
			JP 2003511670 A	25-03-2003
			JP 2010263898 A	25-11-2010
			MX PA02003295 A	02-09-2002
			PT 1218751 E	30-06-2006
			PT 1672368 E	20-01-2010
			US 7144569 B1	05-12-2006
			US 2008175971 A1	24-07-2008
			US 2009269285 A1	29-10-2009
WO 0125793 A2	12-04-2001			
WO 03104273	A	18-12-2003	AU 2003244771 A1	22-12-2003
			CA 2488218 A1	18-12-2003
			EP 1513873 A2	16-03-2005
			EP 2292649 A2	09-03-2011
			JP 2006512893 A	20-04-2006
			JP 2010229138 A	14-10-2010
			MX PA04012117 A	19-04-2005
			NZ 537226 A	30-06-2008
			US 2006178299 A1	10-08-2006
			WO 03104273 A2	18-12-2003
			ZA 200409740 A	27-09-2006
WO 02083722	A	24-10-2002	CA 2443886 A1	24-10-2002
			MX PA03009313 A	12-11-2004
			NO 20034588 A	10-12-2003
			US 2004241161 A1	02-12-2004
			WO 02083722 A2	24-10-2002
EP 1332760	A1	06-08-2003	AU 2003207415 A1	02-09-2003
			CA 2475055 A1	14-08-2003
			EP 1332760 A1	06-08-2003
			EP 1471929 A2	03-11-2004
			MX PA04007494 A	10-11-2004

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 10 17 1494

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-12-2011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		US 2005244823 A1	03-11-2005
		WO 03066079 A2	14-08-2003
-----			
WO 03096979	A2	27-11-2003	
		AU 2003234597 A1	02-12-2003
		AU 2003234634 A1	02-12-2003
		CA 2487247 A1	27-11-2003
		EP 1507549 A2	23-02-2005
		WO 03096979 A2	27-11-2003
		WO 03096984 A2	27-11-2003
-----			
US 2003215438	A1	20-11-2003	
		US 2003215438 A1	20-11-2003
		US 2008145356 A1	19-06-2008
		US 2008213245 A1	04-09-2008
		US 2008213427 A1	04-09-2008
		US 2008213822 A1	04-09-2008
		US 2009280555 A1	12-11-2009
		US 2011293724 A1	01-12-2011
-----			

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 03066079 A [0006] [0205]
- WO 02083722 A [0007] [0009] [0088]
- WO 0125793 A [0008] [0088] [0215]
- WO 03104273 A [0010] [0088] [0203] [0205] [0215]
- WO 9823960 A [0100]
- EP 0693119 A [0115]
- EP 0255378 A [0179]
- WO 9217580 A [0179]
- WO 9845460 A [0179]
- WO 9845461 A [0179]
- WO 9920775 A [0179]
- US 4459355 A [0182]
- US 4536475 A [0182]
- US 5464763 A [0182]
- US 5177010 A [0182]
- US 5187073 A [0182]
- EP 267159 A [0182]
- EP 604662 A [0182]
- EP 672752 A [0182]
- US 4945050 A [0182]
- US 5036006 A [0182]
- US 5100792 A [0182]
- US 5371014 A [0182]
- US 5478744 A [0182]
- US 5179022 A [0182]
- US 5565346 A [0182]
- US 5484956 A [0182]
- US 5508468 A [0182]
- US 5538877 A [0182]
- US 5554798 A [0182]
- US 5489520 A [0182]
- US 5510318 A [0182]
- US 5204253 A [0182]
- US 5405765 A [0182]
- EP 442174 A [0182]
- EP 486233 A [0182]
- EP 486234 A [0182]
- EP 539563 A [0182]
- EP 674725 A [0182]
- WO 9102071 A [0182]
- WO 9506128 A [0182] [0191]
- EP 0293358 A [0190]
- WO 9200377 A [0190]
- EP 0242236 A [0190]
- EP 0369367 A [0190]
- WO 9102701 A [0191]

## Non-patent literature cited in the description

- **Vader W. et al.** *J. Exp. Med.*, 2002, vol. 195, 643-649 [0006] [0205]
- **Fleckenstein B.** *J Biol Chem*, 2002, vol. 277, 34109-16 [0006] [0205]
- **Vader et al.** *J Exp Med. J. Exp. Med.*, 2002, vol. 195, 643-649 [0006]
- **Arentz-Hansen H.** *J. Exp. Med.*, 2000, vol. 191, 603-612 [0007]
- **Arentz-Hansen H.** *Gastroenterology*, 2002, vol. 123, 803-809 [0007] [0009]
- **Sjostrom H. et al.** *Scand. J. Immunol.*, 1998, vol. 48, 111-115 [0007]
- **van de Wal, Y. et al.** *J. Immunol.*, 1998, vol. 161 (4), 1585-1588 [0007] [0217]
- **van de Wal, Y. et al.** *Eur. J. Immunol.*, 1999, vol. 29, 3133-3139 [0007]
- **Vader W. et al.** *Gastroenterology*, 2002, vol. 122, 1729-1737 [0007]
- **Anderson, RP et al.** *Nat. Med.*, 2000, vol. 6, 337-342 [0008] [0215]
- **Arentz-Hansen H. et al.** *J. Exp. Med.*, 2000, vol. 191, 603-612 [0008]
- **Arentz-Hansen H. et al.** *Gastroenterology*, 2002, vol. 123, 803-809 [0008]
- **Lundin KEA et al.** *Gut*, 2003, vol. 52, 1649-52 [0013]
- **van de Wal et al.** *J. Immunol.*, 1998, vol. 161 (4), 1585-1588 [0056]
- **Devereux et al.** *Nucleic Acids Research*, 1984, vol. 12, 387-395 [0073]
- **Altschul S. F.** *J Mol Evol*, 1993, vol. 36, 290-300 [0073]
- **Altschul, S, F et al.** *J Mol Biol*, 1990, vol. 215, 403-10 [0073]
- **Henikoff ; Henikoff.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 10915-10919 [0074]
- **Karlin ; Altschul.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 5873-5787 [0075]
- **Lalvani et al.** *J. Exp. Med.*, 1997, vol. 186, 859-865 [0105]
- **Ota et al.** *Nature*, 1990, vol. 346, 183-187 [0106]
- **Yoshida et al.** *Clin. Immunol. Immunopathol.*, 1997, vol. 82, 207-215 [0123]
- **Thurau et al.** *Clin. Exp. Immunol.*, 1997, vol. 109, 370-6 [0123]

- **Weiner et al.** *Res. Immunol.*, 1997, vol. 148, 528-33 [0123]
- **Kricka LJ.** *J. Biolumin. Chemilumin.*, 1998, vol. 13, 189-93 [0133]
- **Sambrook et al.** *Molecular Cloning: A Laboratory Manual*. 1989 [0155]
- **Kohler ; Milstein.** *Nature*, 1975, vol. 256, 495-497 [0163]
- **Delta et al.** *Biotechnology Ann. Rev.*, 1997, vol. 3, 269-296 [0179]
- **Vasil V et al.** *Biotechnology*, 1992, vol. 10, 667-674 [0181]
- **Molberg O et al.** *Nature Med.*, 1998, vol. 4, 713-717 [0247]
- **Quarsten H et al.** *Eur. J. Immunol.*, 1999, vol. 29, 2506-2514 [0247]
- **Greenberg CS et al.** *FASEB*, 1991, vol. 5, 3071-3077 [0247]
- **Mantzaris G ; Jewell D.** *Scand. J. Gastroenterol.*, 1991, vol. 26, 392-398 [0247]
- **Mauri L et al.** *Scand. J. Gastroenterol.*, 1996, vol. 31, 247-253 [0247]
- **Bunce M et al.** *Tissue Antigens*, 1995, vol. 46, 355-367 [0247]
- **Olerup O et al.** *Tissue antigens*, 1993, vol. 41, 119-134 [0247]
- **Mullighan CG et al.** *Tissue-Antigens.*, 1997, vol. 50, 688-92 [0247]
- **Plebanski M et al.** *Eur. J. Immunol.*, 1998, vol. 28, 4345-4355 [0247]
- **Anderson DO ; Greene FC.** The alpha-gliadin gene family. II. DNA and protein sequence variation, sub-family structure, and origins of pseudogenes. *Theor Appl Genet*, 1997, vol. 95, 59-65 [0247]
- **Arentz-Hansen H ; Korner R ; Molberg O ; Quarsten H ; Van der Wal Y ; Kooy YMC ; Lundin KEA ; Koning F ; Roepstorff P ; Sollid LM.** The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. *J Exp Med.*, 2000, vol. 191, 603-12 [0247]
- **Vader LW ; de Ru A ; van der Wal ; Kooy YMC ; Benckhuijsen W ; Mearin ML ; Drijfhout JW ; van Veelen P ; Koning F.** Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. *J Exp Med*, 2002, vol. 195, 643-649 [0247]
- **van der Wal Y ; Kooy Y ; van Veelan P ; Pena S ; Mearin L ; Papadopoulos G ; Koning F.** Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. *J Immunol.*, 1998, vol. 161, 1585-8 [0247]
- **van der Wal Y ; Kooy Y ; van Veelan P ; Pena S ; Mearin L ; Molberg O ; Lundin KEA ; Sollid L ; Mutis T ; Benckhuijsen WE.** *Proc Natl Acad Sci USA*, 1998, vol. 95, 10050-10054 [0247]
- **Vader W ; Kooy Y ; Van Veelen P et al.** The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. *Gastroenterology*, 2002, vol. 122, 1729-37 [0247]
- **Arentz-Hansen H ; McAdam SN ; Molberg O et al.** Celiac lesion T cells recognize epitopes that cluster in regions of gliadin rich in proline residues. *Gastroenterology*, 2002, vol. 123, 803-809 [0247]

专利名称(译)	表位与乳糜泻有关		
公开(公告)号	<a href="#">EP2412380A1</a>	公开(公告)日	2012-02-01
申请号	EP2010171494	申请日	2005-04-28
[标]申请(专利权)人(译)	英国技术集团国际有限公司		
申请(专利权)人(译)	BTG国际有限公司		
当前申请(专利权)人(译)	BTG国际有限公司		
[标]发明人	ANDERSON ROBERT BEISSBATH TIM TYE DIN JASON		
发明人	ANDERSON, ROBERT BEISSBATH, TIM TYE-DIN, JASON		
IPC分类号	A61K38/16 A61P1/00 A23L7/10 A61K38/00 A61K38/10 C07K14/415 C12N15/11 C12N15/29 G01N33/53		
CPC分类号	A61K38/168 A61P1/00 A61K39/00		
代理机构(译)	DOLAN , ANTHONY PATRICK		
优先权	2004201774 2004-04-28 AU 2005900650 2005-02-11 AU		
外部链接	<a href="#">Espacenet</a>		

摘要(译)

本文公开的发明涉及可用于诊断，治疗和预防乳糜泻的方法中的表位。提供了包含至少一个表位的治疗组合物。

Figure 1

